0001628280-24-044196.txt : 20241030 0001628280-24-044196.hdr.sgml : 20241030 20241030075331 ACCESSION NUMBER: 0001628280-24-044196 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 241407490 BUSINESS ADDRESS: STREET 1: 135 ROUTE 202/206 STREET 2: SUITE 6 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (646) 440-9333 MAIL ADDRESS: STREET 1: 135 ROUTE 202/206 STREET 2: SUITE 6 CITY: BEDMINSTER STATE: NJ ZIP: 07921 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 itci-20240930.htm 10-Q itci-20240930
000156751412-312024Q3false14098104xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesitci:segmentxbrli:pure00015675142024-01-012024-09-3000015675142024-10-2800015675142024-09-3000015675142023-12-310001567514us-gaap:ProductMember2024-07-012024-09-300001567514us-gaap:ProductMember2023-07-012023-09-300001567514us-gaap:ProductMember2024-01-012024-09-300001567514us-gaap:ProductMember2023-01-012023-09-300001567514us-gaap:GrantMember2024-07-012024-09-300001567514us-gaap:GrantMember2023-07-012023-09-300001567514us-gaap:GrantMember2024-01-012024-09-300001567514us-gaap:GrantMember2023-01-012023-09-3000015675142024-07-012024-09-3000015675142023-07-012023-09-3000015675142023-01-012023-09-300001567514us-gaap:CommonStockMember2022-12-310001567514us-gaap:AdditionalPaidInCapitalMember2022-12-310001567514us-gaap:RetainedEarningsMember2022-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100015675142022-12-310001567514us-gaap:CommonStockMember2023-01-012023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100015675142023-01-012023-03-310001567514us-gaap:RetainedEarningsMember2023-01-012023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001567514us-gaap:CommonStockMember2023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-03-310001567514us-gaap:RetainedEarningsMember2023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100015675142023-03-310001567514us-gaap:CommonStockMember2023-04-012023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000015675142023-04-012023-06-300001567514us-gaap:RetainedEarningsMember2023-04-012023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001567514us-gaap:CommonStockMember2023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-06-300001567514us-gaap:RetainedEarningsMember2023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000015675142023-06-300001567514us-gaap:CommonStockMember2023-07-012023-09-300001567514us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001567514us-gaap:RetainedEarningsMember2023-07-012023-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001567514us-gaap:CommonStockMember2023-09-300001567514us-gaap:AdditionalPaidInCapitalMember2023-09-300001567514us-gaap:RetainedEarningsMember2023-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000015675142023-09-300001567514us-gaap:CommonStockMember2023-12-310001567514us-gaap:AdditionalPaidInCapitalMember2023-12-310001567514us-gaap:RetainedEarningsMember2023-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001567514us-gaap:CommonStockMember2024-01-012024-03-310001567514us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100015675142024-01-012024-03-310001567514us-gaap:RetainedEarningsMember2024-01-012024-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001567514us-gaap:CommonStockMember2024-03-310001567514us-gaap:AdditionalPaidInCapitalMember2024-03-310001567514us-gaap:RetainedEarningsMember2024-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100015675142024-03-310001567514us-gaap:CommonStockMember2024-04-012024-06-300001567514us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000015675142024-04-012024-06-300001567514us-gaap:RetainedEarningsMember2024-04-012024-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001567514us-gaap:CommonStockMember2024-06-300001567514us-gaap:AdditionalPaidInCapitalMember2024-06-300001567514us-gaap:RetainedEarningsMember2024-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000015675142024-06-300001567514us-gaap:CommonStockMember2024-07-012024-09-300001567514us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001567514us-gaap:RetainedEarningsMember2024-07-012024-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001567514us-gaap:CommonStockMember2024-09-300001567514us-gaap:AdditionalPaidInCapitalMember2024-09-300001567514us-gaap:RetainedEarningsMember2024-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-3000015675142024-04-012024-04-3000015675142024-04-300001567514itci:ThreeMajorWholesalersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001567514itci:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001567514itci:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001567514itci:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001567514itci:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001567514itci:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001567514itci:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001567514itci:FDICCertificatesOfDepositMember2024-09-300001567514us-gaap:CertificatesOfDepositMember2024-09-300001567514us-gaap:CommercialPaperMember2024-09-300001567514us-gaap:CorporateDebtSecuritiesMember2024-09-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514itci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:CertificatesOfDepositMember2023-12-310001567514us-gaap:CommercialPaperMember2023-12-310001567514us-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:DebtSecuritiesMember2024-09-300001567514us-gaap:DebtSecuritiesMember2023-12-310001567514us-gaap:FairValueInputsLevel3Member2023-12-310001567514us-gaap:FairValueInputsLevel3Member2024-09-300001567514us-gaap:CashAndCashEquivalentsMember2024-09-300001567514us-gaap:CashAndCashEquivalentsMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001567514stpr:NY2018-09-300001567514stpr:NJ2024-05-310001567514us-gaap:VehiclesMember2024-09-300001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2005-05-312024-09-300001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2024-09-300001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2005-05-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMembersrt:MinimumMember2005-05-312005-05-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMembersrt:MaximumMember2005-05-312005-05-310001567514itci:BristolMyersSquibbCompanyMemberus-gaap:ProductMember2024-01-012024-09-300001567514us-gaap:PurchaseCommitmentMember2024-09-300001567514us-gaap:PurchaseCommitmentMember2023-12-310001567514itci:InventoriableCostsMember2024-07-012024-09-300001567514itci:InventoriableCostsMember2023-07-012023-09-300001567514itci:InventoriableCostsMember2024-01-012024-09-300001567514itci:InventoriableCostsMember2023-01-012023-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-3000015675142023-01-012023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2024-09-300001567514itci:TimeBasedRestrictedStockUnitsRSUMember2024-09-300001567514us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001567514us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001567514us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001567514us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001567514itci:MichaelI.HalsteadTradingArrangementAug13PlanMemberitci:MichaelIHalsteadMember2024-07-012024-09-300001567514itci:MichaelI.HalsteadTradingArrangementAug13PlanMemberitci:MichaelIHalsteadMember2024-09-300001567514itci:MichaelI.HalsteadTradingArrangementJan2PlanMemberitci:MichaelIHalsteadMember2024-07-012024-09-300001567514itci:MichaelI.HalsteadTradingArrangementJan2PlanMemberitci:MichaelIHalsteadMember2024-09-300001567514itci:SharonMatesPh.DMember2024-07-012024-09-300001567514itci:SharonMatesPh.DMember2024-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_________to_________
Commission File Number: 001-36274
_______________________
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
_______________________
Delaware36-4742850
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
135 Route 202/206, Suite 6
Bedminster, New Jersey
07921
(Address of principal executive offices)(Zip Code)
(646) 440-9333
(Registrant’s telephone number, including area code)
_______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common StockITCI
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filero
 
Non-accelerated fileroSmaller reporting companyo
 
  Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 28, 2024, the registrant had 106,017,103 shares of common stock outstanding.

Intra-Cellular Therapies, Inc.
Index to Form 10-Q
In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiary. “ITI” refers to our wholly-owned subsidiary ITI, Inc.
i
PART I: FINANCIAL INFORMATION
Item 1.    FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Balance Sheets (in thousands except share and per share amounts)
September 30, 2024December 31, 2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents$464,312 $147,767 
Investment securities, available-for-sale542,250 350,174 
Restricted cash1,750 1,750 
Accounts receivable, net145,608 114,018 
Inventory23,539 11,647 
Prepaid expenses and other current assets94,272 42,443 
Total current assets1,271,731 667,799 
Property and equipment, net2,005 1,654 
Right of use assets, net14,011 12,928 
Inventory, non-current30,479 38,621 
Other assets6,219 7,293 
Total assets$1,324,445 $728,295 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$10,338 $11,452 
Accrued and other current liabilities51,540 27,944 
Accrued customer programs70,536 53,173 
Accrued employee benefits29,496 27,364 
Operating lease liabilities4,203 3,612 
Total current liabilities166,113 123,545 
Operating lease liabilities, non-current13,506 13,326 
Total liabilities179,619 136,871 
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 105,998,786 and 96,379,811 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
11 10 
Additional paid-in capital2,818,137 2,208,470 
Accumulated deficit(1,674,951)(1,617,160)
Accumulated comprehensive income
1,629 104 
Total stockholders’ equity1,144,826 591,424 
Total liabilities and stockholders’ equity$1,324,445 $728,295 
See accompanying notes to these condensed consolidated financial statements.
1
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Operations (in thousands except share and per share amounts) (Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenues
Product sales, net$175,159 $125,810 $481,278 $330,669 
Grant revenue216 363 351 1,602 
Total revenues, net175,375 126,173 481,629 332,271 
Operating expenses:
Cost of product sales15,304 9,129 36,558 23,043 
Selling, general and administrative132,101 105,207 366,760 305,144 
Research and development66,819 41,550 165,835 129,368 
Total operating expenses214,224 155,886 569,153 457,555 
Loss from operations(38,849)(29,713)(87,524)(125,284)
Interest income12,899 5,498 30,523 14,377 
Loss before provision for income taxes(25,950)(24,215)(57,001)(110,907)
Income tax expense(374)(43)(790)(188)
Net loss$(26,324)$(24,258)$(57,791)$(111,095)
Net loss per common share:
Basic & Diluted$(0.25)$(0.25)$(0.57)$(1.16)
Weighted average number of common shares:
Basic & Diluted105,768,38696,143,083102,135,53095,745,641
See accompanying notes to these condensed consolidated financial statements.
2
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Comprehensive Loss (in thousands) (Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net loss$(26,324)$(24,258)$(57,791)$(111,095)
Other comprehensive gain:
Unrealized gain on investment securities
2,297 933 1,525 2,855 
Comprehensive loss$(24,027)$(23,325)$(56,266)$(108,240)
See accompanying notes to these condensed consolidated financial statements.
3
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Stockholders’ Equity (in thousands except share and per share amounts) (Unaudited)
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Comprehensive
(Loss) Income		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202294,829,794$9 $2,137,737 $(1,477,486)$(4,190)$656,070 
Exercise of stock options and issuances of restricted stock849,8271 3,639 — — 3,640 
Stock issued for services408— 22 — — 22 
Share-based compensation—— 10,439 — — 10,439 
Net loss—— — (44,053)— (44,053)
Other comprehensive gain—— — — 1,492 1,492 
Balance at March 31, 202395,680,029$10 $2,151,837 $(1,521,539)$(2,698)$627,610 
Exercise of stock options and issuances of restricted stock402,994— 8,585 — — 8,585 
Stock issued for services364— 23 — — 23 
Share-based compensation—— 13,226 — — 13,226 
Net loss—— — (42,784)— (42,784)
Other comprehensive gain—— — — 430 430 
Balance at June 30, 202396,083,387$10 $2,173,671 $(1,564,323)$(2,268)$607,090 
Exercise of stock options and issuances of restricted stock141,780— 2,581 — — 2,581 
Stock issued for services450— 24 — — 24 
Share-based compensation—— 14,311 — — 14,311 
Net loss—— — (24,258)— (24,258)
Other comprehensive gain
—— — — 933 933 
Balance at September 30, 202396,225,617$10 $2,190,587 $(1,588,581)$(1,335)$600,681 

Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Stockholders’ Equity (in thousands except share and per share amounts) (Unaudited) (continued)
Common StockAdditional Paid-in CapitalAccumulated DeficitAccumulated Comprehensive (Loss) IncomeTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 202396,379,811$10 $2,208,470 $(1,617,160)$104 $591,424 
Exercise of stock options and issuances of restricted stock1,097,668— 9,989 — — 9,989 
Stock issued for services339— 23 — — 23 
Share-based compensation—— 13,843 — — 13,843 
Net loss—— — (15,247)— (15,247)
Other comprehensive loss—— — — (534)(534)
Balance at March 31, 202497,477,818$10 $2,232,325 $(1,632,407)$(430)$599,498 
Common shares issued7,876,7131 543,085 — — 543,086 
Exercise of stock options and issuances of restricted stock270,026— 2,093 — — 2,093 
Stock issued for services345— 23 — — 23 
Share-based compensation—— 16,370 — — 16,370 
Net loss—— — (16,220)— (16,220)
Other comprehensive loss—— — — (238)(238)
Balance at June 30, 2024105,624,902$11 $2,793,896 $(1,648,627)$(668)$1,144,612 
Exercise of stock options and issuances of restricted stock373,638— 6,734 — — 6,734 
Stock issued for services246— 18 — — 18 
Share-based compensation—— 17,489 — — 17,489 
Net loss—— — (26,324)— (26,324)
Other comprehensive gain—— — — 2,297 2,297 
Balance at September 30, 2024105,998,786$11 $2,818,137 $(1,674,951)$1,629 $1,144,826 

See accompanying notes to these condensed consolidated financial statements.
4
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited)
Nine Months Ended September 30,
20242023
Cash flows used in operating activities
Net loss$(57,791)$(111,095)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation399 392 
Share-based compensation47,702 37,976 
Stock issued for services64 69 
Amortization of premiums and accretion of discounts on investment securities, net(6,043)(5,861)
Changes in operating assets and liabilities:
Accounts receivable, net(31,590)(27,481)
Inventory(3,750)(19,066)
Prepaid expenses and other assets(50,755)(16,805)
Accounts payable(1,114)218 
Accrued and other current liabilities23,596 8,172 
Accrued customer programs17,363 9,997 
Accrued employee benefits2,132 2,452 
Operating lease liabilities, net(312)(1,106)
Net cash used in operating activities(60,099)(122,138)
Cash flows (used in) provided by investing activities
Purchases of investments(482,077)(310,805)
Maturities of investments297,568 369,192 
Purchases of property and equipment(749)(268)
Net cash (used in) provided by investing activities
(185,258)58,119 
Cash flows provided by financing activities
Proceeds from exercise of stock options18,816 14,806 
Proceeds from sale of common stock, net
543,086 — 
Net cash provided by financing activities561,902 14,806 
Net increase (decrease) in cash, cash equivalents, and restricted cash
316,545 (49,213)
Cash, cash equivalents, and restricted cash at beginning of period149,517 150,365 
Cash, cash equivalents, and restricted cash at end of period$466,062 $101,152 
Non-cash investing and financing activities
Right of use assets under operating leases$2,548 $— 
Supplemental cash flow information
Cash paid for taxes
$1,364 $— 
5
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
September 30,
20242023
Cash and cash equivalents$464,312 $99,402 
Restricted cash1,750 1,750 
Total cash, cash equivalents and restricted cash$466,062 $101,152 
See accompanying notes to these condensed consolidated financial statements.
6
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
September 30, 2024
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.
In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.1 million.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
7
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
3. Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$135,801 $158 $(13)$135,946 
FDIC Certificates of Deposit980 — — 980 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper51,637 63 (1)51,699 
Corporate Notes/Bonds315,499 1,453 (31)316,921 
$563,917 $1,674 $(45)$565,546 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2024 and December 31, 2023, the Company held $164.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. Accrued interest receivable from investment securities as of September 30, 2024 and December 31, 2023 was $3.7 million and $2.3 million, respectively, and are included within prepaid expenses and other current assets.
8
The aggregate related fair value of investments with unrealized losses as of September 30, 2024 was $66.2 million, which consisted of $30.5 million of U.S. government agency securities, $6.0 million of commercial paper, and $29.7 million of corporate notes/bonds. $1.0 million of the aggregate fair value of investments with unrealized losses as of September 30, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $65.2 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for more than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
4. Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $225.1 million as of September 30, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $6.4 million, corporate bonds of $4.8 million, and U.S. government agency securities of $12.1 million as of September 30, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.
9
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$225,099 $225,099 $— $— 
U.S. Government Agency Securities135,946 — 135,946 — 
FDIC Certificates of Deposit980 — 980 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper51,699 — 51,699 — 
Corporate Notes/Bonds316,921 — 316,921 — 
$790,645 $225,099 $565,546 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
5. Inventory
Inventory consists of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$30,479 $38,621 
Work in process13,048 4,277 
Finished goods10,491 7,370 
Total54,018 50,268 
Less: Current portion(23,539)(11,647)
Total inventory, non-current$30,479 $38,621 
As of September 30, 2024 and December 31, 2023, the Company has recorded $8.0 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but the Company believes it is probable that such inventory has future economic benefit.
10
6. Prepaid and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
September 30,
2024		December 31,
2023
Prepaid operating expenses$31,400 $19,465 
Production campaign deposits30,139 15,127 
Clinical trial advances33,389 11,630 
Prefunded customer programs5,563 3,514 
Total100,491 49,736 
Less: Current portion(94,272)(42,443)
Total other assets$6,219 $7,293 
7. Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, Leases, for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In May 2024, the Company entered into a long-term lease of office space in Bedminster, New Jersey. The lease has a term of 5.7 years ending in February 2030.
The Company has also entered into agreements (the “Vehicle Leases”) with providers (the “Lessors”) to acquire motor vehicles for certain employees. The Vehicle Leases provide for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the related Lessor may draw upon in the event the Company defaults on the related Vehicle Leases, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
Other information
Weighted average remaining lease term4.7 years5.3 years
Weighted average discount rate8.82 %9.07 %
11
The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands):
Nine Months Ended September 30,
20242023
Lease cost
Operating lease cost$3,027$2,921
Variable lease cost1,2541,130
Short-term lease cost1,8541,757
$6,135$5,808
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2024$1,112 
Year ending December 31, 20254,436 
Year ending December 31, 20264,513 
Year ending December 31, 20274,573 
Year ending December 31, 20284,707 
Thereafter2,457 
Total21,798 
Less: Present value discount(4,089)
Total operating lease liability17,709 
Less: Current portion(4,203)
Operating lease liabilities, non-current$13,506 
8. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
12
Purchase Commitments
The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The manufacturing service agreements commit the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (“API”) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan set forth in their respective agreements. The Company has paid deposits of $30.1 million and $15.1 million as of September 30, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $30.1 million balance as of September 30, 2024, $24.0 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $6.1 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after September 30, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet.
9. Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Inventoriable costs$497 $424 $1,405 $1,186 
Selling, general and administrative11,898 9,564 31,923 25,269 
Research and development5,094 4,323 14,374 11,521 
Total share-based compensation expense$17,489 $14,311 $47,702 $37,976 
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 202434,539
Options exercised 2024(933,601)
Options canceled or expired 2024(11,460)
Outstanding at September 30, 20243,329,460$30.74 5.2 years
Vested and expected to vest at September 30, 20243,329,460$30.74 
Exercisable at September 30, 20242,968,706$28.00 4.8 years
13
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 years
Time-based RSUs granted in 20241,100,255
Time-based RSUs vested in 2024(732,992)
Time-based RSUs cancelled in 2024(61,611)
Outstanding at September 30, 20241,950,782$60.35 1.2 years
As of September 30, 2024, there were $95.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
10. Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023:
Three and Nine Months Ended September 30,
20242023
Stock options3,329,4604,385,555
RSUs2,175,2841,755,460
14
Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed on February 22, 2024. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form 10-K filed on February 22, 2024, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders.
Commercial Product
In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (FDA), for the treatment of schizophrenia in adults (42 mg/day) and we initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day). We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). We initiated the commercial launch of these special population doses in August 2022. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.
Clinical and Nonclinical Development Programs
Lumateperone Program
Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD. In April 2024 and June 2024, we announced positive topline results from our Phase 3 clinical trials, Study 501 and Study 502, respectively, evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. In both studies, lumateperone 42 mg given once daily as adjunctive therapy to antidepressants met the primary endpoint by demonstrating a statistically significant and clinically meaningful reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo at Week 6. In Study 501, in the modified intent-to-treat (mITT) study population, the least squares (LS) mean reduction from baseline for lumateperone 42 mg was 14.7 points, versus 9.8 points for placebo (LS mean difference = -4.9 points; p<0.0001; ES= 0.61). In Study 502, in the mITT study population, the LS mean reduction from baseline for lumateperone 42 mg was 14.7 points, versus 10.2 points for placebo (LS mean difference= -4.5 points; p<0.0001; ES= 0.56). Lumateperone 42 mg also met the key secondary endpoint in both studies by demonstrating a statistically significant and clinically meaningful reduction in the Clinical Global Impression Scale for Severity of Illness (CGI-S) score compared to placebo at Week 6 (Study 501: p<0.0001; ES= 0.67; Study 502: p<0.0001; ES= 0.51). In Study 501, statistically significant efficacy was seen at the earliest time point tested (Week 1) and maintained throughout the study in both the primary and the key secondary endpoints. In Study 502, numerical improvement versus placebo on the MADRS total score was seen as early as Week 1 and statistically significant efficacy was seen at Week 2 and maintained throughout the study, and statistically significant separation on the CGI-S versus placebo was observed starting at Week 3 and maintained throughout the study. In both Studies 501 and 502, lumateperone 42 mg robustly improved depressive symptoms as reported by patients as measured by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR-16) (p<0.0001). Lumateperone was generally safe and well-tolerated in these studies. In the pooled safety data for Studies 501 and 502, the most commonly reported adverse events that were observed at a rate greater than or equal to 5% and greater than twice the rate of placebo in the total population were dizziness (16.6% v. 5.0%), dry mouth (12.6% v. 3.3%), somnolence (12.4% v. 2.3%), nausea (8.5% v. 4.0%) and fatigue (7.7% v. 1.7%).
15
Adverse events were mostly mild to moderate and resolved within a short period of time. These adverse events were similar to those seen in prior studies of lumateperone as a treatment for bipolar depression and schizophrenia.
We recently completed clinical conduct of our open label roll-over study, Study 503, to assess long-term safety in patients with MDD. We expect to submit a supplemental new drug application, or sNDA, with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in the fourth quarter of 2024.
We are currently conducting an additional global Phase 3 clinical trial, Study 505, evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. Following our positive results in Studies 501 and 502, we have amended the entry criteria of Study 505 to obtain additional clinical experience with lumateperone in patients who have had an inadequate response to a greater number of antidepressants. The objective of this study is to further expand the large body of evidence supporting lumateperone antidepressant efficacy across different patient populations.
In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with bipolar I or bipolar II disorder and mixed features in patients with MDD. In March 2023, we announced positive topline results from Study 403 as lumateperone 42 mg given once daily met the primary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the MADRS total score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (5.7 point reduction vs. placebo; p<0.0001; Cohen’s d effect size (ES) of 0.64). Robust results were also seen in the individual patient population of MDD with mixed features (5.9 point reduction vs. placebo; p<0.0001; ES= 0.67), and in the individual patient population of bipolar depression with mixed features (5.7 point reduction vs. placebo; p<0.0001; ES= 0.64). Additionally, lumateperone 42 mg met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment of improvement in the overall severity on the CGI-S score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (p<0.0001; ES= 0.59) and in the individual patient population of MDD with mixed features (p=0.0003; ES= 0.57), as well as the individual patient population of bipolar depression with mixed features (p<0.0001; ES=0.61).
We also have an ongoing study, Study 304, evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase; a 6-week, open-label run-in phase during which all patients will receive 42 mg of lumateperone per day; a 12-week, open-label stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase, 26 weeks in duration, during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio); and a 2-week safety follow-up phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. We expect to complete Study 304 and report topline results in the fourth quarter of 2024.
Within the lumateperone portfolio, we have conducted or are in the process of conducting studies with pediatric patients in schizophrenia, bipolar disorder and irritability associated with autism spectrum disorder. Our lumateperone pediatric program includes a double-blind, placebo-controlled study in bipolar depression and two double-blind, placebo-controlled studies in irritability associated with autism spectrum disorder. Additionally, the program includes an open-label safety study in schizophrenia and bipolar disorder. Patient enrollment is ongoing in the open-label safety study as well as in the double-blind, placebo-controlled study in bipolar depression. We expect to begin enrollment in the two double-blind, placebo-controlled studies in irritability associated with autism spectrum disorder in the fourth quarter of 2024. Also, in the second quarter of 2024, we initiated two multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies evaluating lumateperone in adults in the acute treatment of manic or mixed episodes associated with bipolar I disorder (bipolar mania). In addition, we are developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have conducted a Phase 1 single ascending dose study with an LAI formulation. This study evaluated the pharmacokinetics, safety and tolerability of a lumateperone LAI in patients with stable symptoms of schizophrenia and was generally safe and well-tolerated. We are evaluating several additional formulations of a lumateperone LAI with treatment durations of one month and longer, and have commenced clinical conduct in a Phase 1 study with additional formulations of our LAI. Given the encouraging efficacy and favorable safety profile to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients.
16
ITI-1284 Program
We are developing ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in Alzheimer's disease and agitation in patients with Alzheimer's disease. ITI-1284-ODT-SL is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. ITI-1284-ODT-SL is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of ITI-1284-ODT-SL. In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated Phase 2 programs evaluating ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in Alzheimer's disease and agitation in patients with Alzheimer’s disease. The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the non-clinical data from lumateperone may not be broadly applied to ITI-1284-ODT-SL, and we conducted additional toxicology studies. These studies have been completed and patient enrollment is ongoing in our Phase 2 study evaluating ITI-1284-ODT-SL as adjunctive therapy to anti-anxiety medications in patients with generalized anxiety disorder. We expect to initiate patient enrollment in our Phase 2 study evaluating ITI-1284-ODT-SL as monotherapy in patients with generalized anxiety disorder in the fourth quarter of 2024. We have also initiated patient enrollment in a Phase 2 clinical study evaluating ITI-1284-ODT-SL in patients with psychosis associated with Alzheimer’s disease and in a Phase 2 clinical study evaluating ITI-1284-ODT-SL in patients with agitation associated with Alzheimer’s disease. We are continuing with Phase 1 studies with ITI-1284-ODT-SL, including drug-drug interaction studies.
PDE1 Program
We have another major program that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states, and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several central nervous system, or CNS, and non-CNS conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Lenrispodun (ITI-214) is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for lenrispodun for Parkinson’s disease and conducted a Phase 1/2 clinical trial of lenrispodun in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and non-motor exploratory endpoints. In this study, lenrispodun was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. Our Phase 2 clinical trial of lenrispodun evaluating improvements in motor symptoms, changes in cognition, and inflammatory biomarkers in patients with Parkinson’s disease is ongoing. We expect to complete this study by the end of 2025. We also have an active Investigational New Drug application, or IND, to evaluate our newest candidate within the PDE1 inhibitor program, ITI-1020, as a novel cancer immunotherapy. Our Phase 1 program with ITI-1020 in healthy volunteers is ongoing.
ITI-333 Program
We also have a development program with our ITI-333 compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors. These combined actions support the potential utility of ITI-333 in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. We have conducted a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. In this study, ITI-333 achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have an ongoing neuroimaging study to investigate brain occupancy for receptors that play a role in substance use disorder and also have applicability for pain. The results of this study will support the dose selection for future studies. In addition, we completed a multiple ascending dose study with ITI-333 in healthy volunteers. In this study, ITI-333 was generally safe and well-tolerated.
17
ITI-1500 Program
We also have the ITI-1500 program focused on the development of novel non-hallucinogenic psychedelics, which we refer to as neuroplastogens. Compounds in this series interact with serotonergic (5-HT2a) receptors in a unique way, potentially allowing the development of this new drug class in mood, anxiety and other neuropsychiatric disorders without the liabilities of known psychedelics including the hallucinogenic potential and risk for cardiac valvular pathologies. Our lead compound in this program, ITI-1549, is currently being evaluated in IND enabling studies and is expected to enter human testing in 2025.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues
Revenues are comprised primarily of net product sales of our commercial product, CAPLYTA, in the United States. Our net product sales of CAPLYTA represent sales primarily to wholesalers and specialty distributors and reflect certain adjustments deducted from gross product sales to arrive at product sales, net.
Expenses
Our operating expenses are comprised of (i) costs of product sales; (ii) selling expenses; (iii) general and administrative expenses; and (iv) research and development expenses.
Costs of product sales are comprised of:
•royalty payments on product sales;
•direct costs of formulating, manufacturing and packaging drug product; and
•overhead costs consisting of labor, share-based compensation, shipping, external inventory manufacturing and other miscellaneous operating costs.
Selling expenses are incurred in three major categories:
•salaries, share-based compensation, incentives and related benefit costs of a dedicated sales force and commercial organization;
•marketing and promotion expenses; and
•sales operation costs.
General and administrative expenses are incurred in three major categories:
•salaries, share-based compensation and related benefit costs;
•patent, legal and professional costs; and
•office, facilities and infrastructure overhead.
Research and development costs are comprised of:
•fees paid to external parties that provide us with contract services, such as pre-clinical testing, manufacturing and related testing, clinical trial activities and license milestone payments; and
•internal recurring costs, such as costs relating to labor and fringe benefits, share-based compensation, materials, supplies, facilities and maintenance.
18
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. The costs associated with the commercialization of CAPLYTA and development of our product candidates are substantial, and we have not yet generated sufficient revenue to offset our operating costs. Costs for the clinical development of lumateperone-related projects, including for the treatment of MDD, consume and, together with our required post-marketing studies and other anticipated clinical development programs, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
A portion of product sold through September 30, 2024 consisted of active pharmaceutical ingredient (API) and drug product that was previously charged to research and development expenses prior to FDA approval of CAPLYTA. Because the Company’s policy does not allow for the capitalization of the cost of drug product that was incurred prior to FDA approval, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales for the three and nine-month periods ended September 30, 2024 and 2023. We expect to continue to have this favorable impact on cost of product sales and related product gross margins until the cost of our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We expect that this will be the case for the remainder of the year and, as a result, our cost of product sales is less than we anticipate it will be in future periods. In addition, as our net product sales increase and we exceed certain sales thresholds, the applicable royalty rate for payments we make under our License Agreement with Bristol Myers Squibb (BMS) increases, which results in an increase to cost of product sales.
We expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with our recently completed and future sales force expansions, promotional activities to support the commercial sales of CAPLYTA, as well as costs associated with expanding our infrastructure and anticipated increases in professional fees. During the third quarter of 2024, we expanded our sales force by approximately 150 representatives who will focus on commercial sales of CAPLYTA to primary care physicians. We also expect to further expand our sales force in 2025. We also expect that research and development expenses will increase moderately as we are expanding our clinical trial programs and pre-clinical development activities. We granted significant share-based awards in 2024 and 2023. We expect to continue to grant share-based awards in the future. We expect that our growing employee base will increase our share-based compensation expense in future periods. In addition, inflation has and may continue to affect us by increasing clinical trial, selling, labor and other operational costs.
The following table sets forth our revenues, operating expenses, interest income, income tax expense and net loss for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenues
Product sales, net$175,159 $125,810 $481,278 $330,669 
Grant revenue216 363 351 1,602 
Total revenues175,375 126,173 481,629 332,271 
Expenses
Cost of product sales15,304 9,129 36,558 23,043 
Selling, general and administrative132,101 105,207 366,760 305,144 
Research and development66,819 41,550 165,835 129,368 
Total operating expenses214,224 155,886 569,153 457,555 
Loss from operations(38,849)(29,713)(87,524)(125,284)
Interest income12,899 5,498 30,523 14,377 
Income tax expense(374)(43)(790)(188)
Net loss$(26,324)$(24,258)$(57,791)$(111,095)
19
Comparison of Three and Nine-Month Periods Ended September 30, 2024 and September 30, 2023
Product Sales, Net
Net product sales for the periods presented are comprised of sales of CAPLYTA for the treatment of schizophrenia and bipolar depression. Net product sales were $175.2 million and $481.3 million for the three and nine-month periods ended September 30, 2024 compared to $125.8 million and $330.7 million for the three and nine-month periods ended September 30, 2023, which represents increases of 39% and 46%, respectively. These increases are primarily due to continued growth in sales volume of CAPLYTA for the treatment of schizophrenia and for the treatment of bipolar depression, driven primarily by prescription growth.
Cost of Product Sales
Cost of product sales was $15.3 million and $36.6 million for the three and nine-month periods ended September 30, 2024, compared to $9.1 million and $23.0 million for the three and nine-month periods ended September 30, 2023, which represents increases of 68% and 59%, respectively. Cost of product sales consisted primarily of product royalty fees, direct costs and overhead, all of which increased as a result of the increased sales volume.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three-month period ended September 30, 2024 were $132.1 million as compared to $105.2 million in the three-month period ended September 30, 2023, which represents an increase of 26%.
Selling costs were $98.7 million for the three-month period ended September 30, 2024 as compared to selling costs of $80.9 million in the same period in 2023, which represents an increase of 22%. This increase is primarily due to increases of salaries, benefits, and share-based compensation of $11.0 million mainly driven by the primary care sales force expansion that occurred this quarter, professional fees and other costs of $3.4 million and marketing and advertising costs of $3.4 million. Compensation and related benefit costs for our commercial functions for the three-month periods ended September 30, 2024 and 2023 constituted 35% and 35%, respectively, of our selling costs.
General and administrative expenses were $33.4 million for the three-month period ended September 30, 2024 as compared to $24.3 million in the same period in 2023, which represents an increase of 37%. This increase is due to increases in IT related services of $3.8 million, salaries of $3.0 million and professional fees and other costs of $2.3 million. Compensation and related benefit costs for our general and administrative functions for the three-month periods ended September 30, 2024 and 2023 constituted 24% and 18%, respectively, of our general and administrative costs.
Selling, general and administrative expenses for the nine-month period ended September 30, 2024 were $366.8 million as compared to $305.1 million in the nine-month period ended September 30, 2023, which represents an increase of 20%.
Selling costs were $279.3 million for the nine-month period ended September 30, 2024 as compared to selling costs of $233.5 million in the same period in 2023, which represents an increase of 20%. This increase is primarily due to increases of salaries, benefits and share-based compensation of $23.3 million mainly driven by the primary care sales force expansion that occurred this quarter, marketing and advertising costs of $11.2 million, commercialization costs of $9.2 million and professional fees and other costs of $2.1 million. Compensation and related benefit costs for our commercial functions for the nine-month periods ended September 30, 2024 and 2023 constituted 33% and 35%, respectively, of our selling costs.
General and administrative expenses were $87.5 million for the nine-month period ended September 30, 2024 as compared to $71.6 million in the same period in 2023, which represents an increase of 22%. This increase is due to increases in IT related services of $9.0 million, salaries of $4.7 million and professional fees and other costs of $2.2 million. Compensation and related benefit costs for our general and administrative functions for the nine-month periods ended September 30, 2024 and 2023 constituted 24% and 22%, respectively, of our general and administrative costs.
20
Research and Development Expenses
The following tables set forth our research and development expenses for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
External service costs$53,188 $29,123 $126,029 $94,579 
Internal and other costs13,631 12,427 39,806 34,789 
Total research and development expenses$66,819 $41,550 $165,835 $129,368 
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Lumateperone costs$40,605 $23,149 $100,328 $78,510 
Non-lumateperone costs16,383 9,614 37,859 27,670 
Overhead and other costs9,831 8,787 27,648 23,188 
Total research and development expenses$66,819 $41,550 $165,835 $129,368 
Research and development expenses were $66.8 million for the three-month period ended September 30, 2024 as compared to $41.6 million in the same period in 2023, which represents an increase of 61%. This increase is due primarily to increases of $17.4 million for lumateperone costs, $6.8 million for non-lumateperone costs and $1.0 million for overhead and other costs. External service costs increased by $24.0 million for the period due to the increased number of clinical trials for lumateperone and non-lumateperone projects. Internal and other costs increased by $1.2 million for the period due primarily to labor related costs and share-based compensation.
Research and development expenses were $165.8 million for the nine-month period ended September 30, 2024 as compared to $129.4 million in the same period in 2023, which represents an increase of 28%. This increase is due primarily to increases of $21.8 million for lumateperone costs, $10.2 million for non-lumateperone costs and $4.4 million for overhead and other costs. External service costs increased by $31.4 million for the period due to the increased number of clinical trials for lumateperone and non-lumateperone projects. Internal and other costs increased by $5.0 million for the period due primarily to labor related costs and share-based compensation.
Liquidity and Capital Resources

Sources of Liquidity
To date, we have funded our operations through proceeds from public and private offerings of our common stock and other securities, as well as collections from net product revenue related to the sales of CAPLYTA. As of September 30, 2024, our cash and cash equivalents, investment securities, and restricted cash totaled approximately $1.0 billion, which we believe, along with cash generated from ongoing operations, will enable us to fund our operating expenses and capital expenditure requirements for at least the foreseeable future from the filing date of this report. During that time, we expect to have increased net product revenue as well as increases in our operating expenses.
We balance the level of cash, cash equivalents and investments on hand with our projected needs. We then assess the availability of funding on favorable terms with minimal risk. Subject to market conditions, interest rates, results of our clinical trials, progress of our commercialization efforts and other factors, we may pursue opportunities to obtain additional financing in the future, which could include public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, and licensing a portion or all of our product candidates and technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
21
Our cash, cash equivalents, and investments are maintained in checking accounts, money market accounts, money market funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Our aim is to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances and investments with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such balances because these financial institutions are highly-rated institutions and custodians of our investments.

Cash Flows

The following table summarizes our cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):

Nine Months Ended September 30,
20242023Change
Net cash used in operating activities$(60,099)$(122,138)$62,039 
Net cash (used in) provided by investing activities(185,258)58,119 (243,377)
Net cash provided by financing activities561,902 14,806 547,096 
Net increase (decrease) in cash, cash equivalents, and restricted cash$316,545 $(49,213)$365,758 
Net cash used in operating activities totaled $60.1 million for the nine months ended September 30, 2024 compared to $122.1 million of net cash used in operating activities for the nine months ended September 30, 2023. This decrease in cash used in operations primarily resulted from an increase in our net product sales.
Net cash used in investing activities totaled $185.3 million for the nine months ended September 30, 2024 compared to $58.1 million of cash provided by investing activities for the nine months ended September 30, 2023. The increase in net cash used in investing activities was primarily due to an increase in purchases of investment securities.
Net cash provided by financing activities totaled $561.9 million for the nine months ended September 30, 2024 compared to $14.8 million of cash provided by financing activities for the nine months ended September 30, 2023. This increase in net cash provided by financing activities was attributable primarily to the completion of an underwritten public offering of shares of our common stock in April 2024 resulting in net proceeds of approximately $543.1 million, after deducting underwriting discounts and commissions and offering expenses.

Operational and Capital Funding Requirements
Our cash requirements in the short and long term consist of operational, manufacturing, and capital expenditures, a portion of which contain contractual or other obligations. Our material long-term contractual commitments are comprised of licensing and royalty commitments with BMS, operating leases for our office and laboratory spaces, and purchase obligations supporting our commercial and R&D operations. Refer to our discussion of Liquidity and Capital Resources in “Part II, Item 7 — Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2023, and Note 7, Right of Use Assets and Lease Liabilities, and Note 8, Commitments and Contingencies, in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Financial Statements, of this Quarterly Report on Form 10-Q for the discussion of our contractual commitments.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our critical accounting policies during the nine-month period ended September 30, 2024.
22
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates and under different assumptions or conditions.
Recently Issued Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA; the supply and availability of and demand for our product; our recently completed and future sales force expansions; the initiation, cost, timing, progress and results of our development activities, non-clinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates, including through our litigation against the ANDA Filers; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk, inflation risk, capital market risk, foreign currency fluctuations and geopolitical instability; and our ability to attract and retain key scientific, management, or sales and marketing personnel.
23
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; whether CAPLYTA receives adequate reimbursement from third-party payers; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients; challenges associated with supply and manufacturing activities, which in each case could limit our sales and the availability of our product; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities; there is no guarantee that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents; there is no guarantee that our planned sNDA for the treatment of MDD will be submitted or approved, if at all, on the timeline that we expect; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development, commercialization, manufacturing or supply of our product and product candidates; risks related to changes in interest rates, high rates of inflation, global supply chain disruptions, and geopolitical instability on our business; disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the COVID-19 pandemic), the conflicts in the Ukraine, Russia or the Middle East, man-made or natural disasters, global economic uncertainty, market disruptions, cybersecurity incidents or other causes; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity. As of September 30, 2024, we had cash, cash equivalents, investment securities and restricted cash of approximately $1.0 billion, consisting of cash deposited in highly rated financial institutions in the United States and in short-term U.S. Treasury bonds, money market funds, as well as high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations and we do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest rates as we intend and have the ability to hold our investments to maturity. During the third quarter of 2024, there was an unrealized gain due to a decline in interest rates that resulted in a net unrealized gain position of $1.6 million as of September 30, 2024.
Inflation Risk. Inflation generally affects us by increasing our cost of labor, clinical trial costs, and other outsourced activities. To date, inflation has not had a material impact on our business. Should global inflation increase in the future, we expect increases in clinical trial, selling, labor, and other operating costs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases of our product. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.
24
Capital Market Risk. Although we receive product revenues from commercial sales of CAPLYTA, we may in the future raise funds through other sources. One possible source of funding is through further securities offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price among other things.
Foreign Currency Risk. Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, our foreign currency exposure has been limited so we have not hedged for this exposure. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our results of operations or our cash flows. For the nine-month periods ended September 30, 2024 and 2023, changes in foreign currency exchange rates did not have a material impact on our historical financial position, our business, our financial condition, our results of operations or our cash flows.
Item 4.    CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three-month period ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
25
PART II: OTHER INFORMATION
Item 1.    LEGAL PROCEEDINGS
As previously disclosed, in February 2024, we received notices from Alkem Laboratories Ltd., Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Inc. (on behalf of Dr. Reddy’s Laboratories Ltd.), MSN Laboratories Private Ltd., Sandoz Inc., Hetero USA, Inc. (the U.S. Regulatory Agent for Hetero Labs Limited Unit - V, a division of Hetero Labs Limited) and Zydus Pharmaceuticals (USA), Inc., which we refer to as ANDA Filers, that each company had filed an abbreviated new drug application, or ANDA, with the FDA seeking approval of generic version of CAPLYTA. The ANDAs each contained Paragraph IV Patent Certifications alleging that certain of our patents covering CAPLYTA are invalid and/or will not be infringed by each ANDA Filer’s manufacture, use or sale of the medicine for which the ANDA was submitted.
Under the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, or the FDCA, we had 45 days from receipt of the notice letters to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court to trigger a stay precluding the FDA’s approval of any ANDA from being effective any earlier than 7.5 years from the date of approval of the CAPLYTA new drug application or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. After conducting the necessary due diligence, and within the 45 day period required under the FDCA, we filed lawsuits on March 27, 2024 and March 28, 2024 in the U.S. District Court for the District of New Jersey against each of the seven generic drug manufacturers who notified us of their ANDA filings. Our lawsuits seek a declaratory judgment that our patents have been infringed by the respective ANDA Filer, an order that any FDA approval of the ANDA Filer's product be not earlier than the date of the expiration of our applicable patents, injunctions against the commercialization of the ANDA Filer's product prior to such expiration date, and an award for attorneys' fees, costs and expenses. In the ANDA Filers’ respective answers to our complaints filed in May, June and July 2024, five of the ANDA Filers asserted counterclaims against us seeking a declaratory judgment of noninfringement and invalidity of our patents.
On July 16, 2024, the U.S. District Court for the District of New Jersey issued an order consolidating the cases described above for all pretrial purposes. A scheduling conference for the consolidated cases was held on July 29, 2024 and on August 8, 2024, the U.S. District Court for the District of New Jersey issued a scheduling order that set the date for the bench trial to begin on October 27, 2026.
In July and August 2024, we received an additional notice from each of (i) Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd., and (ii) Alkem Laboratories Ltd., respectively, each of which is an ANDA Filer, that such ANDA Filer had filed an additional Paragraph IV Patent Certification alleging that an additional patent covering CAPLYTA is invalid and/or will not be infringed by such ANDA Filer’s manufacture, use or sale of the medicine for which the ANDA was submitted. On August 29, 2024, we filed additional lawsuits in the U.S. District Court for the District of New Jersey against each of the seven ANDA Filers with respect to two additional patents covering CAPLYTA (including the patent referenced in the July and August ANDA Filer notices) seeking a declaratory judgment that our patents have been infringed by the respective ANDA Filer, an order that any FDA approval of the ANDA Filer’s product be not earlier than the date of expiration of our applicable patents, injunctions against the commercialization of the ANDA Filer’s product prior to such expiration date, and an award for attorneys’ fees, costs and expenses. In the ANDA Filers’ respective answers to these complaints filed up to the date of this report, two of the ANDA Filers asserted counterclaims against us seeking a declaratory judgment of noninfringement and invalidity of our patents. On October 15, 2024, the U.S. District Court for the District of New Jersey issued an order consolidating these additional cases with the consolidated case described above for all pretrial purposes.
While we intend to vigorously defend and enforce our intellectual property rights protecting CAPLYTA, we can offer no assurance as to when the lawsuits will be decided, whether the lawsuits will be successful, or that a generic equivalent of CAPLYTA will not be approved and enter the market before the expiration of our patents.
Item 1A. RISK FACTORS
There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 22, 2024.
26
Item 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended September 30, 2024.
Item 3.    DEFAULTS UPON SENIOR SECURITIES
Not applicable.
Item 4.    MINE SAFETY DISCLOSURES
Not applicable.
Item 5.    OTHER INFORMATION

During the fiscal quarter ended September 30, 2024, the following director and executive officers adopted a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act):
•On August 13, 2024, Michael I. Halstead, President, adopted a Rule 10b5-1 Sales Plan having an end date of December 31, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 41,583 shares of our common stock upon the exercise of stock options. On August 13, 2024, Mr. Halstead adopted a subsequently commencing Rule 10b5-1 Sales Plan with a start date of January 2, 2025 and an end date of April 10, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 32,717 shares of our common stock upon the vesting of restricted stock units and (ii) an indeterminate number of shares of our common stock sufficient to cover Mr. Halstead’s tax liability upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions.
•On September 3, 2024, Sharon Mates, Ph.D., Chairman and Chief Executive Officer, adopted a Rule 10b5-1 Sales Plan having an end date of December 16, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 102,697 shares of our common stock upon the exercise of stock options.

There were no other “Rule 10b5-1 trading arrangements” or "non-Rule 10b5-1 trading arrangements" (as each term is defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended September 30, 2024 by our directors and executive officers.
27
Item 6.    EXHIBITS
Exhibit
Number
Exhibit Description
Filed
Herewith
Incorporated by
Reference herein
from Form
or Schedule
Filing Date
SEC File/
Reg. Number
10.18-K
(Exhibit 10.1)		8/7/2024
001-36274
10.2
8-K
(Exhibit 10.2)
8/7/2024
001-36274
10.3
8-K
(Exhibit 10.3)
8/7/2024
001-36274
10.4
8-K
(Exhibit 10.4)
8/7/2024
001-36274
10.5
8-K
(Exhibit 10.5)
8/7/2024
001-36274
10.6
X
10.7
X
31.1X
31.2X
32X
28
101
The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2024 and 2023, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2024 and 2023, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2024 and 2023, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2024 and 2023, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).
X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X

*     Management contract or compensatory plan or arrangement.
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTRA-CELLULAR THERAPIES, INC.
Date: October 30, 2024
By:/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman and Chief Executive Officer
Date: October 30, 2024
By:
/s/ Sanjeev Narula
Sanjeev Narula
Executive Vice President, Chief Financial Officer and Treasurer
30
 EX-10.6 2 itci-20240930xex106.htm EX-10.6 Document

Exhibit 10.6
Schedule B
RELEASE OF CLAIMS
This Release of Claims (Release”) is made as of _______________ by and between ________________ (“the Executive”) and Intra-Cellular Therapies, Inc. (the “Company”) (together, the “Parties”).
1.    In consideration for Executive’s execution of this Release, the Company will make a severance payment to Executive in the amount set forth in the Employment Agreement between the Executive and the Company. This amount will be paid following the Effective Date (as defined below) in accordance with the Employment Agreement, provided the Company has received the executed Agreement from Executive on or before that date. This payment will be subject to standard payroll deductions and withholdings. If Executive timely elects and remains eligible for continued coverage under COBRA, the Company will pay that portion of Executive’s COBRA premiums it was paying prior to the Separation Date for the time period set forth in the Employment Agreement between the Executive and the Company.
2.    Executive hereby releases, acquits and forever discharges the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, stockholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, which were known or through reasonable diligence should have been known, arising out of or in any way related to Releases, events, acts or conduct at any time prior to the date Executive executes this Settlement Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with Executive’s employment with the Company, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, any and all claims and causes of action that the Company, its parents and subsidiaries, and its and their respective officers, directors, agents, servants, employees, attorneys, shareholders, successors, assigns or affiliates:
•has violated its personnel policies, handbooks, contracts of employment, or covenants of good faith and fair dealing;

B-1


•has discriminated against Executive on the basis of age, race, color, sex (including sexual harassment), national origin, ancestry, disability, religion, sexual orientation, marital status, parental status, source of income, entitlement to benefits, any union activities or other protected category in violation of any local, state or federal law, constitution, ordinance, or regulation, including but not limited to: Title VII of the Civil Rights Act of 1964, as amended; 42 U.S.C. § 1981, as amended; the Equal Pay Act; the Americans With Disabilities Act; the Family and Medical Leave Act; the New York State Human Rights Law; the New York City Human Rights Law; the Employee Retirement Income Security Act; Section 510; and the National Labor Relations Act;

•has violated any statute, public policy or common law (including but not limited to claims for retaliatory discharge; negligent hiring, retention or supervision; defamation; intentional or negligent infliction of emotional distress and/or mental anguish; intentional interference with contract; negligence; detrimental reliance; loss of consortium to Executive or any member of Executive’s family and/or promissory estoppel).
Excluded from this Release are any claims which cannot be waived by law. Executive is waiving, however, Executive’s right to any monetary recovery should any governmental agency or entity, such as the EEOC or the DOL, pursue any claims on Executive’s behalf. Executive acknowledges that Executive is knowingly and voluntarily waiving and releasing any rights Executive may have under the ADEA, as amended. Executive also acknowledges that (i) the consideration given to Executive in exchange for the waiver and release in this Release is in addition to anything of value to which Executive was already entitled, and (ii) that Executive has been paid for all time worked, have received all the leave, leaves of absence and leave benefits and protections for which Executive is eligible, and have not suffered any on-the-job injury for which Executive has not already filed a claim. Executive further acknowledges that Executive has been advised by this writing that: (a) Executive’s waiver and release do not apply to any rights or claims that may arise after the execution date of this Release; (b) Executive has been advised hereby that Executive has the right to consult with an attorney prior to executing this Release; (c) Executive has twenty-one (21) days to consider this Release (although Executive may choose to voluntarily execute this Release earlier and if Executive does Executive will sign the Consideration Period waiver below); (d) Executive has seven (7) days following Executive’s execution of this Release to revoke the Release; and (e) this Release shall not be effective until the date upon which the revocation period has expired unexercised (the “Effective Date”), which shall be the eighth day after Executive executes this Release.
B-2


Notwithstanding the foregoing, the waiver and release contained in this Release does not apply to any claim which, as a matter of law, cannot be released by private agreement. If any provision of the waiver and release contained in this Release is found to be unenforceable, it shall not affect the enforceability of the remaining provisions and all remaining provisions shall be enforceable to the fullest extent permitted by law. No provision of this Release shall prevent or restrict Executive from disclosing information about unlawful workplace acts, including but not limited to factual information relating to any claims of harassment, discrimination, or retaliation under Title VII the New York State Human Rights Law, including claims based on race, sexual orientation, religion, color, national origin, ancestry, disability, medical condition, and age. No provision of this Release is intended to limit, or shall be interpreted as limiting, Executive’s right to file administrative charges with any Governmental Entity (as defined below) charged with enforcement of any law, including but not limited to the Equal Employment Opportunity Commission, New York State Division of Human Rights and the New York City Commission on Human Rights, the Securities and Exchange Commission, and National Labor Relations Board, and to participate in agency investigations. Additionally, nothing herein is intended to restrict, or shall be interpreted as restricting, Executive’s right to engage in concerted activity protected by Section 7 of the National Labor Relations Act or Executive’s right to file for or collect unemployment benefits and/or to seek and receive remedies for workplace injuries under the provisions of any applicable workers’ compensation act.
Nothing in this Release shall prohibit or impede Executive from communicating, cooperating or filing a complaint with any U.S. or foreign federal, state or local governmental or law enforcement branch, federal or state attorney general, agency, entity, commission or other governmental authority or instrumentality of competent jurisdiction (collectively, a “Governmental Entity”) or any attorney retained by Executive, with respect to possible violations of any U.S. or foreign federal, state or local law or regulation, or otherwise making disclosures to any Governmental Entity, in each case, that are protected under the whistleblower provisions of any such law or regulation; provided, that in each case such communications and disclosures are consistent with applicable law. Executive does not need the prior authorization of (or to give notice to) the Company regarding any such communication or disclosure.
3.    On or before the last day of Executive’s employment, Executive agrees to return to the Company all Company documents (and all copies thereof) and other Company property that Executive has had in Executive’s possession at any time, including, but not limited to, Company files, notes, drawings, records, business plans and forecasts, financial information, specifications, computer-recorded information, tangible property (including, but not limited to, computers), credit cards, entry cards, identification badges and keys; and, any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof). Executive shall coordinate the return of Company property with the General Counsel, Chief Human Resources Officer, or other appropriate officer designated by the Board of Directors.
B-3


4.    Executive further agrees that both during and after Executive’s employment Executive acknowledges Executive’s continuing obligations under Executive’s Proprietary Information, Inventions and Non-Competition Agreement not to use or disclose any confidential or proprietary information of the Company and to refrain from certain solicitation and competitive activities.
5.    It is understood that Executive shall hold the provisions of this Release in strictest confidence and shall not publicize or disclose it in any manner whatsoever; provided, however, that: (a) Executive may disclose this Release to Executive’s immediate family; (b) Executive may disclose this Release in confidence to Executive’s attorney, accountant, auditor, tax preparer, and financial advisor; and (c) Executive may disclose this Release insofar as such disclosure may be required by law.
6.    Executive agrees not to disparage the Company, and the Company’s attorneys, directors, managers, partners, employees, agents and affiliates, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that Executive may respond accurately and fully to any question, inquiry or request for information when required by legal process.
7.    This Release does not constitute an admission by the Company of any wrongful action or violation of any federal, state, or local statute, or common law rights, including those relating to the provisions of any law or statute concerning employment actions, or of any other possible or claimed violation of law or rights.
8.    Executive agrees that upon any breach of this Release Executive will forfeit all amounts paid or owing to Executive under this Release. Executive further acknowledges that it may be impossible to assess the damages caused by violation of the terms of paragraphs 3, 4, 5 and 6 of this Release and further agree that any threatened or actual violation or breach of those paragraphs of this Release will constitute immediate and irreparable injury to the Company. Executive therefore agrees that any such breach of this Release is a material breach of this Release, and, in addition to any and all other damages and remedies available to the Company upon Executive’s breach of this Release, the Company shall be entitled to an injunction to prevent Executive from violating or breaching this Release. Executive agrees that if the Company is successful in whole or part in any legal or equitable action against Executive under this Release, Executive agree to pay all of the costs, including reasonable attorney’s fees, incurred by the Company in enforcing the terms of this Release.
B-4


9.    This Release constitutes the complete, final and exclusive embodiment of the entire Release between the Parties with regard to this subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Release may not be modified or amended except in a writing signed by both Executive and a duly authorized officer of the Company. This Release will bind the heirs, personal representatives, successors and assigns of the Parties, and inure to the benefit of the Parties, their heirs, successors and assigns. If any provision of this Release is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Release and the provision in question will be modified by the court so as to be rendered enforceable. This Release will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of New York as applied to contracts made and to be performed entirely within New York.
IN WITNESS WHEREOF, the Parties have duly authorized and caused this Agreement to be executed as follows:
INTRA-CELLULAR THERAPIES, INC.

_____________________________        By: ______________________________
    


_____________________________        __________________________________
Date    Date
B-5

 EX-10.7 3 itci-20240930xex107.htm EX-10.7 Document

Exhibit 10.7

INTRA-CELLULAR THERAPIES, INC.

[AMENDED AND RESTATED] EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS, AND NON-COMPETITION AGREEMENT

In consideration of my employment or continued employment by INTRA-CELLULAR THERAPIES, INC. (the “Company”), and the compensation now and hereafter paid to me, I hereby agree as follows:

1.NONDISCLOSURE.

1.1Recognition of Company’s Rights; Nondisclosure. At all times during my employment and thereafter, I will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (defined below), except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an officer of the Company expressly authorizes such in writing. I will obtain Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at Company and/or incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns. I have been informed and acknowledge that the unauthorized taking of the Company’s trade secrets may subject me to civil and/or criminal penalties.

1.2Proprietary Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company. By way of illustration but not limitation, “Proprietary Information” includes (a) tangible and intangible information relating to antibodies and other biological materials, cell lines, samples of assay components, media and/or cell lines and procedures and formulations for producing any such assay components, media and/or cell lines, formulations, products, processes, know-how, designs, formulas, methods, developmental or experimental work, clinical data, improvements, discoveries, plans for research, new products (“Inventions”); (b) marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (c) information regarding the skills and compensation of other employees of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry, which is not gained as result of a breach of this Agreement, and my own, skill, knowledge, know-how and experience to whatever extent and in whichever way I wish.



1.3Third Party Information. I understand, in addition, that the Company has received and in the future will receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing.
1.4No Improper Use of Information of Prior Employers and Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person. I will use in the performance of my duties only information which is generally known and used by persons with training and experience comparable to my own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company.

2.ASSIGNMENT OF INVENTIONS.

2.1Proprietary Rights. The term “Proprietary Rights” shall mean all trade secret, patent, copyright, mask work and other intellectual property rights or “moral rights” throughout the world. “Moral rights” refers to any rights to claim authorship of an Invention or to object to or prevent the modification of any Invention, or to withdraw from circulation or control the publication or distribution of any Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a “moral right.”

2.2Prior Inventions. Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A (Previous Inventions) attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit A for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention.
2


Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent.

2.3Assignment of Inventions. Subject to Sections 2.4, and 2.6, I hereby assign and agree to assign in the future (when any such Inventions or Proprietary Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all my right, title and interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during the period of my employment with the Company. Inventions assigned to the Company, or to a third party as directed by the Company pursuant to this Section 2, are hereinafter referred to as “Company Inventions.”

2.4Unassigned Inventions. I recognize that this Agreement will not be deemed to require assignment of any Invention that was developed entirely on my own time without using the Company’s equipment, supplies, facilities, or trade secrets and neither related to the Company’s actual or anticipated business, research or development, nor resulted from work performed by me for the Company.

2.5Obligation to Keep Company Informed. During the period of my employment and for six (6) months after termination of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of employment. The Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement.

2.6Government or Third Party. I also agree to assign all my right, title and interest in and to any particular Company Invention to a third party, including without limitation the United States, as directed by the Company.

2.7Works for Hire. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101).

3


2.8Enforcement of Proprietary Rights. I will assist the Company in every proper way to obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance.

In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned hereunder to the Company.

2.9Defend Trade Secrets Act. I hereby acknowledge notice under 18 U.S.C § 1833(b)(1), which states, in pertinent part: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.”

4


2.10Preserved Rights. No provision of this Agreement shall prevent or restrict me from disclosing information about unlawful workplace acts, including but not limited to factual information relating to any claims of harassment, discrimination, or retaliation under Title VII the New York State Human Rights Law or any other similar federal, state, or local law, including claims based on race, sexual orientation, religion, color, national origin, ancestry, disability, medical condition, and age. No provision of this Agreement is intended to limit, or shall be interpreted as limiting, my right to file administrative charges with any Governmental Entity (as defined below) charged with enforcement of any law, including but not limited to the Equal Employment Opportunity Commission, New York State Division of Human Rights and the New York City Commission on Human Rights, the Securities and Exchange Commission, and National Labor Relations Board, and to participate in agency investigations. Additionally, nothing herein is intended to restrict, or shall be interpreted as restricting, my right to engage in concerted activity protected by Section 7 of the National Labor Relations Act or my right to file for or collect unemployment benefits and/or to seek and receive remedies for workplace injuries under the provisions of any applicable workers’ compensation act. Nothing in this Agreement shall prohibit or impede me from communicating, cooperating or filing a complaint with any U.S. or foreign federal, state or local governmental or law enforcement branch, federal or state attorney general, agency, entity, commission or other governmental authority or instrumentality of competent jurisdiction (collectively, a “Governmental Entity”) or any attorney retained by me, with respect to possible violations of any U.S. or foreign federal, state or local law or regulation, or otherwise making disclosures to any Governmental Entity, in each case, that are protected under the whistleblower provisions of any such law or regulation (including, but not limited, under the federal securities laws, including the Dodd-Frank Act); provided, that in each case such communications and disclosures are consistent with applicable law. I do not need the prior authorization of (or to give notice to) the Company regarding any such communication or disclosure.

3.RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of the Company at all times.

4.DUTY OF LOYALTY DURING EMPLOYMENT. I understand that my employment with the Company requires my full attention and effort. I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, engage in any employment or business activity other than for the Company, including but not limited to employment or business activity which is competitive with, or would otherwise conflict with, my employment by the Company.

5


5.NO SOLICITATION OF EMPLOYEES, CONSULTANTS, CONTRACTORS OR CUSTOMERS. I agree that for the period of my employment by the Company and for one (1) year after the date my employment by the Company ends for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, either directly or through others, (i) solicit or attempt to solicit any employee of the Company to end his or her relationship with the Company; and (ii) solicit any consultant, contractor, or customer of the Company, with whom I had contact or whose identity I learned as a result of my employment with the Company to diminish or materially alter its relationship with the Company.

The parties agree that for purposes of this Agreement, a customer is any person or entity to which the Company has provided goods or services at any time during the period commencing six (6) months prior to my employment with the Company and ending on the date my employment with the Company ends.

6.NON-COMPETE PROVISION. I agree that for the period of my employment with the Company, and for the period of one (1) year after the later of (1) the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company; or (2) the date a court of competent jurisdiction enters an order enforcing this provision, I will not provide services, similar to those I provided to the Company, to any person or entity in competition (as defined below) with the Company. I acknowledge that this non-compete provision is limited to the types of activities and services I provided in my employment with the Company.

At the present time, the Company engages in the development and commercialization of drugs that address medical needs in psychiatric and neurological disorders, including, without limitation, schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, psychosis, agitation, Parkinson’s Disease, Alzheimer’s Disease, and autism spectrum disorder, and therefore entities and individuals which provide similar products or services are defined as in competition with the  Company. The parties understand that the scope and nature of my activities and services, and the Company’s business, products or services, may change as the Company develops. The parties agree that the scope of this provision will change to cover any changes in my activities or services, as well as any changes in the Company’s business, products or services, during my employment.

7.NO CONFLICTING AGREEMENT OR OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement or obligation of any kind made prior to my employment by the Company, including agreements or obligations I may have with prior employers or entities for which I have provided services. I have not entered into, and I agree I will not enter into, any agreement or obligation either written or oral in conflict herewith.

6


8.RETURN OF COMPANY DOCUMENTS. When I leave the employ of the Company, I will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Proprietary Information of the Company. I further agree that any property situated on the Company’s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. Prior to leaving, I will cooperate with the Company in completing and signing the Company’s termination statement.

9.LEGAL AND EQUITABLE REMEDIES. I recognize that in the course of employment with the Company, I will have access to Proprietary Information, to Third Party Information, and to employees, consultants, contractors, clients, and customers of the Company. I also recognize that the services I will be employed to provide are personal and unique. I understand that because of this the Company may sustain irreparable injury if I violate this Agreement. In order to limit or prevent such irreparable injury, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.

10.NOTICES. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or if sent by certified or registered mail, three (3) days after the date of mailing.

11.NOTIFICATION OF NEW EMPLOYER. In the event that I leave the employ of the Company, I authorize the Company to provide notice of my rights and obligations under this Agreement to my subsequent employer and to any other entity or person to whom I provide services.

12.GENERAL PROVISIONS.

12.1Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the State of New York, as such laws are applied to agreements entered into and to be performed entirely within New York between New York residents. I hereby expressly consent to the personal jurisdiction of the state and federal courts for New York County, New York in any lawsuit filed there against me by Company arising from or related to this Agreement.

7


12.2Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. Moreover, if any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

12.3Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns.

12.4Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee.

12.5Employment At-Will. I agree and understand that I am employed at-will, and that nothing in this Agreement shall change this at-will status or confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without cause.

12.6Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement.

12.7Entire Agreement. The obligations pursuant to Sections 1 and 2 of this Agreement shall apply to any time during which I was previously employed, or am in the future employed, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.

[This Agreement shall be effective as of the first day of my employment with the Company, namely: [____________].] [This Agreement, effective as of [_______], amends and restates the Employee Proprietary Information, Inventions, and Non-Competition Agreement dated as of [____] by and between the Company and me.]


8


I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS. I HAVE COMPLETELY FILLED OUT EXHIBIT A TO THIS AGREEMENT.

Dated: _______________, ____


_______________________________________________

(Signature)


_______________________________________________

(Printed Name)

ACCEPTED AND AGREED TO:

INTRA-CELLULAR THERAPIES, INC.


By:_____________________________________
Name:
Title:

________________________________________
(Address)

Dated: _______________, ____

9


Exhibit A

Previous Inventions
                    
10

 EX-31.1 4 itci-20240930xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS UNDER SECTION 302
I, Sharon Mates, Ph.D., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 30, 2024
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman and Chief Executive Officer
(principal executive officer)

 EX-31.2 5 itci-20240930xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS UNDER SECTION 302
I, Sanjeev Narula, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 30, 2024
/s/ Sanjeev Narula
Sanjeev Narula
Executive Vice President, Chief Financial Officer and Treasurer
(principal financial officer)

 EX-32 6 itci-20240930xex32.htm EX-32 Document

Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended September 30, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 30, 2024
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman and Chief Executive Officer
(principal executive officer)
Dated: October 30, 2024
/s/ Sanjeev Narula
Sanjeev Narula
Executive Vice President, Chief Financial Officer and Treasurer
(principal financial officer)

EX-101.SCH 7 itci-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Prepaid and Other Assets link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Prepaid and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Loss Per Share - (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Investment Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Prepaid and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Prepaid and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 itci-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 itci-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 itci-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Range [Domain] Statistical Measurement [Domain] Unrealized (Losses) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Prepaid Expenses and Other Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cover [Abstract] Cover [Abstract] Debt Securities Debt Securities [Member] Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule Of Maturity Analysis Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Prepaid operating expenses Prepaid Operating Expenses Prepaid Operating Expenses Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Clinical trial advances Clinical Trial Advances Clinical Trial Advances Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable, net Increase (Decrease) in Accounts Receivable Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating lease liabilities, net Increase (Decrease) in Operating Lease Liability Right of Use Assets and Lease Liabilities Right Of Use Assets And Lease Liabilities [Text Block] Right of use assets and lease liabilities. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Exercise of stock options and issuances of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Lease cost Lease, Cost [Abstract] Operating lease liabilities, non-current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Accrued interest receivable Interest Receivable Offering price (in dollars per share) Sale of Stock, Price Per Share Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Other assets Total other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money Market Funds Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Aggregate gross proceeds Sale of Stock, Consideration Received on Transaction Cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Equity Components [Axis] Equity Components [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Estimated Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Corporate bonds ,at carrying value Corporate Bonds, at Carrying Value Corporate Bonds, at Carrying Value Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Payment of milestone amount Possible Milestone Payments Remaining Payment of milestone amount. Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Investments [Domain] Investments [Domain] Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Unrealized gain on investment securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Number of anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Aggregate related fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amortization of premiums and accretion of discounts on investment securities, net Accretion (Amortization) of Discounts and Premiums, Investments Current assets: Assets, Current [Abstract] Thereafter Lessee Operating Lease Liability Payments Due after Year Four Lessee operating lease liability payments due after Year four. Inventory Inventory Disclosure [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Stock options Share-Based Payment Arrangement, Option [Member] Share-Based Payment Arrangement, Option [Member] Short-term lease cost Short-Term Lease, Cost Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Corporate Notes/Bonds Corporate Debt Securities [Member] FDIC Certificates of Deposit FDIC Certificates Of Deposit [Member] FDIC certificates of deposit. Work in process Inventory, Work in Process, Net of Reserves Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Quantitative Information About Operating Leases Schedule of Quantitative Information About Operating Leases [Table Text Block] Schedule of Quantitative Information About Operating Leases Expiration Date Trading Arrangement Expiration Date Cash flows (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities Less: Current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk (as a percent) Concentration Risk, Percentage Carrying value of cash held in commercial paper, government securities US Government Agencies Securities, at Carrying Value Michael I. Halstead Trading Arrangement, Aug 13 Plan [Member] Michael I. Halstead Trading Arrangement, Aug 13 Plan Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash paid Cash Options exercised, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Purchase Commitment Purchase Commitment [Member] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in share) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Product sales, net Product Product [Member] Aggregate fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Customer Three Customer Three [Member] Customer three. All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax Restricted cash Restricted Cash, Current Document Type Document Type Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Exercisable at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Time based RSU's vested, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Customer Two Customer Two [Member] Customer two. Accounts payable Accounts Payable, Current Investment Type [Axis] Investment Type [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Less: Present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease cost Lease, Cost Range [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Production campaign deposits Deposit Assets Name Outstanding Recovery, Individual Name Variable lease cost Variable Lease, Cost Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Carrying value of cash held in money market funds Money Market Funds, at Carrying Value Non-PEO NEO Non-PEO NEO [Member] Accrued and other current liabilities Accrued Liabilities and Other Liabilities Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Purchase Commitment, Excluding Long-Term Commitment [Line Items] Purchase Commitment, Excluding Long-Term Commitment [Line Items] Prefunded customer programs Prefunded Customer Program Prefunded Customer Program Accrued employee benefits Accrued Employee Benefits, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of operating segments Number of Operating Segments Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity Cash paid for taxes Income Taxes Paid Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Share-based compensation Total share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Other current assets Deposits Assets, Current Investment securities, available-for-sale Debt Securities, Available-for-Sale, Current Options canceled or expired, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Total revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Customer One Customer One [Member] Customer one. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total liabilities and stockholders’ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Purchase Commitment, Excluding Long-Term Purchase Commitment [Table] Purchase Commitment, Excluding Long-Term Purchase Commitment [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Company made an upfront payment Collaborative Agreement Upfront Payments Collaborative Agreement Upfront Payments Summary of Information Regarding RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Right of use assets under operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Exercise of stock options and issuances of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Name of Property [Domain] Name of Property [Domain] Inventory Less: Current portion Inventory, Net U.S. Government Agency Securities US Government Agencies Debt Securities [Member] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Other information Other Information [Abstract] Other information. Michael I. Halstead Trading Arrangement, Jan 2 Plan [Member] Michael I. Halstead Trading Arrangement, Jan 2 Plan Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Vested or expected to vest at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Investment securities, available for sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Schedule of Investment Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right of use assets, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding at beginning of period, Number of Shares (in shares) Outstanding at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Loss Per Share Earnings Per Share [Text Block] Accrued employee benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Operating expenses: Costs and Expenses [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Continuous unrealized losses, value remaining Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Name of Property [Axis] Name of Property [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant accounting policies. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Obliged to make milestone payments Collaborative Arrangement Amount Payable Collaborative arrangement amount payable. Unrecognized compensation costs related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Guarantor obligations, value Guarantor Obligations, Current Carrying Value Prepaid and Other Assets Other Assets Disclosure [Text Block] Total operating expenses Operating Expenses Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Sharon Mates, Ph.D [Member] Sharon Mates, Ph.D Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Stock issued for services Stock Issued During Period, Value, Issued for Services Common Stock Common Stock [Member] Measure: Measure [Axis] Asset Class [Domain] Asset Class [Domain] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Common shares issued (in shares) Stock Issued During Period, Shares, New Issues Options granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Entity Emerging Growth Company Entity Emerging Growth Company Liabilities measured using quoted prices Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Grant revenue Grant [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Inventory subject to supplemental regulatory procedures Inventory, Net, Subject To Supplemental Regulatory Procedures Inventory, Net, Subject To Supplemental Regulatory Procedures Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Michael I. Halstead [Member] Michael I. Halstead Exercisable at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Cost of product sales Cost Of Product Sales Cost of product sales. Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Investment Securities Investment [Text Block] Year ending December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net loss per common share: Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Inventoriable costs Inventoriable Costs [Member] InventoriableCostsMember. Accumulated deficit Retained Earnings (Accumulated Deficit) Accrued customer programs Increase Decrease In Accrued Customer Programs Increase decrease in accrued customer programs. Inventory Increase (Decrease) in Inventories Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liability Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Vehicle Lease Vehicles [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common shares issued Stock Issued During Period, Value, New Issues Total Prepaid Expense and Other Assets Entity Address, Postal Zip Code Entity Address, Postal Zip Code Share-Based Payment Arrangement, Expensed and Capitalized, Amount Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 105,998,786 and 96,379,811 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Certificates of Deposit Certificates of Deposit [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] License expiration period Collaborative Arrangement License Expiration Term Collaborative arrangement license expiration description. Commercial paper, at carrying value Commercial Paper, at Carrying Value Basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from sale of common stock, net Proceeds from Issuance of Common Stock Other assets Deposits Assets, Noncurrent Cash and Cash Equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Time Based Restricted Stock Units Time Based Restricted Stock Units R S U [Member] Time based restricted stock units. Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Restricted stock outstanding, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Time based RSU's granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Stock issued for services Issuance of Stock and Warrants for Services or Claims Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Year ending December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-Based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Royalty payment, percentage (as a percent) Royalty Payment Percentage Royalty Payment Percentage Stock issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Time based RSU's cancelled, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Weighted average number of common shares: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Term of long term lease Lessee, Operating Lease, Term of Contract Assets measured using quoted prices Available-for-sale investment securities Assets, Fair Value Disclosure Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Three months ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total Lessee, Operating Lease, Liability, to be Paid Outstanding at beginning of year, Number of Shares (in shares) Outstanding at end of year, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] NEW JERSEY NEW JERSEY Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Year ending December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Certificates of deposits Certificates of Deposit, at Carrying Value Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Less: Current portion Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Three Major Wholesalers Three Major Wholesalers [Member] Three Major Wholesalers Document Quarterly Report Document Quarterly Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Bristol-Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb company. Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Inventory, non-current Total inventory, non-current Inventory, Noncurrent RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] NEW YORK NEW YORK Purchases of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Revenue Benchmark Revenue Benchmark [Member] Accrued customer programs Accrued Customer Programs Current Accrued customer programs current. Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Total Inventory, Current And Noncurrent, Net Of Reserves Inventory, Current And Noncurrent, Net Of Reserves Company Selected Measure Name Company Selected Measure Name EX-101.PRE 11 itci-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2024
Oct. 28, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-36274  
Entity Registrant Name INTRA-CELLULAR THERAPIES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 36-4742850  
Entity Address, Address Line One 135 Route 202/206, Suite 6  
Entity Address, City or Town Bedminster  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07921  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Trading Symbol ITCI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   106,017,103
Entity Central Index Key 0001567514  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 464,312 $ 147,767
Investment securities, available-for-sale 542,250 350,174
Restricted cash 1,750 1,750
Accounts receivable, net 145,608 114,018
Inventory 23,539 11,647
Prepaid expenses and other current assets 94,272 42,443
Total current assets 1,271,731 667,799
Property and equipment, net 2,005 1,654
Right of use assets, net 14,011 12,928
Inventory, non-current 30,479 38,621
Other assets 6,219 7,293
Total assets 1,324,445 728,295
Current liabilities:    
Accounts payable 10,338 11,452
Accrued and other current liabilities 51,540 27,944
Accrued customer programs 70,536 53,173
Accrued employee benefits 29,496 27,364
Operating lease liabilities 4,203 3,612
Total current liabilities 166,113 123,545
Operating lease liabilities, non-current 13,506 13,326
Total liabilities 179,619 136,871
Stockholders’ equity:    
Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 105,998,786 and 96,379,811 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 11 10
Additional paid-in capital 2,818,137 2,208,470
Accumulated deficit (1,674,951) (1,617,160)
Accumulated comprehensive income 1,629 104
Total stockholders’ equity 1,144,826 591,424
Total liabilities and stockholders’ equity $ 1,324,445 $ 728,295
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 105,998,786 96,379,811
Common stock, shares outstanding (in shares) 105,998,786 96,379,811
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Total revenues, net $ 175,375 $ 126,173 $ 481,629 $ 332,271
Operating expenses:        
Cost of product sales 15,304 9,129 36,558 23,043
Selling, general and administrative 132,101 105,207 366,760 305,144
Research and development 66,819 41,550 165,835 129,368
Total operating expenses 214,224 155,886 569,153 457,555
Loss from operations (38,849) (29,713) (87,524) (125,284)
Interest income 12,899 5,498 30,523 14,377
Loss before provision for income taxes (25,950) (24,215) (57,001) (110,907)
Income tax expense (374) (43) (790) (188)
Net loss $ (26,324) $ (24,258) $ (57,791) $ (111,095)
Net loss per common share:        
Basic (in dollars per share) $ (0.25) $ (0.25) $ (0.57) $ (1.16)
Diluted (in dollars per share) $ (0.25) $ (0.25) $ (0.57) $ (1.16)
Weighted average number of common shares:        
Basic (in shares) 105,768,386 96,143,083 102,135,530 95,745,641
Diluted (in share) 105,768,386 96,143,083 102,135,530 95,745,641
Product sales, net        
Total revenues, net $ 175,159 $ 125,810 $ 481,278 $ 330,669
Grant revenue        
Total revenues, net $ 216 $ 363 $ 351 $ 1,602
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net loss $ (26,324) $ (24,258) $ (57,791) $ (111,095)
Other comprehensive gain:        
Unrealized gain on investment securities 2,297 933 1,525 2,855
Comprehensive loss $ (24,027) $ (23,325) $ (56,266) $ (108,240)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Beginning balance at Dec. 31, 2022 $ 656,070 $ 9 $ 2,137,737 $ (1,477,486) $ (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   849,827      
Exercise of stock options and issuances of restricted stock 3,640 $ 1 3,639    
Stock issued for services (in shares)   408      
Stock issued for services 22   22    
Share-based compensation 10,439   10,439    
Net loss (44,053)     (44,053)  
Other comprehensive gain (loss) 1,492       1,492
Ending balance (in shares) at Mar. 31, 2023   95,680,029      
Ending balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Beginning balance at Dec. 31, 2022 656,070 $ 9 2,137,737 (1,477,486) (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (111,095)        
Ending balance (in shares) at Sep. 30, 2023   96,225,617      
Ending balance at Sep. 30, 2023 600,681 $ 10 2,190,587 (1,588,581) (1,335)
Beginning balance (in shares) at Mar. 31, 2023   95,680,029      
Beginning balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   402,994      
Exercise of stock options and issuances of restricted stock 8,585   8,585    
Stock issued for services (in shares)   364      
Stock issued for services 23   23    
Share-based compensation 13,226   13,226    
Net loss (42,784)     (42,784)  
Other comprehensive gain (loss) 430       430
Ending balance (in shares) at Jun. 30, 2023   96,083,387      
Ending balance at Jun. 30, 2023 607,090 $ 10 2,173,671 (1,564,323) (2,268)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   141,780      
Exercise of stock options and issuances of restricted stock 2,581   2,581    
Stock issued for services (in shares)   450      
Stock issued for services 24   24    
Share-based compensation 14,311   14,311    
Net loss (24,258)     (24,258)  
Other comprehensive gain (loss) 933       933
Ending balance (in shares) at Sep. 30, 2023   96,225,617      
Ending balance at Sep. 30, 2023 600,681 $ 10 2,190,587 (1,588,581) (1,335)
Beginning balance (in shares) at Dec. 31, 2023   96,379,811      
Beginning balance at Dec. 31, 2023 591,424 $ 10 2,208,470 (1,617,160) 104
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   1,097,668      
Exercise of stock options and issuances of restricted stock 9,989   9,989    
Stock issued for services (in shares)   339      
Stock issued for services 23   23    
Share-based compensation 13,843   13,843    
Net loss (15,247)     (15,247)  
Other comprehensive gain (loss) (534)       (534)
Ending balance (in shares) at Mar. 31, 2024   97,477,818      
Ending balance at Mar. 31, 2024 599,498 $ 10 2,232,325 (1,632,407) (430)
Beginning balance (in shares) at Dec. 31, 2023   96,379,811      
Beginning balance at Dec. 31, 2023 591,424 $ 10 2,208,470 (1,617,160) 104
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (57,791)        
Ending balance (in shares) at Sep. 30, 2024   105,998,786      
Ending balance at Sep. 30, 2024 1,144,826 $ 11 2,818,137 (1,674,951) 1,629
Beginning balance (in shares) at Mar. 31, 2024   97,477,818      
Beginning balance at Mar. 31, 2024 599,498 $ 10 2,232,325 (1,632,407) (430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued (in shares)   7,876,713      
Common shares issued 543,086 $ 1 543,085    
Exercise of stock options and issuances of restricted stock (in shares)   270,026      
Exercise of stock options and issuances of restricted stock 2,093   2,093    
Stock issued for services (in shares)   345      
Stock issued for services 23   23    
Share-based compensation 16,370   16,370    
Net loss (16,220)     (16,220)  
Other comprehensive gain (loss) (238)       (238)
Ending balance (in shares) at Jun. 30, 2024   105,624,902      
Ending balance at Jun. 30, 2024 1,144,612 $ 11 2,793,896 (1,648,627) (668)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   373,638      
Exercise of stock options and issuances of restricted stock 6,734   6,734    
Stock issued for services (in shares)   246      
Stock issued for services 18   18    
Share-based compensation 17,489   17,489    
Net loss (26,324)     (26,324)  
Other comprehensive gain (loss) 2,297       2,297
Ending balance (in shares) at Sep. 30, 2024   105,998,786      
Ending balance at Sep. 30, 2024 $ 1,144,826 $ 11 $ 2,818,137 $ (1,674,951) $ 1,629
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows used in operating activities    
Net loss $ (57,791) $ (111,095)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 399 392
Share-based compensation 47,702 37,976
Stock issued for services 64 69
Amortization of premiums and accretion of discounts on investment securities, net (6,043) (5,861)
Changes in operating assets and liabilities:    
Accounts receivable, net (31,590) (27,481)
Inventory (3,750) (19,066)
Prepaid expenses and other assets (50,755) (16,805)
Accounts payable (1,114) 218
Accrued and other current liabilities 23,596 8,172
Accrued customer programs 17,363 9,997
Accrued employee benefits 2,132 2,452
Operating lease liabilities, net (312) (1,106)
Net cash used in operating activities (60,099) (122,138)
Cash flows (used in) provided by investing activities    
Purchases of investments (482,077) (310,805)
Maturities of investments 297,568 369,192
Purchases of property and equipment (749) (268)
Net cash (used in) provided by investing activities (185,258) 58,119
Cash flows provided by financing activities    
Proceeds from exercise of stock options 18,816 14,806
Proceeds from sale of common stock, net 543,086 0
Net cash provided by financing activities 561,902 14,806
Net increase (decrease) in cash, cash equivalents, and restricted cash 316,545 (49,213)
Cash, cash equivalents, and restricted cash at beginning of period 149,517 150,365
Cash, cash equivalents, and restricted cash at end of period 466,062 101,152
Non-cash investing and financing activities    
Right of use assets under operating leases 2,548 0
Supplemental cash flow information    
Cash paid for taxes $ 1,364 $ 0
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Dec. 31, 2022
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 464,312 $ 147,767 $ 99,402  
Restricted cash 1,750 1,750 1,750  
Total cash, cash equivalents and restricted cash $ 466,062 $ 149,517 $ 101,152 $ 150,365
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Organization
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.
In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.1 million.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Investment Securities
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Investment Securities Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$135,801 $158 $(13)$135,946 
FDIC Certificates of Deposit980 — — 980 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper51,637 63 (1)51,699 
Corporate Notes/Bonds315,499 1,453 (31)316,921 
$563,917 $1,674 $(45)$565,546 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2024 and December 31, 2023, the Company held $164.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. Accrued interest receivable from investment securities as of September 30, 2024 and December 31, 2023 was $3.7 million and $2.3 million, respectively, and are included within prepaid expenses and other current assets.
The aggregate related fair value of investments with unrealized losses as of September 30, 2024 was $66.2 million, which consisted of $30.5 million of U.S. government agency securities, $6.0 million of commercial paper, and $29.7 million of corporate notes/bonds. $1.0 million of the aggregate fair value of investments with unrealized losses as of September 30, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $65.2 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for more than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $225.1 million as of September 30, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $6.4 million, corporate bonds of $4.8 million, and U.S. government agency securities of $12.1 million as of September 30, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$225,099 $225,099 $— $— 
U.S. Government Agency Securities135,946 — 135,946 — 
FDIC Certificates of Deposit980 — 980 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper51,699 — 51,699 — 
Corporate Notes/Bonds316,921 — 316,921 — 
$790,645 $225,099 $565,546 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$30,479 $38,621 
Work in process13,048 4,277 
Finished goods10,491 7,370 
Total54,018 50,268 
Less: Current portion(23,539)(11,647)
Total inventory, non-current$30,479 $38,621 
As of September 30, 2024 and December 31, 2023, the Company has recorded $8.0 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but the Company believes it is probable that such inventory has future economic benefit.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid and Other Assets
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid and Other Assets Prepaid and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
September 30,
2024		December 31,
2023
Prepaid operating expenses$31,400 $19,465 
Production campaign deposits30,139 15,127 
Clinical trial advances33,389 11,630 
Prefunded customer programs5,563 3,514 
Total100,491 49,736 
Less: Current portion(94,272)(42,443)
Total other assets$6,219 $7,293 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Right of Use Assets and Lease Liabilities
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Right of Use Assets and Lease Liabilities Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, Leases, for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In May 2024, the Company entered into a long-term lease of office space in Bedminster, New Jersey. The lease has a term of 5.7 years ending in February 2030.
The Company has also entered into agreements (the “Vehicle Leases”) with providers (the “Lessors”) to acquire motor vehicles for certain employees. The Vehicle Leases provide for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the related Lessor may draw upon in the event the Company defaults on the related Vehicle Leases, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
Other information
Weighted average remaining lease term4.7 years5.3 years
Weighted average discount rate8.82 %9.07 %
The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands):
Nine Months Ended September 30,
20242023
Lease cost
Operating lease cost$3,027$2,921
Variable lease cost1,2541,130
Short-term lease cost1,8541,757
$6,135$5,808
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2024$1,112 
Year ending December 31, 20254,436 
Year ending December 31, 20264,513 
Year ending December 31, 20274,573 
Year ending December 31, 20284,707 
Thereafter2,457 
Total21,798 
Less: Present value discount(4,089)
Total operating lease liability17,709 
Less: Current portion(4,203)
Operating lease liabilities, non-current$13,506 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The manufacturing service agreements commit the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (“API”) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan set forth in their respective agreements. The Company has paid deposits of $30.1 million and $15.1 million as of September 30, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $30.1 million balance as of September 30, 2024, $24.0 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $6.1 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after September 30, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Inventoriable costs$497 $424 $1,405 $1,186 
Selling, general and administrative11,898 9,564 31,923 25,269 
Research and development5,094 4,323 14,374 11,521 
Total share-based compensation expense$17,489 $14,311 $47,702 $37,976 
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 202434,539
Options exercised 2024(933,601)
Options canceled or expired 2024(11,460)
Outstanding at September 30, 20243,329,460$30.74 5.2 years
Vested and expected to vest at September 30, 20243,329,460$30.74 
Exercisable at September 30, 20242,968,706$28.00 4.8 years
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 years
Time-based RSUs granted in 20241,100,255
Time-based RSUs vested in 2024(732,992)
Time-based RSUs cancelled in 2024(61,611)
Outstanding at September 30, 20241,950,782$60.35 1.2 years
As of September 30, 2024, there were $95.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023:
Three and Nine Months Ended September 30,
20242023
Stock options3,329,4604,385,555
RSUs2,175,2841,755,460
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net loss $ (26,324) $ (16,220) $ (15,247) $ (24,258) $ (42,784) $ (44,053) $ (57,791) $ (111,095)
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2024
shares
Sep. 30, 2024
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
•On August 13, 2024, Michael I. Halstead, President, adopted a Rule 10b5-1 Sales Plan having an end date of December 31, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 41,583 shares of our common stock upon the exercise of stock options. On August 13, 2024, Mr. Halstead adopted a subsequently commencing Rule 10b5-1 Sales Plan with a start date of January 2, 2025 and an end date of April 10, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 32,717 shares of our common stock upon the vesting of restricted stock units and (ii) an indeterminate number of shares of our common stock sufficient to cover Mr. Halstead’s tax liability upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions.
•On September 3, 2024, Sharon Mates, Ph.D., Chairman and Chief Executive Officer, adopted a Rule 10b5-1 Sales Plan having an end date of December 16, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 102,697 shares of our common stock upon the exercise of stock options.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Sharon Mates, Ph.D [Member]    
Trading Arrangements, by Individual    
Name Sharon Mates, Ph.D.  
Title Chairman and Chief Executive Officer,  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date September 3, 2024  
Expiration Date December 16, 2024  
Arrangement Duration 104 days  
Aggregate Available 102,697 102,697
Michael I. Halstead Trading Arrangement, Aug 13 Plan [Member] | Michael I. Halstead [Member]    
Trading Arrangements, by Individual    
Name Michael I. Halstead  
Title President  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date August 13, 2024,  
Expiration Date December 31, 2024  
Arrangement Duration 140 days  
Aggregate Available 41,583 41,583
Michael I. Halstead Trading Arrangement, Jan 2 Plan [Member] | Michael I. Halstead [Member]    
Trading Arrangements, by Individual    
Name Mr. Halstead  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date August 13, 2024  
Expiration Date April 10, 2025  
Arrangement Duration 98 days  
Aggregate Available 32,717 32,717
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers.
Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Investment Securities (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$135,801 $158 $(13)$135,946 
FDIC Certificates of Deposit980 — — 980 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper51,637 63 (1)51,699 
Corporate Notes/Bonds315,499 1,453 (31)316,921 
$563,917 $1,674 $(45)$565,546 
December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$150,651 $148 $(204)$150,595 
FDIC Certificates of Deposit4,410 2 (12)4,400 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper78,610 59 (27)78,642 
Corporate Notes/Bonds118,899 281 (143)119,037 
$412,570 $490 $(386)$412,674 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2024		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$225,099 $225,099 $— $— 
U.S. Government Agency Securities135,946 — 135,946 — 
FDIC Certificates of Deposit980 — 980 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper51,699 — 51,699 — 
Corporate Notes/Bonds316,921 — 316,921 — 
$790,645 $225,099 $565,546 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$10,698 $10,698 $— $— 
U.S. Government Agency Securities150,595 — 150,595 — 
FDIC Certificates of Deposit4,400 — 4,400 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper78,642 — 78,642 — 
Corporate Notes/Bonds119,037 — 119,037 — 
$423,372 $10,698 $412,674 $— 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$30,479 $38,621 
Work in process13,048 4,277 
Finished goods10,491 7,370 
Total54,018 50,268 
Less: Current portion(23,539)(11,647)
Total inventory, non-current$30,479 $38,621 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid and Other Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Assets
Prepaid expenses and other assets consist of the following (in thousands):
September 30,
2024		December 31,
2023
Prepaid operating expenses$31,400 $19,465 
Production campaign deposits30,139 15,127 
Clinical trial advances33,389 11,630 
Prefunded customer programs5,563 3,514 
Total100,491 49,736 
Less: Current portion(94,272)(42,443)
Total other assets$6,219 $7,293 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Right of Use Assets and Lease Liabilities (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Quantitative Information About Operating Leases
The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023:
September 30, 2024December 31, 2023
Other information
Weighted average remaining lease term4.7 years5.3 years
Weighted average discount rate8.82 %9.07 %
The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands):
Nine Months Ended September 30,
20242023
Lease cost
Operating lease cost$3,027$2,921
Variable lease cost1,2541,130
Short-term lease cost1,8541,757
$6,135$5,808
Schedule Of Maturity Analysis Under Lease Agreements
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2024$1,112 
Year ending December 31, 20254,436 
Year ending December 31, 20264,513 
Year ending December 31, 20274,573 
Year ending December 31, 20284,707 
Thereafter2,457 
Total21,798 
Less: Present value discount(4,089)
Total operating lease liability17,709 
Less: Current portion(4,203)
Operating lease liabilities, non-current$13,506 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Inventoriable costs$497 $424 $1,405 $1,186 
Selling, general and administrative11,898 9,564 31,923 25,269 
Research and development5,094 4,323 14,374 11,521 
Total share-based compensation expense$17,489 $14,311 $47,702 $37,976 
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20234,239,982$28.22 5.2 years
Options granted 202434,539
Options exercised 2024(933,601)
Options canceled or expired 2024(11,460)
Outstanding at September 30, 20243,329,460$30.74 5.2 years
Vested and expected to vest at September 30, 20243,329,460$30.74 
Exercisable at September 30, 20242,968,706$28.00 4.8 years
Summary of Information Regarding RSU Activity Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20231,645,130$48.92 1.0 years
Time-based RSUs granted in 20241,100,255
Time-based RSUs vested in 2024(732,992)
Time-based RSUs cancelled in 2024(61,611)
Outstanding at September 30, 20241,950,782$60.35 1.2 years
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share - (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023:
Three and Nine Months Ended September 30,
20242023
Stock options3,329,4604,385,555
RSUs2,175,2841,755,460
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Organization - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Apr. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Shares sold (in shares) 7,876,713    
Offering price (in dollars per share) $ 73.00    
Aggregate gross proceeds $ 575,000    
Proceeds from sale of common stock, net $ 543,100 $ 543,086 $ 0
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Additional Information (Detail) - segment
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Significant Accounting Policies [Line Items]    
Number of operating segments 1  
Revenue Benchmark | Customer Concentration Risk | Three Major Wholesalers    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 98.00%  
Revenue Benchmark | Customer Concentration Risk | Customer One    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 37.00% 36.00%
Revenue Benchmark | Customer Concentration Risk | Customer Two    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 33.00% 32.00%
Revenue Benchmark | Customer Concentration Risk | Customer Three    
Significant Accounting Policies [Line Items]    
Concentration risk (as a percent) 28.00% 29.00%
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Investment Securities - Summary of Investment Securities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 563,917 $ 412,570
Unrealized Gains 1,674 490
Unrealized (Losses) (45) (386)
Estimated Fair Value 565,546 412,674
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 135,801 150,651
Unrealized Gains 158 148
Unrealized (Losses) (13) (204)
Estimated Fair Value 135,946 150,595
FDIC Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 980 4,410
Unrealized Gains 0 2
Unrealized (Losses) 0 (12)
Estimated Fair Value 980 4,400
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 60,000 60,000
Unrealized Gains 0 0
Unrealized (Losses) 0 0
Estimated Fair Value 60,000 60,000
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 51,637 78,610
Unrealized Gains 63 59
Unrealized (Losses) (1) (27)
Estimated Fair Value 51,699 78,642
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 315,499 118,899
Unrealized Gains 1,453 281
Unrealized (Losses) (31) (143)
Estimated Fair Value $ 316,921 $ 119,037
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Investment Securities - Additional Information (Detail) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Investment securities, available for sale, noncurrent $ 164.0 $ 77.8
Aggregate related fair value of investments with unrealized losses 66.2 165.2
Aggregate fair value of investments with unrealized losses 1.0 70.1
Continuous unrealized losses, value remaining 65.2 95.1
Debt Securities    
Debt Securities, Available-for-Sale [Line Items]    
Accrued interest receivable 3.7 $ 2.3
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 30.5  
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 6.0  
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses $ 29.7  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Additional Information (Detail) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying value of cash held in money market funds $ 225,100,000 $ 10,700,000
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Commercial paper, at carrying value 6,400,000  
Corporate bonds ,at carrying value 4,800,000  
Carrying value of cash held in commercial paper, government securities 12,100,000 2,500,000
Certificates of deposits   60,000,000.0
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities measured using quoted prices 0 0
Assets measured using quoted prices $ 0 $ 0
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 0 $ 0
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 790,645,000 423,372,000
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 225,099,000 10,698,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 565,546,000 412,674,000
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 225,099,000 10,698,000
Fair Value, Measurements, Recurring | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 225,099,000 10,698,000
Fair Value, Measurements, Recurring | Money Market Funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Money Market Funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 135,946,000 150,595,000
Fair Value, Measurements, Recurring | U.S. Government Agency Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | U.S. Government Agency Securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 135,946,000 150,595,000
Fair Value, Measurements, Recurring | U.S. Government Agency Securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 980,000 4,400,000
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 980,000 4,400,000
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000,000 60,000,000
Fair Value, Measurements, Recurring | Certificates of Deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Certificates of Deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000,000 60,000,000
Fair Value, Measurements, Recurring | Certificates of Deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 51,699,000 78,642,000
Fair Value, Measurements, Recurring | Commercial Paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Commercial Paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 51,699,000 78,642,000
Fair Value, Measurements, Recurring | Commercial Paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 316,921,000 119,037,000
Fair Value, Measurements, Recurring | Corporate Notes/Bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Fair Value, Measurements, Recurring | Corporate Notes/Bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 316,921,000 119,037,000
Fair Value, Measurements, Recurring | Corporate Notes/Bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 0 $ 0
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 30,479 $ 38,621
Work in process 13,048 4,277
Finished goods 10,491 7,370
Total 54,018 50,268
Less: Current portion (23,539) (11,647)
Total inventory, non-current 30,479 38,621
Inventory subject to supplemental regulatory procedures $ 8,000 $ 7,700
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Prepaid and Other Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid operating expenses $ 31,400 $ 19,465
Production campaign deposits 30,139 15,127
Clinical trial advances 33,389 11,630
Prefunded customer programs 5,563 3,514
Total 100,491 49,736
Less: Current portion (94,272) (42,443)
Total other assets $ 6,219 $ 7,293
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Right of Use Assets and Lease Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
May 31, 2024
Sep. 30, 2018
Operating Leased Assets [Line Items]      
Term of long term lease 12 months    
Vehicle Lease      
Operating Leased Assets [Line Items]      
Guarantor obligations, value $ 1,750    
NEW YORK      
Operating Leased Assets [Line Items]      
Term of long term lease     14 years 3 months 18 days
NEW JERSEY      
Operating Leased Assets [Line Items]      
Term of long term lease   5 years 8 months 12 days  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Other information      
Weighted average remaining lease term (in years) 4 years 8 months 12 days   5 years 3 months 18 days
Weighted average discount rate (as a percent) 8.82%   9.07%
Lease cost      
Operating lease cost $ 3,027 $ 2,921  
Variable lease cost 1,254 1,130  
Short-term lease cost 1,854 1,757  
Total lease cost $ 6,135 $ 5,808  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Leases [Abstract]    
Three months ending December 31, 2024 $ 1,112  
Year ending December 31, 2025 4,436  
Year ending December 31, 2026 4,513  
Year ending December 31, 2027 4,573  
Year ending December 31, 2028 4,707  
Thereafter 2,457  
Total 21,798  
Less: Present value discount (4,089)  
Total operating lease liability 17,709  
Less: Current portion (4,203) $ (3,612)
Operating lease liabilities, non-current $ 13,506 $ 13,326
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 9 Months Ended 232 Months Ended
May 31, 2005
Sep. 30, 2024
Sep. 30, 2024
Dec. 31, 2023
Purchase Commitment        
Purchase Commitment, Excluding Long-Term Commitment [Line Items]        
Cash paid   $ 30,100 $ 30,100 $ 15,100
Other current assets   24,000 24,000 7,900
Other assets   6,100 6,100 $ 7,200
Product | Bristol-Myers Squibb Company        
Purchase Commitment, Excluding Long-Term Commitment [Line Items]        
Company made an upfront payment     10,800  
Payment of milestone amount   $ 5,000 $ 5,000  
Obliged to make milestone payments $ 14,750      
License expiration period   10 years    
Product | Bristol-Myers Squibb Company | Minimum        
Purchase Commitment, Excluding Long-Term Commitment [Line Items]        
Royalty payment, percentage (as a percent) 5.00%      
Product | Bristol-Myers Squibb Company | Maximum        
Purchase Commitment, Excluding Long-Term Commitment [Line Items]        
Royalty payment, percentage (as a percent) 9.00%      
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 17,489 $ 14,311 $ 47,702 $ 37,976
Inventoriable costs        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 497 424 1,405 1,186
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 11,898 9,564 31,923 25,269
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 5,094 $ 4,323 $ 14,374 $ 11,521
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Number of Shares    
Outstanding at beginning of period, Number of Shares (in shares) 4,239,982  
Options granted, Number of Shares (in shares) 34,539  
Options exercised, Number of Shares (in shares) (933,601)  
Options canceled or expired, Number of Shares (in shares) (11,460)  
Outstanding at end of period, Number of Shares (in shares) 3,329,460 4,239,982
Vested or expected to vest at end of period, Number of Shares (in shares) 3,329,460  
Exercisable at end of period, Number of Shares (in shares) 2,968,706  
Weighted- Average Exercise Price    
Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) $ 28.22  
Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) 30.74 $ 28.22
Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) 30.74  
Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) $ 28.00  
Outstanding at end of period, Weighted-Average Contractual Life (in years) 5 years 2 months 12 days 5 years 2 months 12 days
Exercisable at end of period, Weighted-Average Contractual Life (in years) 4 years 9 months 18 days  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Number of Shares    
Outstanding at beginning of year, Number of Shares (in shares) 1,645,130  
Time based RSU's granted, Number of Shares (in shares) 1,100,255  
Time based RSU's vested, Number of Shares (in shares) (732,992)  
Time based RSU's cancelled, Number of Shares (in shares) (61,611)  
Outstanding at end of year, Number of Shares (in shares) 1,950,782 1,645,130
Weighted-Average Grant Date Fair Value Per Share    
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 48.92  
Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 60.35 $ 48.92
Restricted stock outstanding, Weighted-Average Contractual Life (in years) 1 year 2 months 12 days 1 year
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Share-Based Compensation - Additional Information (Detail)
$ in Millions
Sep. 30, 2024
USD ($)
Time Based Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation costs related to unvested RSUs $ 95.5
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 3,329,460 4,385,555 3,329,460 4,385,555
RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 2,175,284 1,755,460 2,175,284 1,755,460
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

:2",4+MR9^\9+[5H[7)B][E\+PTTB>WCFC- ;P7@^P6=@THC&M @ =@< !@ !X;"]W;W)KI>EP"&/%1T4>9LW5!#LU3)+5$V&MGL MP.7&H=$-$_84YT;A6X8XDTVE*/!,H" XTI*S@AJ<7%-.10YD;HDU.9M1!<*4 M8%A.^3GY2-X3G^@25W7J&]1AV?R\W?.ZV3,ZL><4DYG4S%7:SZN%-@KK M[=E2>C:E%*QOUC1UD:S>E1[0S[8$Q4.!X'[/9+_FL@# M!X/.P>#M#IC6ZY?5#YYJ"@;C\6@X2AZI?QHY3N+A>!2>2'_2B4_>+AYO#6VH M*)A8O>0@>;6#IY$G'/A[7='>2%^I6C&A"8$#E4T^6;B9&U:Y0+:;#M MNF&)%R,H&X#OEU*:W<3VWNZJS?X!4$L#!!0 ( *T^7EE&XM4L\P4 *X< M 8 >&PO=V]R:W-H965T&ULK5EM;]LV$/XKA%<,+=#& M(BGJ)7,,-):[%5BWH&G7SXS%V$(ET1-I)_OWHR1;LJF3ZFSZ$DO*'!]\3M8; M73Z8SF=;OA;W0G_=WA7F;MJPQ$DFH ME/(@Y??RYF-\,W'*-Q*I6.F2@IN?O5B(-"V9S'O\?2"=-&.6AJ?71_8/E7@C MYH$KL9#IMR36FYM),$&Q>.2[5'^63[^)@R!6\JUDJJJ_Z*G&^G2"5CNE978P M-F^0)7G]RY\/CC@Q,#RP 3D8$-O [3&@!P-ZZ0CNP<"]= 1V,*BD3VOME>,B MKOE\5L@G5)1HPU9>5-ZOK(V_DKQ,E'M=F/\FQD[/%S*/3=A%C,R5DFD2H:_W$7K]Z@UZA9()YK&93;=ZFY)RN M#B/?UB.3GI$I^B1SO5%H:=X@!NRC8?MPP'YJO-"X@AQ=<4L&">_%]@I1YRTB M#G&!]UE<;DXA.?]O].5_'OW,&;3)"UKQN3U\7Z3FJ:D$>Y'OA'J+PY9=&*6$^+B!G2EV&\5N M94=[%!^2/%\C\;PMIX2ZAA2[0VXKR_JUVO*5N)F8NJU$L1>3^<\_8<_Y!02I=E9UO(>+?22/%4@ 6FIF&G:<6HXUK)UT6% MV,ZIJ NB'F.!E7E=%#'C43CQO$:N-RCWWGPE3=J]16N1FQ1,D:FGB,>FV"=* MERFY%Y!XKRN>$NQ@2ST FYJ3RFWY\8%D^YTW\+P 6^%<=%$N9LQ2$W51V&,!M:K7$H"1D'H! M+#IH1 <75%C9J3J0Z*";=]@EQ,[T+LR(#@+/DMV%,2\T,\>2W86YS&>,P;+# M1G8X*/MWJ11Z+&1VE&ZZ"DARV!G]'0T"UPXT ".AC^TO"P +?&8[< G ,&$D MZ,EO[+1=EC.H^F.NA2F4VO1,*YF!\_G <)YF06@+!F#,#:U"%0$H,U&)'6)H M3)?Z?H_\:C6F1*&3)ASDR6JPTO!-@ZXE%[QU'9HE'9EF.QG8>E[1_Q M< -YRU6R0J_-^C26:G*R[2;Q<#L9)>FN7,*_0+YWF?R+8!$,Z\H'8 /RVU82^X-3\ENU-63T\[UI M+]8"Y;OLP<@WZXG3"0HO[O!@G_KB&3HF6S0JVW(LMO,HM;TO'FY^VQE:1P/. M2Z"?=9CO!=1N:1< -/1,*^,$G:\C1$HP96;E:*#1#.5>^*=9%?3A6WVBYK4Y_'J36 M,JLN-X+'HB@!YO^/4NKC33E 61,HO1XU P M9 L !@ !X;"]W;W)K6 MHP."'!*E&6)\K6$,>:Z),(R?-:?5N-3 W?&6_5V9.^;R$$L8\_PK354VLGH6 M26$>KW)UQS?OH M#?#:@,X!@%\#_.=ZZ-2 SG,]!#6@3-VNTS16.)DI?*$$,O(YXRL9LU0.;851:6X[J2.XJB+P#D3@DQO.5";)%"-) M#?C)<7S_"-[&:C0E\;8EN?*.$LY@>4%\YPWQ'*]CB&?\?+AO2N?_O$__V?M> M,?Q&'W[)YQ_BVPKAJ0ZN6<(+(-\N'Z02>."_F_:^8N^8V?5/<""7<0(C"XDE MB#58T6OD&&)U%?& M.CKW0E\+:[U;6)-9QPMZ^V83@UG0[?;=?;.IP09-GL%1*7Y2 M&0B2[&EP@3?AP)1X<$K=G9)LX:-24Y_XW6AMX'@ MM4_9&J0J?Q<2DI6@BH)1EQ5SL",1S^MW6ZI\:M3W_98DG]JX@1>T!&GPU@L. MJ+';9-\]FOW^O_#0^>N:#I;CM3,UF?E^.X^)P2P(O3!LI6LP^FUE;.^T M#06(1=FO23QA*Z:J&Z)9;5K"R[(3:JU?N8.Q:UB?8 M9=7Q_Z:O^\R86"\HD MR6&.KIR++FZ.J'JZ:J+XLFQ:'KC"%J@<9M@&@] &^'W.N=I.M(.FL8[^ %!+ M P04 " "M/EY9"2TP5&L- ! BP & 'AL+W=OW5VVW5WWUQ<;&>WS:K>?MW>-6OSEW?M9E5WYNOFYF)[MVGJ^:[2:GG!TE1> MK.K%^NSZ[-YOKR_:^6R[6S9M-LKU?K>K-']\UR_;AZBP[^_B+GQ8WMUW_ MBXOKR[OZIGG;=+_\K[$K\>]$\ M; \^)_VI_-JV[_LO/\ROSM+^B)IE,^MZB-K\^-!,FN6R1S+'\=L>].R)LZ]X M^/DCNMZ=O#F97^MM,VF7_UG,N]NKL_(LF3?OZOME]U/[\'VS/Z&\QYNUR^WN M_^1A7S8]2V;WVZY=[2N;(U@MUH\_Z]_W#7%0(>-'*K!]!3:T M]7X%X%5ARI M(/85A%_AV#GD^PJY5T$2N[1\;:]?2T[JKKR\W[4.RZ4L;M/[#3JY= M;=/ BW7?L]YV&_/7A:G774_:]=STDV:>F$_;=KF8UYWY\K8S/TP'ZK9)^\Y\ M:V?O;]OEO-EL_Y*HW^X7W1_)>?++VVGRY1=?)5\DBW7R\VU[OZW7\^WE16>. MJT>_F.V/X;O'8V!'CN'GMJN71+5)O-JD7:U,W]P='%%[&J_][7R^Z/MVO4S> MU(OYN3F%27VWH(]$G<":S>Y7]\M=RTV;=XO9HB- ]' 0]*<[9C$$:;OFIO%>KU8WY@QN:S7,\-@SGY[ M6V\:0U-WYAQF7R<\^VO"4L8H/:/X_63XS?:NGC579^8LMLWF0W-V_><_93+] M&Z7R(UB^ ^LGP@_7E2A9553B\N+#H:!(5H4$TR P1TW^I"8?J>80!1\QY4&C MRURF1>HV^20L5GFBA"58QHN"%VXY%98[ST11B%*Z!3514&25/3"GD<13(XE= M-7ZDDGIIF5VG[[J)RUR8OOO3^URF9CKUD.]F?^/:CR![/Y(L"D2 M3"'!- C,43]_4C^/#A'U>[.9+8SZYEJV[25/VKM^[M\FYH*5++;;^W[<["YU MAKS;+&;])/Q8\F!JI+I"E'AL5\B#F; 45A*CB0O1#Y;P/F>>)6?7?F4B@[B7+7ASRRK)'=/JJJ/R)*LX[ M6ALDFH*BZ5/MX2IC+84L[BFH]3QB*/Q8;Y["44ZJ!'44,L)2R&69ILR/7J&\ M"HJF46BNHM96R.*^@J?H(!5YT.Z2%3+SE\U9&./[9:8$%LORK R,!:+@>9:; MLO[U2%,EF:S*(WW?>@M9-'@%^&EQ@M'=7PQUU*"\"HJF46BNJ-8RR.*>P?-L MM2P,X4E?;5\N9JP14+2S1A0\8JU1)8][:YF-O#/YBNY:A@R')U"T*11-0=$T M"LWM!#;TS^*Q?W2)'(;DYUF6I57NCPMD*#V%HBDHFD:AN6K90#^+1_KQ]=K; MYL[,554#2-0G,5M8Y!%K<,PO7::17#.%ZF MJ2PS?U16 ]9K(18SEY:\#"Y784&S7BO+W*?59$G.<_IRQ6PPS^+!_,GUVLF% M;IQ@] W0,/@^$JY >1443:/07%&M-<#BU@"Y7CLM9!@-DQ'+OEQT!!!8=,1" M%#P2L5 ECT9J;2T*%K@PF.NWOYB/']/HD3R$4T$Y M-0K-5;J89T*=B)+8<3-518Z%QEG3/J*0'V+8:0*2JI1 M:*XHUI!@<4,B9A^QT!\X%ZPHA:\"--\ BJ8&GH-&L;HR6!>!Q5V$9]QA96&8 M+G@00$'S#Z!H"HJF3S2'F^-K/0L>]RSB?MW?[]=QIR>./G9!P G#0J8EY[[9 M,X7R*BB:1J&YBEK#@L<-B]"O.ZTBX5:D15H%6=L#W H"BV4%EX7GPBFBX'F6 M2\']18*F2IJKUA&W@ENW@K^F6\&A;@44;0I%4U TC4)S.\'!4PZ?S:V(,X_N M$:%;D8FL*(,!"'4KH&@:A>9J;=T*_JIN!0^= Q;<;9C$CVGT2!["J:"<&H7F MJF;="OZ)W(HX[NCQ%[H5(@\&']2M@*)I%)HKHW4K.-"MX(1WX$=E<;[1 ^LT MHX(R:A2:JX=U*SC.K>"$<2!X%DQU4+=B&*F"DFH4FBN*=2OX\]T*3D3Z3)C9 MWU2AQ]] .VE%M!9A=!>1443:/07$6M6R'&NA6G5:3<"B*[2 QP*P@L M.KN(*'@DNX@L>32[2%BW0@!W5Z ;#NI0".)A",F+JO2OT%,HKX*B:12:*ZIU M'\0+-UF@A0RM@+S*1+!"%@.>AR"P&$M+X:>6*Z+@>6;F.M,6_@@@G(I4'.G_ M!SLMB%=TZP0R0IY T:90- 5%TR@TMQ-8+T!\MAT7XLRC>T3H%F1I54CI/S . MI550-(U"<\6VCH%XU9T71!CA5U7I/\\4=K ]V^ 8JF3[6'JXPU+7+4 M]@V"5 GJ6.2$8U&(HB@S?U$.Y550-(U"9Y(SD0:3%U'R:&9=;OV*/)YL\'*_+DXPNO>'F0-'_#HH MKX*B:12:*^K!AH\OW+V!%C(T TB_+@]W;P@' +%] ^G7$06/^'5$R:-^76ZC M]_PU-V_(H9LW0-&F4#0%1=,H-+<36#,@?_[F#3FQ>4->%)5_'R=.,5HL:,@/ M1=,H-%1F)O$76)-]N>A^]$>@@FD.Z@:@T-QVMFZ _&S9"''FT8.*, V*-/67=%,H MJX*B:12:J_7!6R!>]S40Q.,&:>7?H8L?T^CKWA!.!>74*#17->L_R$^4C!#' M'3W^B&0$D?N##^I,0-$T"LV5T3H3$IB,( Y\'.Q7'&T8H,(E504HU"0P%/1BBH#0ZX;S?$>4=K TU&@*+I4^WA*F,=CN(ER0B'NV20 MME R2H B3$;(TETQ4J?<2D2F46$'1- K-E=3Z%<78;(33,A)/)V1"R,Q_ M=TM!I"/X82\!QHJ*EY6_IQ91T$Q>HI3^6_@T55(>V^RDL)Y (5[1WBN@J0E0 MM"D434'1- K-[036L"@^FV$19Q[=(XBM(0LN_6OB%,JJH&@:A>9J;0V+XE4- MBR(T#V01)$S&CVGT2!["J:"<&H7FJG;PHLM/]:9+[*LN0\.""=\MA%(J*)I& MH;DR6L.B !H6!9'J$"S^H8;% $8%9=0H-%-DTWK;OZ M^O*NOFE^K#-.E]LM-Z>+I>JV+":JC=BRQKX92UD337J:RH=WK!)WYPN\>'SPA=]LM'FP M7)UMZ0V[8OKK]E+"W;+74O*:-8J+!DFV/E^\Q:<786P66(D_.;M3>]?(F'(M MQ#=S\[$\7P0&$:M8H8T*"O]NV06K*J,)<'SOE"[Z=YJ%^]>/VC]8X\&8:ZK8 MA:C^XJ7>G"^R!2K9FNXJ_47<_<8Z@RS 0E3*_D5WG6RP0,5.:5%WBP%!S9OV M/[WO'+&W /2X%Y!N 1DOB&86A-V"T!K:(K-FO:>:KLZDN$/22(,V# M-;PQ8;S2$G[EL$ZO+D130E!8B>!*B8J75,/-E89_$"VMD%BC"ZHVZ -$7*$3 M]/7J/7KYXA5Z@7B#_MB(G:)-J_.[]LUDYLTY^B0:O5'H5T!0 M'JY?@A6]*>31E'?$J_"*;=^@,'B-2$ B!YZ+YR\//7#"WK.AU1?.>=8X;6V= MMC/^!6]!\4FJ>7/39B_7G#D=URJ.W(I-89^J+2W8^0(J5S%YRQ:KGW_"2?"+ MR^HC*3OP0=3[(/)I7WV&/E0)Y32R79G8E:;9W*Y.XC3-\=GR=A^^0PQC'.1Q M+W> +.Z1Q=[HO"W_AN)J,UP+:$B%: I>,=1TD,U3.HR+CYF!(^D M[,!/2>^GQ!O!]PR4%IR:GNLRM%T=[X4GS/-1"%TRQ!V^M(>5>F%=;:AD)Z9_ MEZ@0-9":FH683EX?I6E 1B"G4F&:IXD;9M;#S/PPM2B^(:[4#G "YR(3'EZX MJSZ;($BB$4B'2.Y&F/<(#@> "?Q_> MT.:&J5'Y*L5T:V3%Z36OYDNY4W^D6CZ6MD-G[+$]]H>[Z&((1CN+GD2!IE@'.(X3Q(9@H; M#^R.O<2YNI1L2WF)V+UI/JS-):$W3';)Y00=.G(\2.-XC-HAAY,LF"$]// Q M]A-R'_\M?3#!=X*,'"_'>-R+'&($9S, !UK&7C8S *5IEH,WH;M(TV?VZM2) M.I["">,\&:.>BF4XG6$C/+ D]M/D(^QV8@?46REN)*W=4*>$B-,P&?=#AUB> MY^D,U($YL9\Z'Z&R>EN)!\;0-6O8FL\D[)06"0['W.F2BN(YIP[DB?WL^7O? MKBL&3+^? ?--:TJ1T+0F@!U2,%3.-86!3+&?33\_9V!TPG929# 9I5QRF$!( M9@J/##1)GJ#)8;ORLD/_RF3Q+8?=&;I^Z"C_:5/(4?GR6-H.O3+P)?'SY>5. M%AMJVCM,0,/0XS;281N-*<4F1 M9*Y,!@(E3^]H;87_SR)Q<6P6DWCB_*E@G&$\,_63@6>)?_^[5^[[^->\H; / M?AK_43>XQ])VZ(N!O(F?O"^E*!@K%5I+4<- QV3!@6X@*97=OXFMV0.Y_>"@ M\BS#XZG#)19EU]$_RGUIMP=)S#2CSG>(>?S^<#QY&F.YPULC,U(\K)D[=4KP_;& MIM>M9::#W4(\H/>^MBT-$E=+7IB/JT; :=F4W$.86.(:'LT-_,M,_1.)S\_<:>'BIDOXBT MQTS]T_Z$\JT]EQL]?X=/+]ISQD%->^SYB4KHB0HR;@TJ@SV@>[?[]H)$864H:HOQ';. M.;[WW(N=_IJ+)YD!*/)2Y*4<6)E2U95MRR2#@LH+7D&);^9<%%3A5"QL60F@ MJ2$5N>TY3F07E)56W#=K$Q'W^5+EK(2)(')9%%3\O8&6:VT6[MDB4WK! MCOL57< 4U&,U$3BS6Y64%5!*QDLB8#ZPKMVK<:CQ!O"3P5INC8G.9,;YDYY\ M3P>6HP."'!*E%2@^5C"$/-="&,9SHVFU6VKB]GBC?FMRQUQF5,*0Y[]8JK*! M]=4B*)%0\8("E;63_K2^+!%<(,W M"%Y#\(XE^ W!/Y80-(3@6$+8$$SJ=IV[,6Y$%8W[@J^)T&A4TP/COF&C7ZS4 M?3)5 M\RY*EXR,L4JPXIP9'D.4NIPLE4X0/;04G"YV1(949NL:4D.9U0@-+2D][*2)Y*:.Q'LCDBE4%\1W MSHGG>$$'?7B8/H($Z:ZA^QWTT?&[=]''Q^_NO:;;6)&V+%Y;%L_H^6^%L_%_ MQ_[?US.I!/Z[_G097&L&W9KZQ+F2%4U@8.&1(D&LP(H_?W(CYUN7W1\I-OI( ML?$'B;TJC-\6QC^D'IM:8(.31 _@>#LB(T/AO]. S[HLJ07" M[5Q[H;-CR#&@T3&@\<%XW^E&V+H1'G3C@2N:&R/.][K%M)#XOUUA1P=%3K3; M0?LP-[@,W=T.ZH YKAONME '+'3\*&QAM1WVUJVCORE^4+%@I20YS)'H7/10 M1]3W=#U1O#(7T8PKO-;,,,-/&Q :@._GG*O-1-]M[<=2_ ]02P,$% @ MK3Y>62NF.O? ! + L !@ !X;"]W;W)K D"U9@W8RFW5 ,^T"+UQ)1BM1(*J[[ZW;YV_E.HB*+X7!L;+K(JQN;U:!2*BFH9AJXABY65 M\[6,&/IR%!I/4B6CVHSR\?CYJ);:9K/S-+?PLW/71J,M+;P(;5U+O[DDX]87 MV23;3KS3915Y8C0[;V1)MQ0_- N/T6B'HG1--FAGA:?513:?O+Z<\OZTX7=- MZW#O6["2I7.?>/!&761C)D2&BL@($G]W=$7&,!!H_-UC9KLCV?#^]Q;])FF' MEJ4,=.7,'UK%ZB)[F0E%*]F:^,ZM?Z9>SRGC%>+='9187LLH9^?>K87GW4#CCR0U68.R2/D#<25L\$9K627$%:)A:= -G83;B5N MM)6VT-*(6TP2LB\&\>=\&:)'_OQUR$,=@>EA EQ3KT,C"[K(&C[+WU$V>_ID M\GQ\]H"\Z4[>]"'T?XW>XZW%&PN)S[@\6B.]>%^1EXVF,,!*,11'L2+Q],G+ M/!^?7;FZD7:31I.SXX&(E7=M60D-9ZTK9\SFF5M;4@*]PP/>EBCZ9=!*H^X! M^/[-%K5'Q,P>30&5=VM'1PGF&& M4"^NJ:!Z21ZI/GF%W)PO?OGX?H[4>#$]$T>F1<DX/@"K1Z_07^ M]F2U9!E2H:D%<33-15V.E-PJD;QYFJB LK71+_._-''CR$YY5FGR.-D(C@,4=: M&):7#W8R=M+BVG%B]19"N8#[3R!N9$ONIGL& S$9#T\A):G()_Q5R"8@2U&9 MT0E&U(JV&)Z2'MNUN) $-/A.?:QP%JLZ2AN1K5%^2H49D6*EP+[:*:Y6..KC MXF0^A8I*+W5T'B=]?_K7T&L=JST 5@)*T).HB+<40L/UVBJ+W^7S'=H 6S:$!3X.VM#2T+T#4WQHW /]_I>D@'6VY#79Y MMJ0-'/J-)&9TH%@.W7NC>R\8A+],[S3.V-;&[C&SF]T]!>?="VB_O7M'HM64 M&I0,K6 Z'KXXS83OWF;=(+HFO8>6+N)UE3XK/&?)\P:LKQR2I!_P ;L'\NP? M4$L#!!0 ( *T^7EE!PKN6?0< ,,1 9 >&PO=V]R:W-H965T<'6^=_Y3J(BB^M+4-ER, MJAC;-]-I*"IJ=)BXEBS>;)QO=,2MWTY#ZTF78M34T_EL]G+::&-'E^?R[,9? MGKLNUL;2C5>A:QKM[ZZH=ON+TTHKB;7OC<3<=O)2F M(1N,L\K3YF*T/'ES=W#P;7B2-;.?>*;#^7%:,: J*8BL@>-?SNZ MIKIF1X#Q.?L<#5NRX>%U[_V]Q(Y8UCK0M:M_,V6L+D9G(U721G=U_.CV_Z < MSPOV5[@ZR%^U3VM/%R-5="&Z)AL#06-L^J^_Y#P<&)S-'C&89X.YX$X;".,+"56L KPUL(N7JU0,Y39J9;;6;$RA;53+HG"= MC<9NU8VK36$HG$\C]F.K:9%]7R7?\T=\OU8_.1NKH'ZP)94/[:? .8"=]V"O MYD\Z7%$[48O96,UG\],G_"V&X!?B;_&(OR-1JO\LUR%ZD.6_QP)._DZ/^^,& M>A-:7=#%"!T2R.]H=/GM-R>C./M@ M48GGW+)=K3V[\[K%=F.\*29*VU(9K-Q7KJX!)$G6U#V$4A9Q];1*=VVR*%> MUZ2V'?(AJX)JB%.-]V++%[RW[F+EO.'T[KY&PMNJ !E'= @KHSTH%M;94OLR MJ&M72C&E2#WLY>JZ1RV9/6IYVW+%#FQN!QMD@C=\/]3RJ(,KAW^#_?OEZNH@ M574-V)%\9DQ?FB!X0 4;M&AY."@MU0:RJ.-0W$PK+)L( :^SLZ+SJ$%DHK0H M+:<,!LY2OF><@;9,OHGZY>M'P.")Y=XPR710C!'&F:D:0!@Y&(3BZC7&'VAI MB@KV8![GK#2A\!29 VF6D$0T M#[/%_$\B]=TVS56JQ0(_+;H)_;W MW:\ 7JCYV>S[-^I#TWKV)JZ1YK1,RMA;OD/@M0L=$J_&2/_GSGA)>+=&QS-? M3#1)!,JT]"$W$HL TGA8#^Y[0G+?G+QZJ\*!--.7EN4UE];]TK52!YAA6D!@'K8'0-]+"NUTW:5NY;!; MJ#M2B! ,%A=<1:EEPGUUD]!;T@1+] M$"*ZA]6-P:;!E_B$ET<]'IF),DMRP4+N=RDWBLLBI&C8)8M)U[1)("12+=5, M(ZM)$I[*<#]&'PWNP8%!QB1/!LR];LO#.B9B!)RZ.5U=S6G8\(S<>-? -;?1 M &]\"+YTP N/($!M($0):^B@4\D%CVAP7IRN2;$'#X23/SW^] >=_AS1/^_X MJ+-.K3#P)E6Z/3PHH30]7>_ST@?)+<:\,(%)E0J4PLP^4E)_1JK4O#\I_#F1 M<-2IN_*^(!E?EI6 @XOT8!(VYB=_!:F3V?-_#8/J#IT"K6 G0R,N4B\M)G!H M69+OV7<->3!05!,^'1P3C,5YNTN8TM 8N@>-A>/<[SV5^@PBQ.+0MTS@(CGW M[#QG2P9S?X3P &AVK%UC]&!,;$D?6)@?:1KI4(WEKV+JHZ4'4AJ[ Z>$18'0 M]DD=*P)10*'-@V!,[ 35A#,FP*$U]+SA;Z&L03EI*SY8IJSECYJQ>GWVC'%C MNI0=X@Z:3Z-[<#,?2:6>B>F>F*._B]:5B 1"QD=A8ALO&LLK\,[L3,FU/ @W MI8625$*OO?LB'8.4+UX]&ZO%XEF2TCGP:$8 I<+_Q4M^.>]?OCX"=O-8U.'1 ML),SD6]0NDV3H+Y#XTMMC^7ID!"H-_JN2[/T_YO[(&PO&EGA4[TGS&^T*8'']9PL)6?#T1V;$S?V,/3X1>*9?HPOU^>?M[X27M,G:!JVL!T-GGU M8@2RRD\&Z2:Z5C[3URX"K5Q6I'&XX05XOW%HBWS#&PR_VUS^ 5!+ P04 M" "M/EY9X>;7E70% O#P &0 'AL+W=O[5[-+V1C.!-PKHINJHFIS URN MKP;A8$OXS):EL831[+*F2W@ \Z6^5W@:]5H*5H'03 JB8'$UN XO;A++[QC^ M9+#6>\_$1C*7\JL]?"RN!H%U"#CDQFJ@^+>"6^#<*D(WOG4Z![U)*[C_O-7^ MWL6.L*R;:?_J]PV%/8!(<$8@Z@72JZ)LMRHS3ZX4)TT.L>$ M3Y&3OZ_GVBBLE7\.@=#:2 [;L/USH6N:P]4 &T2#6L%@]OI5F 5O M3T20]!$DI[3_?*9.JCGLY$'=9(^J=]1<8D=J P61"V)*( O)L;696))S)I B M&XW8ZN$%ZJH-5'-0?2;)=2658?^B]!>!0X0_?7RG#<->LT3_P2A_&P(T^3C+R_^WA+;@$-+EB.2K5U^0YJJ9DA MTTE 7K^:1&'TMO^WM&/\6> %P7.1CGPKJPI4SB@G][3&B-/0R^(QR6)T:NA. MTRERJ5HJU$Q^EZA^=",1*!*'J9?@V]!+4F2/D3\.,V\:V<#2+/:FX=A&Y67C MQ :9I$/W(O52#/(.\@[CT&$!EJ<,X<1A'03+LZ.DT/0URXB5A0"+$ M(!K:0_!B^(XG7H:JTRDZ-!ZZ8Q(= 3@,)]X$ 8XF(7J28(V$X=0+8HMJ$D9> M.@[LT]3^GL>3;-C1+=Y_8(6C\9J*#2DIEC^G6J/_B![EW ; C";L8*L@.UU1 MQNF A<\Z;PC8,-HL&G/BFQ)ENMF)SV*#;1 H@&Z#*LWI0I[+: MT3B@/2E$,QQ]!1'6 M*FP[^4@4Z,L< %.0NSQ ]P.W+N%CV*G8W'_F1+\?#K0=?@]C_?>-;: M\[0<"*["? M2PC3%OB?=J>D*ULW)QS:6=XZA CGN6HP)4P83(TVZ$ .;-4F1\GJ>/G^C\20 M-?*?Q?[X<2(B/SZ6!_O>%DW;#^B?!0B+!/=23;$XX7MMB[NM0(DXJ2=MX+ON MI,NE@J7M>07NLG?!=>EL=J.02ZU/1>IBRC(_VL6P+EE>/MZ" M9W'@IWW82'!S=;F;J[2=JSML/=2Z5[(HDN\&7&T'G-?!-]T#U+%M!YQP VYN M!YR/+?!8FWF$R\OA82?@'$"TC8>YHJX6F6APZS]51-Q@MQ[9"6#1("$"Z3X4 MGW6#+>NS+-TA_0LF=K7?V]F.ER-SY 5JQY5(N.\YIF,<^.&+Y^-YRY6T^-5T M[ ;7#W(R3?=">:&<'/H<'NU=8K 3ENZJ9C\W&V':^TQ/[6^#U^TE:,?>7B4_ M4;5DPL["!8H&_C@=$-5>S]J#D;6[$LVEP0N6>RSQ1@O*,N#[A<3FZ@[60']' MGOT'4$L#!!0 ( *T^7EF[O*;]>@8 !H2 9 >&PO=V]R:W-H965T MRW>^2_N-0\^\F5N\4'_XJRD2W;/[.?R3L.NWUK)>,&D MX4H2S1;GO=G!L$?2REA5U,J H.#2_Z??:AXZ"I-HCT)2*R0.MW?D4%Y32R_. MM%H1C=)@#16:?*&B8N2645-I!HQ;<]:W8!Q% M^FEMZ,H;2O88FI);)6UNR,\R8]FV?A] M'K/^;U!PT]#+,/=;)IYR1F2I**M>$EJ7@P)&%9PN4 M?W+R!;.YRD@%B=;D\GY&/JF2IV220++VF:4RVZ(]=(ZVE$G.F:8ZS==$4_G@ MW3Y65'"[=OJ:"4[GW.W5@G!95M8$1&E"#0R5$ML<]I5A&1PZ]8Q9IJ%MJ!L! MH-0)PYM\K#CB 0NLAMDXP=]*,O3F MB%,")A^72S!FV5)IM(N#) ,I)P''S%@BV!,3/BH?@\W!+3?$\*4$/RF5%EU3 M4E)M>5H)JK?3TO)]0MZ^F23)^)3\YHS&N(V3TYN---AMR %7\S6X1(R5I-E7 M&#OP[+%2^*_4/'4U &"H!MJ>*!=T+AC&Z84R3/>0"=YU:^1PS:@4K=LA22CTQ0ZXJJ!4J%42U::$7#VII'_NI: MUS51B #9*U3&!+2'J=(<$( T,(QUI\&^![/F3&1PZ\" J%E$=UCJ2FLU5]HA MF7<9K(&2#"Z?W(RY*$NM M@&* 1GSGH$W?IC@15"5Q=*06\N&*0 @.(R=S,\T8E7(7U(I;2 I9 C!)#(,4 M@$"X-8QSBF0TM0.FNJ7C^%M!/ILID-4]4]>?L]\E8XOGFK6?ZK3MJ<]W6#7 M-%S,EA5S**WF=O;3G:7UT]@]'7CX.$'7B,07 .BGU.0DQTJ#@BU@4K8)7<"5 MXEP<)$7V&!0NO[ACGUF% ;;? 2P#@N6*H9W*J MX':3V%6P,DKPS!O\/XMTW53>5A1J!8GKTG":ZE]57RO Y:$HPTN=,6@7[&RK1?(H(,-MYZ< M*(Q^6'GX&%Z^=$USX]<=Z\;&\:EY7F.N;)IK]#V,A?>&NC:$D>7G1R=>G(K^ MZG"O&O6+S>:MPJ(1:%YWH"H#QLV[D_TO8G8GAW_XXKSS57G?F1'=]:WKTUM? MP3>N3X\(=&D03:=;JWI8=E8NI;]L4GKI4WJ_"3$>C(+I<-QJ[.YOKC_,R&PG MQ]=UCJ>3J!7LKO?)CZ,@BC9B.]O9IK_N7'^-XF ,@37G.]M9VVR_ XNF?^5: M;A"/@VD2MU*[^R-R/(V"\7"TQ=QH/ I&$/6&N0,YW"KA_Y'"&'!,)]W%?TK@ M* I&T]$F@3O[@PDC0 , -L& 9 >&PO=V]R:W-H M965TDTLMJ#6A&E<;R(6L9EL%W[V)W>KE5O M!9=XI\'T;Y8+^R].KS'T<_<\55*&/\+ MAR$W2P.H>F-5.X))096WS++M6JL#:)=- M;&[@K7HTB>/27W'^0C2JOTTSJR1.>"435"KP=H^A/H)7Q4TC8& MWLH:ZY?XB&1,6M*CENOT).$#=C/(XA#2.,U/\&63M\SS9?_E#6ZYJ80RO4;X MZZHT5M-C^/LUQP-A_CJA*Y"5Z5B%FX JP*!^Q&#[RYMD$?]V0FX^R^C2E'E&&M [< V"#LEJ *YW,,YEQ11O6&R-A'?8C5. MDA#NV8%>FT7-F3!PYA+RXM(-EN$B3> SE1P07:=5A<9 DH5QOH0\3(L"WG') MZ676L%>JIC7"7B90A%D1PR=EF8!Y'L;)$N9QF"Z6\#LQK."FUYHL0*>TK]OS M- OGV>4%G"=)N,B+BQ'+CTY#D$K^6HVP'S5>^2-X:=*],"#[+]U2- O]8=VH MMF/R"1IFJ/542M,+A[/E+*8:%,*W$P*?%;/B& @ISW3HFXP@370HDT)0TK/2 ME=34SXC*78X2O*:CK:FK""8K!%_%!@X-KQK@AAIE^0\1@E4T[#J!U R=XH[;V6LO.WK6<%K4>]]6#;GJI1UZSQ2=.O?5T+"^IP]M_R/3>RX-"-P1 M-)X5\P#TT$J'B56=;U^ELM0,_;"AKP]JET#K.Z7L<>(VF+YGVV]02P,$% M @ K3Y>69V,EI?V @ 9 8 !D !X;"]W;W)K&ULE57;;MLP#/T5PBN&%C#J:Y(Z2P(DZ88-6+&@W>5AV(-BTXE06_(DN>GV M]:-LQTNQ),!>K!O/X2$ETI.=5(]ZBVC@N2R$GCI;8ZJQY^ETBR73U[)"02>Y M5"4SM%0;3U<*6=: RL(+?7_HE8P+9S9I]E9J-I&U*;C E0)=ER53OQ98R-W4 M"9S]QCW?;(W=\&:3BFWP *XL)?R8!2= MH^/>[?%-=852W'J4/5H M5$_HS%Z_"H;^FS.QQ7UL\3GV_[K<S'=9ZBWZ<-\)FZA$;=6,C&@K46J:0" MU@9D#K0-N2RH#W"Q@4LN:$?6FB#Z:@QTW0;+-2'MG=]BVBV"_G* 6I%BQH)[ M?Q?6(/9]F@2)&P\'9"RSNBWYE)6$VP@JTTIJ3FJ(.H@2" 9N$(Y@2<'SE!5@ M%*VS?=U2.)JI3<*%9J&+B#8021.PAB^"SI M-4'@^VZ@S+FAZ>,%!)U0B[3&(W'(578N M8.B&04+CR V3"(X]$^^@\DG8INEO-NFU,&T3Z'?[%CIO.\=?\[;_WC&UX4)# M@3E!_>O1P '5]K1V8635])&U-)2%9KJEWP J:T#GN91FO[ .^A_+[ ]02P,$ M% @ K3Y>66%I_7=9!P ]!$ !D !X;"]W;W)K&ULI5AKC]LV%OTK%VZW2 "-'[(]]DQF!IA,4VP721-TTA3%8C_0,FT1 ME42%I.QX?_V>>RGY,:_M8K]8$G7ON>]#RE=;Z_[TN=:!OI5%Y:][>0CUY6#@ MLUR7RO=MK2N\65E7JH!'MQ[XVFFU%*6R&*3#X?F@5*;JW5S)VB=W%IL$=9FE)7WMB* MG%Y=]VY'EV\G+"\"7XS>^J-[XD@6UO[)#S\OKWM#=D@7.@N,H'#9Z#M=% P$ M-[ZVF+V]258\ON_0?Y+8$7UGB]_-,N37O7F/EGJEFB+\:K=_UVT\4\;+ M;.'EE[91=I+V*&M\L&6K# ]*4\6K^M;FX4AA/GQ&(6T54O$[&A(O?U1!W5PY MNR7'TD#C&PE5M.&N)$JD%W1;U[3K?%+5DMYKA$KOC5J8 MP@2C_=4@P!PK#;(6^FV$3I^!OJ /M@JYIW?54B]/]0=P<^]KVOGZ-GT1\%[7 M?1H/$TJ'Z>0%O/$^]K'@C9_!DQ@]_?-VX8-#>_SKJ1@CQ.1I"!Z92U^K3%_W M,!->NXWNW?SPW>A\^.8%!R=[!R*T6A:9"+:Q3P;J=>&=7*Y-IDFA@-!-T4]$OH(0_ M0 G)_JY/MU3J^-I895C1%H:!]ZPSI/Q(OGNF\X:9A"Z MRY4!'U0=!@)!Y)2U64#LO%K M<("K$%0#DO D4CZ,%IEC1,ERX(L1*HT_GIWE=-0Z/KFNX0U"2T(4D$N55RZ7A%*CBM,46>FVJ MBBU^1(>PB5$B5B0T0.AO05<15M+:]DDTP4YCXC;&-KY V=?&^.Z0G%6==<* MQR.12X(ZM-&D/Z:=5NA.O&=/X/$'M6-BO)#PVX?_;4"!?!(H0-_J)38=#Z$X M1?_0SNO=D9L//)OV9X\<^TDO7,--D0['PZC:.23*A;>X\1WHLR=LPWE1;#39L(Z:4JW0SILB[L M3G,CL:^G9CM+HF$0(QX:=$B+%)/B6UHCA5%2N,94@2$0519G=XO0EYKS!F:6 MMOD*'+.*M@Q)8X6SCDQAP$8I@N3]EP>E MP.$+5A:[N'86[)G<\+CK[1[%GY9'8WAQ\-'^>$2XTNRB6.O"AOL+?3#9[[(5 MTW#<@ZY]@#+9X3 T61(5X M]F=!C"=8FRH;D(',KBMA(1MI<@'N8R0Y5?7IW2&M-;N.MM1&"$2V,"%\"0FN M'24*M9?M $=8T+*BK3,!O, V><3:;<(>@$YS7[4VVH9%+K85^CLW-5*4 ,7M M2=?6$A0008'@51_=V#?WD2>G-M E3K?\ VT^PW?D9[ _;;"7\G[[_:@_F^+P M611LIM (0S;0#'H&NU"N@ACL]IPX=H!#M9W:4E-#K=V"]$8VKI.&D".T[[+? MH9S.73=1'/-"ZTK*YI:Q%Y">X$S&6IGR>8>$*5GR[K3D.X\66 KP27G;CH\3 MPJT2)&0Y$S$!,SU 6(C$>V MX!"0SL.6U9UQ!?)'G;6KLLVDX\NG)!])T4=I'U/%#S>NW.]_)0Z:["E\NM]E M'FF>A$3S_CREO]%%?SC#Y;_FLV-#'_9G$#BA6T9JF8CBWOQ,4B3"5])3V$>Q MXE]?TB\ .?GF>$I;--\?//CX@&EE\7L:)\-TAFN:7*0C^H)#53QZ'F1&23J= MX'>S5) MAO.+UZW&PRVS:#]7=C2:P=)%BW77GKQK5(R' B XE[Q^U ?%X6N'V;8ZZX[L M2.0XF0[/Z:D/O,'1EWBIW5K^;\!AE_V-'^7[U?U?&K?Q2_X@'O\/^: &PO=V]R:W-H965T*D?2CZ0$FS$FN* M5$AJU^K7]PREU6KMC9'TQ=92U\0!?%0:N//1T4(U=OIU*<% ME=)/;$4&;Y;6E3+@I\NGOG(DLZA4ZNEB-GL]+:4RHXNS>';K+LYL';0R=.N$ MK\M2NN:*M%V?C^:CS<$'E1>!#Z879Y7,Z8["I^K6X=>TMY*IDHQ7U@A'R_/1 MY?SMU1'+1X$_%*W]X%EP)(FU]_SCE^Q\-&- I"D-;$'BWXJN26LV!!B?.YNC MWB4K#I\WUG^.L2.61'JZMOI/E87B?'0R$ADM9:W#![M^3UT\QVPOM=K'OV+= MRAXO1B*M?;!EIPP$I3+M?_G0\3!0.)E]06'1*2PB[M911/E.!GEQYNQ:.):& M-7Z(H49M@%.&DW(7'-XJZ(6+:UN6*H#EX(4TF;BV)BB3DTD5^;-I@ L6G*:= MN:O6W.(+YMZ(&Q@HO/C)9)3MZD\!K<>WV."[6CQK\(ZJB3B*#0]'\O8^%ULG1?B?<2&]])5,Z'Z%3/+D5 MC2Y>O9B_GIT^$\)1'\+1<]:_/67/FML/]GF:?E4IVI+BFP^VD3HT8JCQNQ$W MLA&'?:Y4DO=WO7[TX62QFIU5UC,E!% MSIJ6#PL'&'H5I6JI$&8*7[8VF9^(CW MMQ%)6,<3^D1@//UF5U0F4#UDTN:S M5KQ#E@G'TP4*J,R>IL@85:$#Q;C]1A A[,' QTP 3CERQ&,3\BHT8Y$IF5 @ M/Q8E+"46GH5O3.9LV0:62I$:3@1[^V:5N3&$46!H(QM03 ] MM0?*#.^UK81UC*0DERJIU;_T#>0Q<,Y8!,ZX:W;]<9A+>.;0>M>YX[S[.NDX MC.'V$AZVS8H:.$D:AKYK34$:BCE>PSTPA9WV1P)_@P3&^@M#!6V[QY@D-J;T7E;*$2%2"Z1$;01+G,N02[A*;H:I5* MO?$743[B6\9K$"3L\DM!\<4X+-1/3T/>[6$FNY09H4V:MN5A]B6*]@1WE-;L M!['WO<(!6GY#:%^#3,BT4 :CS.\%^!KIQHFXM9ZKYC,7FWKS!&O&VT'!@3] M\G@RVSC^"O0E9E-"?8(9FKRGKOCVN.M"88P$Y-NL(2M9G898CQ6+251I#J@0++C*5JR! $0 $[$S"==-W M2XTTL2[0RVLB(XX%#\/Y_%2\^8['C)>Z[83'0?@O-@"@P/R&!3ET#SO&FH,G M*&)MH#318QZCW?6EQZ:W+?EX)-(#AFZ&$<3=TAKEZX:''DQS:XTY!@F[M0FN M.4B:@^XQJG2A\/$F-=C8E.?T.UOG[?3G@G0,9CX3#4G<)'+))TOE?!AT3.0J M@GZ:<1ZO-4JA\\Z3N%+;,%LWL+95C/<)Y#$J.3]/;8Z%8N8H%#9.N%*:>HG] M@Y<15%Z.=U M@['#7TD7V8< V,'JR36].P9M.WQLFM;.83>(;&VLH;\-5Q66@8W^@)VO;LUV M3/?CI+_=!H/.[]S( V8W(XUYVT.W 1V1'S0L[K1@'5\PF*0Y*H97(>F08CQ@ MP_>#^PF;"[XB0%Z-(H$Y- 2*OX6&P55#"S?CSD:T;^V;#K9VE%P>OTU\6U+M M M^?]I\_E^W6OQ5OOYUNI,OY\M>TA.H,4V;4XMG\"+:*WP")#?BBB(\%/N'( ML0#>+ZT-FQ_LH/\HO/@/4$L#!!0 ( *T^7EDMJ(%<'@4 -\, 9 M>&PO=V]R:W-H965T!YR;3F M9>/,S\S>E9R?B4Y790-7DJFNKKF\NX!*[,X=WQDVKLOU1M/&='[6\C7<@/[2 M7DE\FXXH15E#HTK1, FK-??+;/@][!JGW"X.@-PB, MW_8@X^5;KOG\3(H=DZ2-:+0PH1IK=*YLJ"@W6J*T1#L]O]EP":\O,*Z"O1$U MUEIQ2M?95",ZZ4SS'NG"(@6_0,K8!]'HC6*730'%??LI>C6Z%@RN700' 6^@ MG;#0)WR"S-%E+R9@UF_<]BJ;1$FOS[5/ 6.WH: MFUKG1+4\AW,'>T.!W((S?_7"3[S3 YY'H^?1(?3?*M*?(;'/0O.**2->&G&^ M+X9;6@.V8<4U"K5@O*J86#&] 8/$F[N_U#T ON.R4"XKF[SJBK)9,V1S_IV) MEB 5XTV!>)CR,B=(*^R:4BMV].I%&@3>Z?7-%V66_NFQR]98J_YPJ-M*W %8 ME**4V.1"*L3+Q;HI_T.MHI-T)OFG-Q+ :#:8C]B(H[+!'=$IM%#')^RS.6Z_&Q[ ?T0O M#LG-\73TWNI]LT62"EGR907HC<(TO611-J-?5'K)?#?R8O/TTP01*RS^&K,& M#4BL+87#"QPA);&<9B'S?3?-4I:Y<1*QT'>'[*+G]T> XZEF,2*'=7%6]&GN[;&G62#L3MB>1G:%UTN1TV"VJ.QR / MU>[C*.+>8ZJXYH1\0Y-,[?/^$=MIM[&,1R,)_;?8] NB6TJK$_:Q,P?@:=_, M9PV*UWNK3YW&U#0FVURSMY#W_OBNY6KD!F'F9BE5-$@G0<#B2<#ND%"*?>I+ M-S2S87@8N7&8C3*X!9F;7C/2HRP,W<3SCT>%G&,=*NI%2;S"2@ZJR,4H\8X? M^OA$?X5(X8R4B7;>!'G\T\FO6/N>!D3;O)\Z6]Q^-MJE#<*TZ],V@9LE*1(_ ML6GR/!9-TMZ#SS1A>"G9EE<=##-'XWVH[RT:C:Q4S+Z)QLCS2BB*&"=5#@^F M,]'(GYV:28:<&#K)&A;(=-(W59D?TQ X_V//G9FN3;Q)&*/O?4,\=8>9 M[ETZ:Y!K<[4F=G6-MO?/<7>\O2_LI?6GNKWZ?^!R76);5[!"4^R>V&'27J?M MBQ:MN<(NA<8+L5EN\!\(2%) ^4H(/;S0 >-_FOG_4$L#!!0 ( *T^7EGL M1P'*P ( 8& 9 >&PO=V]R:W-H965T):B,;.@MK:=1)$I:I3,G*L6&_)42DMFR=2;R+0: M6>E!4D1)'%]$DO$FF$_]WE+/IZJS@C>XU& Z*9G^O4"AMK-@%.PW[OFFMFXC MFD];ML$5VH=VJKO?L'WSNE,N:&;Q1XCLO;3T+ MQ@&46+%.V'NU_8B[?'+'5RAA_!>V?6P:!U!TQBJY Y,"R9O^SYYW]W &+\& M2': Q.ON#_(JWS/+YE.MMJ!=-+&YA4_5HTD<;]RCK*PF+R>)TGJC8X1<]/GD%?P5WJK&U@=NFQ/(E/B(M@Z!D+VB1G"1<87L.:1Q" M$B?9";YT2##U?.DK?+=,-[S9'"0)/Z[7QFJJAY_'\NWILN-TKDCB_C=";'9(#8[Q?X/K_$_>/A:(U1*4./1#8!Q>V>NA$M@6Z9+ M UND*'PN1$>/![P!2XB"B:(3S#>-JJ#DHK/D;6A"",??$G^AI"2WIX0U%JPS MZ,!< U85=1Q%=*(D%[#&\C-/0NT'S !K6\&)T"I_G.>LM)) DT;[8\E6VCMM MK=%1T/&4ZIETM>8$<$7JT94<4,%8E&L2M:\:'T^+=$(WL,=_(?R+6CT&="!8 M654\DIA>21JFR5687<20A>DX#_,\A_O5@X$D'%WF83+.8!1>YKD+.58!T4%O M2M0;/X&,NY[&]FTZ[ Y#[KKO[;_A_82\8WK#29+ BJ#Q^64>@.ZG3F]8U?I. M7RM+<\,O:QK4J%T ^2NE[-YP!PRC?_X'4$L#!!0 ( *T^7EDOZ%$0X@( M $L+ 9 >&PO=V]R:W-H965T_.WS& M-]@1^LP2A#AXR3/,AD;">=$W318E*(?LAA0(BR=K0G/(Q91N3%90!&,%Y9GI M6%9@YC#%1CA0:TL:#DC)LQ2C)06LS'-(7T0IKO[A2_T>#@#[%.#4 M@/,>\$X ;@VX;0&O!KRV@%\#?EL@J(&@+="I@4[;M]2M@6Y;#[T:Z*ERJ/9/ M;?X8IH+CX1*^@BT#2T35N<$1 N.4 M11EA)47@&CRNQN#+U5=P!5(,?B6D9!#';&!RX5LJF%'M9U3Y<4[X<<$]P3QA M8()C%&OX^7F^=X8W1)IZ[\_B/$I_%Q^?Q M>T@%;I_$)^V#=S7XM'WP.GS6/G@=/O^_-[_X<.Y'A> V)\!5>NY'3H"NT"LY M3R\G[Z8^*V"$AH:X?!BB6V2$GS_9@?5=5V67%!M?4FQR2;'I)<5FEQ2;7U)L M<2&QHSKVFCKVSJF'/T5C)(I6^VVNR$"1LOO9AM=.X,K3MSTL1HV9'3B.=6PV MUIGYCMF =WJQJ>=^LCNS^S->MST2E6C=T_ M^:K-%%_938H9R-!:N+)N.J*#H%7K5DTX*=2]_D2XZ!+4,!'=+J+20#Q?$\+W M$^F@Z9_#-U!+ P04 " "M/EY9NCU' Z<& !T)0 &0 'AL+W=O)HB!WG9!@3 MEO1F9_FS6S$[XYF*6$)O!9)9'!/Q=$$C_G#>(($79[WYNZ'2\_3!GF+/QA]D(UKI*DL./^N;ZZ#\YZC M>T0CZBL-0>#?FE[2*-)(T(\?)6BO\JD-F]<;]%]S\D!F022]Y-&?+%#A>6_: M0P%=DBQ2W_C#9UH2&FL\GTRK9.#_F95#PNC:$',4N*_^2Q#$3#P)NV M&.#2 #\S:/7@E09YY(9%SW):5T21V9G@#TCHUH"F+_+8Y-; AB7Z,]XI 6\9 MV*G9-7R0@ IT+TC DA6:"T&2%84/I>394($'W6[HEV@7!1IN0?/0#4]4*-&G M)*"!P?[2;G]JL1\"LXH>WM"[P%; .YH.D.?T$7;P",F0"&JB=?FS*%N=\ZK8 M>SFLUP)KBGD?+9[0=1*P-0LR$ID^00$Z,H/J:?]!IL2GYSV8UY**->W-WOSB MGC@?3<0/!+;%?U3Q']G09S=$4<%(A.ZIB"7B2],H-$7 "OO:"-C[^.:7*<8G M']'7!,VS%H ^DT@JR*)]= LN848EJH](P%-% T30 MMRRBR'46X_@V(@D*R5JSA2N:!"B <.@@7%&?Q@N8DYY;>!J@^Y"B M5%LPB5BBJ)X=2'$DB6)R^804O"?+)=-Y#;*BSF.0:7.TANNW_COP%:!4/B%40 LK4F0FVE MB%!5$+^0)(.RA'#N:YSS?A;G>2I8!'A%B_\LR&_9NQ9 4>?0?0U>9^O MP:+YH?2,<"Z>_"^FN>O@_LGI;H.P?9Y; MRL*X*@MC:\K]C2?OFY%L% ,T+V)M*@IVT"6,7FI*_U:S/0O@2<7TQ-JI-I;W MFQEK)&K';"5J-=N3Z*0B.MG[D]K)VG%;R5K-]B0[K_38\C9TT/R/Q#8%G_7J==2CGV8D]@T&B\ZS RUQ[AT MLJ+L2ZZQ4'2MO;QG*C*SL]OM5$2-?*VX^_+%-5^\5W*VE* .1"4R8[*RF^U+ MM%Z%NM9%WBPGI+=4KF &FG9[5^H*2/'8RPTW7JEZ=J7<9\>4R:(G:4=X85< M,[(\T,ITFV4MG%R[R&D.TZNLX&ND:H=QG1&HU"?C1HG==%^&M6!R[>IF7BG6 M^9JPB"Q:4E*!,LY1]$[F&DAA4+=GP_46F\YVV_VL]8YK%R:&K0'3YD9?KXEA M05RL$S8J ?UCVEJPB@A[=UY;10^%MAV\6C^YTV,("?>@2NI0:-LQJ+64:Y4J M[5+";F88-T9RQ]!)N-9)V"YX6J5$AUVUMV;UIL%V M3;.S5O@"&@'_M%2P]^:U9?)0:-NQJW46GAQ#*N"#RJ5#H6W'H)9+V+[?U"85 M.LR:>_I&5L<00+@60-BN9/:IIW;$UGIZ##'DU6+(LXN:SGK:9;]=3XT_\AY# M&GFU-/+L0F:'@='O@&N4 MT@,1C6\M9M2Y](;G[1/Z7=!.6G;,XEK+OT3FBGDTC2##/:NE>]#'W['5<^7Q MN)8V?.'8K+V:1,!KZW39&A.#4JCFS[ZW<3@SF":O&*2M01IX-XX"RX_,L<7, MZ",8OYK0?"-(#=9$3BB_*5MG:%:0G5MLF\T O8>MR)78"\Z4@R7GNE9.J!PV M6@HNT,+;4^O=+';DV@/$O'6S:MRDK[CY )^U_#;"==&PG0^B+%;/"^CW;>&SEF,_P/I*#,/TD>[%A M@/151_IJD/0#"0SI-WMW"?5D9CQ:@G6Z7L9W$ MSO*CL%QJ6U/H!B)VW47L>E#?HT6_$9^L$W3_O(1L(C2(T+_#+V&'-O>FHWHS M2/4GETF*'\&'Z1O/FXY@5I-N2R0H+F@0%0:0:^96< M")61$JIOQT+3>K(QY+XO3>*S&DK"\_!2L!""U)33;K1[C"R;&OS?\N8E\YF9 MG/2"Q#V9)A:4=1#LV"'E1H_ *:WVO:Z+;C'71/M,6_ M4$L#!!0 ( *T^7EFN'O:X6P, -D' 9 >&PO=V]R:W-H965TRE%UNDR,?'9U.:GJ3ZH@\ AGQK:J%GWL&8]C8( M='F IM!CV8+ G9U436'05/M MPJ*RB4U=1!2F@9-P84WGSK?@YI/Y='47,"# M(OK8-(7ZOH1:GF8>\YX<[_G^8*PCF$_;8@\;,!_;!X56,*!4O &AN11$P6[F M+=CM,K;Q+N O#B=]MB:VDZV47ZQQ7\T\:@E!#:6Q" 6^'F$%=6V!D,;7'M,; M2MK$\_43^AO7._:R+32L9/TWK\QAYF4>J6!7'&OS7I[^A+Z?Q.*5LM;N24Y= M;((5RZ,VLNF3T6ZXZ-[%MUZ'LX2,/I,0]@FAX]T5:9^;UX!&U094,V4!X5-QPTN?E0;&O0HVE@L(:-#,H> M;]GAA<_@Y>2M%.:@R9VHH/HY/T!N \'PB> RO JX@79,(NJ3D(;Q%;QH:#AR M>-'_-JQ]LH:M(86HR-W7(S??SR7XM-AJH_"G^7Q)A*Y&?+F&':1;W18ES#R< M% WJ$;SYJQ:&Y!DEKUYD(0M?#V_K>RX^I3ZE_TWIW2O9-*!* M7M3DH6BQXX3Y:30A:82D1L[*9'R<8'F%\ MQ%(_#VUC21KY.9O8KOQT$MLFXV3D-A(_P2;74/8:,Z=Q]+LU3JB?)D[CV&D< MTGC4^Y,\N2YR[,>,DA U"$?6H+]-WTGFIPB=Y$AH,G)F'#XC,&.9GZ' 8<:0 M28S_"&.Y3R.K:LQ"/YE0N\KM\R;*TE'OMWI?FM?@[+A%5GMWJ=C). K3G;R# M=[BW%MUQ_2.\N_3>%FK/A28U[#"5CB>)1U1WD72&D:T[O+?2X%7@E@>\>T'9 M -S?26RT-VR!X3:?_PM02P,$% @ K3Y>65O\@_24 P . D !D !X M;"]W;W)K&ULK5;;DMHX$/V5+F[(1\ M4AM$#;_RK%!#9Z-U>>MY*ME@SE1+E%A09"5DSC2Y>:'O=[R< M\<(9#>S:7(X&HM(9+W N055YSN3S!#.Q&SJ!\[+PE:\WVBQXHT')UKA _;V< M2_*\&B7E.1:*BP(DKH;..+B=1";?)OS@N%,-&XR2I1!/QGE(AXYO"&&&B38( MC/ZV.,4L,T!$X^LD!<;)'#%]![,.C*/1&P<(DO JXP+(% M;=^%T ^C*WCM6G+;XK7_7O*,JR031K6"/\9+I24])7]>TKR'C"Y#FI-SJTJ6 MX-"AHZ%0;M$9O7T3=/R[*X2CFG!T#7VTH).85AF"6,%K\Z+0E*D-?/Q9\2W+ M[!HK4AAO&<_,*#_0 ?ZPH @\%%M4VI3! I-*MOP8@W:/L;PS@9$I0A(U%\MR8# 3MV.U'G;KBW+^?/4QABE);-AIMIV=8"L4U]'M^G=BT7\OO^*[O M']/.7)I=CC+A+(,Y*ZE%<>!V2-A+_,R="ED*25O 9^JB\B;"=*8==-Q^&-19 MY_X-=/N^VXGBD\[%G=B-2?6QT>+TMZ-2Z'IIK7FACYM4)H$BJ\$:3XX9H/Z8VGT%U!+ P04 M " "M/EY95;'=E:\" #%!0 &0 'AL+W=O\)+U$(1T0R?K><7K>E QZ.]^S7=>U4 MRXH9O%3BD>=V._/&'N2X9I6P]VKW!=MZ!HXO4\+47]@UN4GL0589JXH63 H* M+IL_>V[/X0 P#M\ Q"T@KG4W&]4JKYAE\ZE6.] NF]CV K@:8_#2SQNM4@:SD6#4?\!LE$Q7M1B_@DX1++,TA"'^(P3D_P)5V12I47-F3#PWB6DHW,W&/O#.()'\B807:E5AL9 E/AA M.H;4CTC$!Z490(&J1]&8QB$?CPKBE M/HO:)=#Z6BF[#]P&7>>>_P%02P,$% @ K3Y>62Y&\&_^ @ 708 !D M !X;"]W;W)K&UL?57;;M- $/V5D4&HE:SZFJ0) M2:0V!8$$HJ(%'A /&WN)]OO!")PA+S*QC$#P\ MX K+TA&QC%\]IS>X=,##^9[];1L[Q[(6A"M=?I.YW2Z\2P]R+$13VL]Z]P[[ M>$:.+],EM5_8=;:3B0=90U97/9@55%)UHWCL\W N R? <0](&YU=XY:E3?" MBN7 MK$ND\WE@V8TS#K*>\KJCC)^AG,)'K>R6X(W*,?\?'["\06.\UW@=GR2\P_H" MDM"'.(S3$WS)$'/2\B7/\-U@@<9@#BM-EGQ8B5I:4/7+:$]"2,8X)/4AX7O/>#AWYTZT=TZ/><%^(+*HV>F-$13#R1^,$$G\4I7"O^?5 %(9^.HT@G?J39 P? MD&@&JX8?FK)0:],*.YNF?CR)S^$LC?TT3PEC/XZF/$[\>)K L6<1 M')0\"]NTC-=Z/PFRD(BBQ8&AX,1EY8+IFUBVL MKML&LM:6L]!.M]S_T3@#/B^TMON%P# #!"0 &0 'AL+W=OO@UVX"3;EB!9$GKI,4P[ -M7=M$*=(CJ;C^][ND9-EI'*]? M))$Z]]S7N2!'6Z6_FC6BA6^%D&8@YZ,5&D%E_B@P91%P?3N&H7:CH-.L-_XQ%=K MZS;"R6C#5CA#^[1YT+0*&Y:<%R@-5Q(T+L?!M#.\SAS> SYSW)JC;W"9S)7Z MZA8?\G$0N8!0X,(Z!D:O9[Q!(1P1A?%OS1DT+IWA\?>>_7>?.^4R9P9OE/C" M<[L>!_T 6389:;4%[=#$YCY\JMZ:@N/2-65F-?WE9&B; M DP/<<^ MF=$LYJ5 UZB/)9.66^;4#!]D-9=.X-,Y#1W<;U#36JZJ%II3J9QW]KA&6"I! MX^I8K.LZ^)PD:B=LO:6MX<(#OHY"NL=)*TH M[M$[;@WB#GQFFOL\CC"=5IRE].PD$CD]YXT[ MMG=7>G>'YK+&)7"O[TH0YE7/'M<$A*)J&K7<->)[+:=4-:IS)X:_2(UOH3)( M6VG2/8OI$B;K)&#F/PQ61^6K,UO^'F:WVEX&G2 MH>2BY)46LB**K\Y&"__D/$%[:_!-\)WNC0E6LI3R!SY8]XQ"T#H'-VP6R M67Y@ALU/E=P1A=: A@-;JO6&Y$2%FW)C%,P*\#/SFPU3_.TYU)63][*$O=;, M+M?1+5L67!^?3@R$0>-)UD*>.\C@&4\?^@_@?2Z'(-]CN?! M(. -K\_#Q7O ML*/#V*BA$UVSC)^-0"2:JRT?S=^\\A/OW4#F49=Y-(3^7YE3 2;;-9VFRR/G>XRP)$6S #DT825A1$ MKHC9<$LS5MW_H1\ L!U3N:9$5%G1Y*):$^!^]H/(&B&U+0CB&R4RA'23326, M)D=O7LV"P'MW??-5VZ'_[IB2-2Q+&YR7=2'O.7QB$E.R8MLNA!-;5 M%KV2!?0_#'$D*G@C&PT>^OB$W-IP?ZK+; !ZD$BABR MT;!,KTF43O$7C%X3GT9>;/_]60*(!6S\&E:-5US!WF(Y+(>&(U *V#F)[]-9 M.B,IC9.(A#Y-,6),@R0EUT ,IK*-6U^^A5Y?6W+&U$LC$M$0;'WXFT8($P<^ M>2&%(,$IC68I#L#?][& *9UZ 0S"*4VG"1D05MP)*QX6EJ73%\LULL"30IC[ M0V(9AKFLW#'I3JPU,'I/JD=D;B/TZ;X30#-@> WD1-):_NHA^C9 !F71%Z7C M)<[#7ABKNL#S9^3B9P-Q@ \9; ?NXE7!JDXQ?5]KCK-[";64]E/PSIO,]<8% MRO0IR&.SAS@:5?"4M-1&R#;8OG1?@4]TAV\KISUP4KR]0UCE KH3ESXAGQL; M *)]M\Y2&(4T\_[@SR!CL0X%=02'#82?WIJ"* M*/&.'^=X0.DAB"E%8Q2 -P9%_4KR&^Q]2P,44-;VORV\?C':A2O"-H[#/@%- MDQE(,''+Y'DD&L]-Y-(CC)Y9;Q]B]X=$T!':EP?$30R>=HF^;0$J^ M_Q+-P&$5>W1JA9UXXS"&W(/G&3OIW:=+KM;VJP$/=;A!N:MU][;[,%FX^_@O M<_=5\XFIM0#E%WP%KB P.$"4^U)P#T;6]G:^E ;N^G:X@8\KKM YE=2FOT# M!N@^U^;_ E!+ P04 " "M/EY9X6"W3.," ^!@ &0 'AL+W=OV6(6C /(,&>UL ^J^8*[?!+'ERIA_"\TK>]5 M$D!:&ZO*'9@4E%RV7_:ZNX<#P#AZ Q#O +'7W0;R*F^99?.I5@UHYTUL;N%3 M]6@2QZ5[E+75=,H)9^??E#&P0@WK@FF$/GQX9!N!YN,TM$3OG,)T1[5HJ>(W MJ*[A7DE;&+B3&6;'^)!D==KBO;9%?)9PC=4%#*,>Q%$\.L,W['(=>K[A&WQW M3$LNMX?Y_KK9&*NI-'Z?RK>E&YVF<^TR,15+<190/QC4+QC,W[\;7$:?SH@= M=6)'Y]CG2U665+5KJ])GN/M3\Q]R34ML ,L*H2G BM\N$\ M9ZY5"32AM ]+MM+^T!8:'06%I]SZI2M,)X K4H^N/H&JRV*Y(5'[$O/^M!A. MX+'#?R?\46&? CK0[JE4U2H9]H;Q=6]T&<&H-QPGO21)X&']9"#N#:Z27CP> MP:!WE23.Y52YA <]7:+>^LEEW/5(V[9WM]L-QYMV)OQW;R?K/=-;3I($Y@2- M+MPLTNVT:@VK*C\A-LK2O/'+@@8\:N= Y[E2=F^X -U?QOP?4$L#!!0 ( M *T^7EFI2(9;. , (T* 9 >&PO=V]R:W-H965T*^R%K4O&*A":24$4Y/-@,;A"L9_$(P;P=B1\5MQ'%;4T&2FY(XH M.QO=;,/!=&K:BDS/0H,1VG7"M(GF MRDN">TRSU9',#L"/6_#C/O=DXP\*XL[("1X1?W!.NP!ZHXDSLG?V?1)? MQ--X@/F_WV?3N^!KV1S)[(#-I&4SZ67S.<]!,5&06K$4')Y,=[I-Z"JEWY==".I+9 :1I"VG:"VE1% H*/(.D4%(C&253@.XK=OJ,RR2> M1%'TA$WO@J]E7:FL*KS%\ .:WIT1 :8+ M5?P(:JJ"B8TX9"C970>XVNK?/'C.T;6KARXE0:+"]&PO=V]R:W-H965T5:VQ=3LHBE?F$'@R5>P SDE^6$ MJY9=H$0D!2H(HXC#?&A=N9=CMZ,#S(BO!#9B[QEI*O>,/>C&=32T')T1)!!* M#8'5WQK&D"0:2>7Q,P>UBCEUX/[S%OV](:_(W&,!8Y;)7( M*=M\@)Q06^.%+!'F%VWRL8Z%PI60+,V#508IH=D_?LR%V M0.-4!7A[@'0:T MG@CP\P#?$,TR,[3>8HF# 6<;Q/5HA:8?C#8F6K$A5"_C3'+52U2<#&;9\B$V M1S.RH&1.0DPEN@I#MJ*2T 6:L(2$! 1ZC:ZBB&CQ<8*N:68AO11G;T%BDIRK M$0(6:HWEP)8J-SV#'>9YC+(\O"?RZ*,;1F4LT#L:052.MQ6G@IBW)3;R:@%G ML+Q OO,*>8[7JLAG_._A?DTZ?J&S;_#\I_#^(NZWCRH 74M(Q?N_:8^11P; M%7+7B"KB&5K;H.EOTCIP!_9ZGTWM?$>R:1=LVK5LIK &N@(T AK&:B,]H-]H M;':MXCAF-%2T>+9+ID3HWMN8 Z ;_(-Q=!>S! 1.@%=2KYWZN6O>$%A)I4ZA M4N>DYN\T*41#8"4ANH40W5J[E!W!M2/.L$ 8J:V@.\ZKV&>0_;T=X%ST>P>; MH';>(UGU"E:]AC=!T?N90A7EVOF>N^ -@96DZ1?2]$_J_'Z30C0$5A+"=7:% MAM.\]W/,LOG][H'YJT=UBE'EC/=*(_=4OK[=L$HZM1,^=SV;0BO+X^WD\4[J M[1R^*3$:0BN+L2OOW-JBZ4AW^U6^]0_=73G*>\+=NSK,K2_$_L?=NH:I)-10 M+983/T5EY^Y*.[=]6G\W6K\UA5868U?!N;5UT9'^[E0XUSLL7:I']0_\;>^= M<94'%^;H+Y!9ENQ46+PMKA>NS*'ZX/U(7SN8L_,.)KNSN,%\0:A "R;51C"/,> (N!Z@^N>,R6U#3U!3[5(2K/.D.#*19;EF'(2),9ODWSVFLPG=\RA,R&,* MV#Z.@_3['8GH<6I X\<7G\.7+<^^,&>37?!"EH0_[1Y3<666*.LP)@D+:0)2 MLID:M_!FCMTL(8_X$I(CJWT&62G/E'[-+A[64\/*&)&(K'@&$8A_!S(G490A M"1[_%J!&.6:66/_\ _T^+UX4\QPP,J?17^&:;Z>&9X UV03[B'^FQ]](49"3 MX:UHQ/*_X%C$6@98[1FG<9$L&,1ABE]#D<=G#\F!,"[FA8,E6>W3 MD(>$@1%8GJ85T U0AUPM" _"Z+V(?5HNP-6[]^ ="!/PYY;N69"LV<3D@E\V MBKDJN-R=N* .+DNRNP;8^@"0A6Q%^ER?OB KD0[S=-Q,-T57RM:@LC4HQ\.= M>,_UBC^ VX,H.'B.R$@LG]$RB CX^Y-( @^5>LIW\_Q, M/ XSQ\4^'$_,0[T(.V4Z+G2(&>ZZ:GEO2<[7T?F4\ M%'(HV-T'80J^!-&>J/BYTMB.ZSBVVZ(HAXGYK?>Y07)WB]O 8?Z8&D M22Y$MR\D67VOK4X58RWDI8MO(+!&]5Y9O??F2N0-V8R!P!K-\,MF^*]4(E]> MZ-CQ+-BZ4Q5ACN4Z4'VG0JMR5.O56E1 - ?W6@150;;70:]F^' (.2I0&EH# M<9NA(@A9'6L=5L8+M5;66Y(*F-9,^Y(FJ>(I@V$UFQ(Y>]([^_G50C)KNU:EM6^4<^&-0G6MM5Z=^\C1$AV M;(F>+J1)K?)SI/?SGD)4H&C9Z4*:["K#1?I-;E\90O(F5CF_Y\*:-"L;1'H; MG-,X)NDJ#"+P&.Q(JJ2HA;AXQ0V$UBRX5\1 MDO>OH_865Q6#QFJ"N+)HT5Q]>VTQ8D113R.DZT<.7H>) 3;*PZ MGFY+DBH(VKB#8N7!>)A3[ +&;GJ5>+K@=)>_C7NFG-,X_[@EP9JD68#X?4.%6!47V0N^\H7N M[']02P,$% @ K3Y>61OY*0 ! 9A, !D !X;"]W;W)K&ULM5A1C^(V$/XK5GJJ[J3=) X08 M(+*M>5^I5JT/;/E1] M,,D UCDVM1VXZZ^OG61# MG<<@H\D#B9^6:^SV-GY,E!R"]J"Z#1UX1Q-76V M6N_N/$]%6TB(@FAW)E-LF=/?Z6:K[0-O-MF1#2Q!/^^>I!EY)4I,$^"* M"HXDK*?.'-\M\,@Z9!9_4CBHRCVR5%9"?+&#QWCJ^#8C8!!I"T',90\+8,PB MF3S^+4"=,J9UK-Z_H/^:D3=D5D3!0K"_:*RW4V?DH!C6)&7ZLSC\!@6A@<6+ M!%/9/SH4MKZ#HE1ID13.)H.$\OQ*OA9"5!QP_Q6'H' (WNK0*QQZ&=$\LXS6 M ]%D-I'B@*2U-FCV)M,F\S9L*+?3N-32O*7&3\\>^1Z4-O.BT1*B5%)-0:%; M-(]C:G4F##WRO%JLZN\?0!/*/AB+Y^4#>O_N WJ'*$>?*&/FO9IXVB1EH;VH M2. ^3R!X)8$E[%S4\V]0X ?]!O=%N_L#1,8=9^Z]NKMGI"CU"$H]@@RO]RK> MJJK$#9KO#5^R8G!K5+A=$@;H[]^-$WK4D*A_F@CG$?K-$>RZO%,[$L'4,0M/ M@=R#,_OY)QSZOS31[PBL)D:O%*/7AEXM#E61A+Q(@HPD2!E);A 7W!A(8]JD M2!XFS,+8C64_PZ&9['V5:&Z#_8K1<.B.2JL:@W[)H-_*8+[92-@0#6;+8>82 MHS6A$NT)2P&)M2G=%X;*+#R]12DWFR&C_QE+)I2"QHK.8V)<234,W>"$4(,5 M#@<5LQJC0#VF@L4^\>OO=^:Z;.[=-%'L0?)LVU]O@$>??M.T;9C7CI17:'5 M%:CT._CJA5N$Z$J0CM#J@AP;'MS:0ESI$UD$K1>Y[PY.JKP]MQ_E?NQO<'N# MLQ!) C*BILM](CN0C4Q:(2Z>[([0ZH2/[1#N7[_Z6UNNBP7I"*TNR+&;PF]M MISJM_O.^*CRM_-:\?I3WL>?"WVNZY$Y(R_L/H4%Y]X+'S51:<2Z>[8[0ZJR/ M#1H>7K_\.^WAND*K"W+LXG!K7W2M\A\U-"_CLQ:G/;=+N7N50Q![ O6)R WE M"C%8&WC?'9H%)_-#G7R@Q2X[%UD)K462W6Z!Q""M@7F_%F9E% -[U%(>K^KY,M9%2?R1P$OEE+E5[7Q=:Z ILXIXWX4!&,_HTQX\W+/-UM@'?CS+Z0:68![R.X4SOT9)609",RF( M@O76,$61,E+_T2R5$PR$&4U^)9=I MRJS2E),;4>:+U?WD&@QE_ -:/"RORXC_5J#J-8@_=4EU)+"6<(-:N$$?>KR@2CU;WCN70')-$JJW M9 L\)4R03 IXQF15C]B.UH5(=9<:Y1)CMX1M.KLXBD9A8#\S?]>D>F@9!I.V M88O&L*8Q?(,&!FWWT@U^?RH8\K%5T!5N+]1[-^](8"W6HYKUZ(?*^M$QA3L2 M6$NX<2W5240-D);%DW,9L<,!M.NYCUKOV=S*8UL^G_:57)P9YNY Z4L'^& M1-M,=Q71Q7YZP#Z,.MO7H6$TZNE>YS6S\WYFH Q;LP1W35M>*>12L^[FU8OT MWAH\/TSH(.@A% :O9Y*@E]*2;82CA.(_"+FRH= 5Q^XB\@+[U,DM[("30??1 MHQ?[O22/A=96HG$Z"W^H)EV%) MJ@T3FG!8HT]P-D&JJKP6E1,CS6$F#]Q0WW.)5$I0UP/=KB7%7$WM9J2^G M\;]02P,$% @ K3Y>6<@C4BSN" MF !D !X;"]W;W)K&ULS9U1;]LV$,>_"N$-0PNTL22*E-PE!E)GV0*T:]8@W<.P M!\5F$J&RY$JRTP+[\*-DQR=6,FW.QT$O3>PB\3VING*7 M99^K%U>SLX%31202,2TK%Y'\LA(3D225)QG'EXW3P?8SJX;-[Y^]7]:=EYVY MBPHQR9(_XUGY>#8(!V0F[J-E4G[,GGX3FPZQRM\T2XKZ7_*TL74&9+HLRFR^ M:2PCF,?I^FOT=9.(1@/7W]' VS3P#FU -PUHW=%U9'6W+J(R&I_FV1/)*VOI MK?JFSDW=6O8F3JMAO"ES^=-8MBO'EU&4UNY(R9 M+1-!LGNRRTK^:!(5C^27+\MX%27U>R\N1!G%R4OIXO;F@KSX\>7IL)215I\W MG&ZB>KN.RML1U8U8G!#JO"*>X_D=S2?ZYA=B*IN[=7.J-A_*_&R3Y&V3Y-7^ M_%WAQ ]I?!]/H[0DMVEV5XA\%=W)U%REBV75Y7=B)1)".WNJ=5U5Z9MB$4W% MV4"68>58#,8__>!RY^>N?B,Y4[) MUF@M7>Z=ZJ\(N=%(63'HW1&WL7179S$ M92R*Y\DQ([) /XKI,L_C]*&V^CU+\^T;;Z,B+LA?[^0'D*M2S(N_NQ)',1.' MY$Q)G+]-G*^=/NV9UYZK M7\FKL7,Z7#5[IK-0PF7;<)DVW.8X-ZO]%0QI5Z1:IZ;#A>1,Z3_?]I_W:IYS MS,0A.5,2%VP3%UB;YVO/K#&+@Y'#?>8XW\_WMJ7O41IX34LE_' ;?GCLO"?_ MD#^662D'_CJ/IW(BQ"DYKT&$O(_RS]54D5TG5S/93BX7R?/\V2P0;N<"H8W* M=/R1G"D)'&T3..I5X8PP$X?D3$FQYS1J%T['::NPT?A MSMIQ&QSI(E1/DZ0^E(\B)Q]VT937S8W:*$P''U.0!U;I:]CNN7GBK"%IUHC-10P:>=/5 >5A]O,]2\6W# M7^1RF4*JK9;GC"F%T.&NU3?6L MY0$M>GI:_*]U867[HH_5^( +R9N:6:!8S^U587FH.(OE34U>XY14?TQZ3&%M M7!]26!VF>PH+F-+3,^41A77TSD8?FO%4L''@Z0'9>GZ_Z@@5<[&\J8#$ MGO[T]JBB"?<7CP(N$N=7M4%125:+&]J\H!HJ?Y<]IBZV+A62(NR4=M%&B8]DM!0%$I&,N;FCR@8&I/14#;XH"= M"U:'Z9X%"UB48B@)3.O*>'.DC])X6M@XM:4 R[1?X@**2M!8WE3]&1"T;T]> MX+7$W(1.1E722EJ"6I%V*1%7'9V1G4\U8L;VJ* M@(O]?LD'?%36Q?*F)@]8U[SH%ORT^Z%ZAVG;:%8H! M@#*S)TQ@;;7!]T6D M-5%#!CQE&$H$@YV/_O.,!]3&62L#_&7]DA". MXW2L+(=8JAT MF088H/_<]^C#]AX?M@X@&7 P:Q?,@2&2KQ8WM3D ?$R>S($ MME^&H#510P;.9!@R!(M;'GU\QA/ QE$K!^[E_1(K<%3*Q?*F)@\HE]L3*_"V M F''TG2(I=H!($V.(56PM.'1QV8\%6RV^@#,QUY M+&]J&H%N@WX)#@)4H,7RIB8/@#:P)S@(.NXKZ%Z,.BSUBU$ 4!E@: [V%)'Q MID8?E/$H'!@3U(0[)<4:$W4D!L78F%("B99 MOLCRJ!1RB$M1#-]F:?<=!OI/,QY.&R>E ;!MT"]M0( *L%C>U.0!P ;VM %! M^YD_E8N)YW:L)AUW&+@CAP:[+UL#C PQ! *=M6'G&C;4@U0L;VIR 7C#?LD% M0E3,Q?*F)@\P-[0G%PCWRP6T)FK( )XRY:>SJ"C6O=I=%:DW7(P\:E\M6-_I*L'N*T((FX MEVV&PO=V]R:W-H965T M%:R$>U!-#DJ>"E&CE+K:MS MUU79$@JJSD0%)3Z9"UE0C5.Y<%4E@>:-J.!NX'FQ6U!6.NFP6;N1Z5#4FK,2 M;B11=5%0^7P)7*Q'CN^\+-RRQ5*;!3<=5G0!4]#WU8W$F=MYR5D!I6*B)!+F M(^?"/Q\/C'UC\)W!6FV-B8ED)L2CF5SG(\S*#)3:/&:%AIWN)42WS*4*?3ZW(%I1;RF9R2*99(7G,@8DZZ]1,R MKJ7$,3F>@*:,?T++^^F$'!]](D>$E>1N*6I%RUP-78U$QJ^;;7:_;'>B2$73)"!I_X;O)F#"5<:%J">3' MQ4QIB>7VTQ9?ZS"R.S0M>*XJFL'(P1Y3(%?@I!\_^+'WV1;M?W+V*O:PBST\ MY#V]I6NL*PV246Y]DZT\;N3F;%BEH1L46=6S10;8' M/ E,I5529*"L=*V#WM:^/N+U=^CVK:(@2>QPO0ZN=Q#NBI4,^R\G"R'L/=#; M9_.B@;_#MF^5A(EG9XL[MO@@VYW0E-N0XKW->I'G[Z;+8N4%<=_.E'1,R4&F MK_@&S[M#I1+2'.N.M]CO*_ON9PYKK3L%2E*=9 M"VV#[>]1V+K#8O5V=PPZU,%!U+^GEJIGO_!Z)%K@L*HXX'5KPI"PJ#EM3)H6 MRO%RR MKT$06I8,40;\H2L]_74-#]PK"-IX$; MLLV%&C#C>8VWL 9Q5Z^8[)F#EXR44'%"*\1@LS"N[%D2*?O6X!N!/3]H(Q7) M/:4/JO,I6QB6 H("4J$\8/G:00)%H1Q)C%^]3V.84@D/VT_>/[2QRUCN,8>$ M%M]))O*%,350!AO<%.*&[C]"'X^O_*6TX.T3[3O;,#10VG!!RUXL"4I2=6_\ MV.?A0&![+PB<7N#\J\#M!6X;:$?6AK7$ L=S1O>(*6OI337:W+1J&0VIU%]< M"R:_$JD3\8I!C4F&<)6AKR('AJXX!\'1^1($)@5_AR[0W7J)SL_>H3-$*G2; MTX9+02KG=RMWG?76W/&:]Q"@M#[C\.; =&_/:-'5CO=:GY3\Z>) M\CXL$ED[&!:DVB)XE&6$@W8-=+Z"UIV\^8>HENU&1ZAC*]NWG5"/Z@^H_DG4 M1 Z0%!=(,"*?.-OA*M4GU!]3NN[TF')L9=N!:^DI@X$R>.W/;YHJDWNDJT5R M%]2,;ADNM:3!B,'W _<(=&SD^K:GYPP'SO DYRV5&U='%(ZS8EE>9!\QCA/H,G,]0TL@:4PE44Z86I@YR.IK](O*Y>LIH MH(Q>3QVB;87#;873(4:C[1HX]O$2'!N%3G2,9QX<5NJB\ 6S+:DX*F C9=9E M* -DW>';=02MV_/KG@JY MMF+N\KP)2!_+ZA5#QUU)$XW(#BOU!+ P04 M" "M/EY9D7=Y)&8# "P$0 &0 'AL+W=O-A1,'VVW9 M?X^=9*%!J>\J>6_6./'GB?W$7NQ,=UQ\DQFB@A\Y*^3,RY0JSWQ?+C/,B3SA M)1;ZRHJ+G"A=%&M?E@))6H5RYD=!,/9S0@LOGE;G;D0\Y1O%:($W N0FSXFX M?XV,[V9>Z#V)6%D M E6-3Q1WNT]37#_ M^('^INJ\[LR"2+S@[#--53;S)AZDN"(;IF[Y[F]L.C0RO"5GLOH+NZ9NX,%R M(Q7/F[!N04Z+^I?\:$3L!<+A@4#4!*+? M'H0�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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 205 220 1 false 47 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 9952158 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 9952159 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 9952160 - Disclosure - Investment Securities Sheet http://www.intracellulartherapies.com/role/InvestmentSecurities Investment Securities Notes 11 false false R12.htm 9952161 - Disclosure - Fair Value Measurements Sheet http://www.intracellulartherapies.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 9952162 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 13 false false R14.htm 9952163 - Disclosure - Prepaid and Other Assets Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssets Prepaid and Other Assets Notes 14 false false R15.htm 9952164 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 15 false false R16.htm 9952165 - Disclosure - Commitments and Contingencies Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 9952166 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 9952167 - Disclosure - Loss Per Share Sheet http://www.intracellulartherapies.com/role/LossPerShare Loss Per Share Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 9954472 - Disclosure - Investment Securities (Tables) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.intracellulartherapies.com/role/InvestmentSecurities 22 false false R23.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.intracellulartherapies.com/role/FairValueMeasurements 23 false false R24.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 24 false false R25.htm 9954475 - Disclosure - Prepaid and Other Assets (Tables) Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables Prepaid and Other Assets (Tables) Tables http://www.intracellulartherapies.com/role/PrepaidandOtherAssets 25 false false R26.htm 9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities 26 false false R27.htm 9954477 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 27 false false R28.htm 9954478 - Disclosure - Loss Per Share - (Tables) Sheet http://www.intracellulartherapies.com/role/LossPerShareTables Loss Per Share - (Tables) Tables http://www.intracellulartherapies.com/role/LossPerShare 28 false false R29.htm 9954479 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 29 false false R30.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 30 false false R31.htm 9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail Investment Securities - Summary of Investment Securities (Detail) Details 31 false false R32.htm 9954482 - Disclosure - Investment Securities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail Investment Securities - Additional Information (Detail) Details 32 false false R33.htm 9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 33 false false R34.htm 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Details 34 false false R35.htm 9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 35 false false R36.htm 9954486 - Disclosure - Prepaid and Other Assets (Details) Sheet http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails Prepaid and Other Assets (Details) Details http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables 36 false false R37.htm 9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails Right of Use Assets and Lease Liabilities - Additional Information (Details) Details 37 false false R38.htm 9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 38 false false R39.htm 9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 39 false false R40.htm 9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 40 false false R41.htm 9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 41 false false R42.htm 9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 42 false false R43.htm 9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 43 false false R44.htm 9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 44 false false R45.htm 9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 45 false false All Reports Book All Reports itci-20240930.htm itci-20240930.xsd itci-20240930_cal.xml itci-20240930_def.xml itci-20240930_lab.xml itci-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "itci-20240930.htm": { "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20240930", "dts": { "inline": { "local": [ "itci-20240930.htm" ] }, "schema": { "local": [ "itci-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "itci-20240930_cal.xml" ] }, "definitionLink": { "local": [ "itci-20240930_def.xml" ] }, "labelLink": { "local": [ "itci-20240930_lab.xml" ] }, "presentationLink": { "local": [ "itci-20240930_pre.xml" ] } }, "keyStandard": 202, "keyCustom": 18, "axisStandard": 20, "axisCustom": 0, "memberStandard": 29, "memberCustom": 12, "hidden": { "total": 8, "http://xbrl.sec.gov/dei/2024": 5, "http://xbrl.sec.gov/ecd/2024": 3 }, "contextCount": 205, "entityCount": 1, "segmentCount": 47, "elementCount": 448, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 574, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 24 }, "report": { "R1": { "role": "http://www.intracellulartherapies.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R3": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R6": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R7": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R9": { "role": "http://www.intracellulartherapies.com/role/Organization", "longName": "9952158 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecurities", "longName": "9952160 - Disclosure - Investment Securities", "shortName": "Investment Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurements", "longName": "9952161 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.intracellulartherapies.com/role/Inventory", "longName": "9952162 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssets", "longName": "9952163 - Disclosure - Prepaid and Other Assets", "shortName": "Prepaid and Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities", "longName": "9952164 - Disclosure - Right of Use Assets and Lease Liabilities", "shortName": "Right of Use Assets and Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingencies", "longName": "9952165 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "longName": "9952166 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.intracellulartherapies.com/role/LossPerShare", "longName": "9952167 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables", "longName": "9954472 - Disclosure - Investment Securities (Tables)", "shortName": "Investment Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.intracellulartherapies.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables", "longName": "9954475 - Disclosure - Prepaid and Other Assets (Tables)", "shortName": "Prepaid and Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables", "longName": "9954476 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "longName": "9954477 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.intracellulartherapies.com/role/LossPerShareTables", "longName": "9954478 - Disclosure - Loss Per Share - (Tables)", "shortName": "Loss Per Share - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "longName": "9954479 - Disclosure - Organization - Additional Information (Detail)", "shortName": "Organization - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-82", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail", "longName": "9954481 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)", "shortName": "Investment Securities - Summary of Investment Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "longName": "9954482 - Disclosure - Investment Securities - Additional Information (Detail)", "shortName": "Investment Securities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "longName": "9954483 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "longName": "9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-104", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:LiabilitiesFairValueDisclosure", "us-gaap:AssetsFairValueDisclosure", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-131", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R35": { "role": "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail", "longName": "9954485 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails", "longName": "9954486 - Disclosure - Prepaid and Other Assets (Details)", "shortName": "Prepaid and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "itci:PrepaidOperatingExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "itci:PrepaidOperatingExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails", "longName": "9954487 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details)", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "longName": "9954488 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail", "longName": "9954489 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954490 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-172", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R41": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "longName": "9954491 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "longName": "9954492 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R43": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "longName": "9954493 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-187", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-189", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "unique": true } }, "R44": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "9954494 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "shortName": "Share-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-191", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "longName": "9954495 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "shortName": "Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-193", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "itci-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r38", "r567" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r709" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums and accretion of discounts on investment securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r65" ] }, "itci_AccruedCustomerProgramsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "AccruedCustomerProgramsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued customer programs", "label": "Accrued Customer Programs Current", "documentation": "Accrued customer programs current." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r40" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r56", "r105", "r405", "r433", "r434" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r17", "r305", "r308", "r358", "r429", "r430", "r691", "r692", "r693", "r699", "r700", "r701", "r702" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r624" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r48" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r443", "r699", "r700", "r701", "r702", "r734", "r788" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r637" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r637" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r32", "r33", "r251" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r670" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r596", "r606", "r616", "r648" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r599", "r609", "r619", "r651" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r671" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r637" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r644" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r600", "r610", "r620", "r644", "r652", "r656", "r664" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r662" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r148" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r78", "r86", "r104", "r123", "r152", "r154", "r160", "r161", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r298", "r302", "r337", "r402", "r473", "r539", "r540", "r567", "r587", "r723", "r724", "r746" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r99", "r107", "r123", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r298", "r302", "r337", "r567", "r723", "r724", "r746" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r315", "r316", "r556" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r171" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (Losses)", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r172" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r169", "r205", "r315", "r395", "r556", "r559", "r711", "r738", "r739", "r740" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available-for-sale", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r166", "r205" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available for sale, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r102", "r166", "r205" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r659" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r658" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r657" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r656" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "itci_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "BristolMyersSquibbCompanyMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb company." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r90", "r403", "r444", "r468", "r567", "r587", "r686" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r101", "r527" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r62", "r121" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r62" ] }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposits", "label": "Certificates of Deposit, at Carrying Value", "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r686" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r7", "r581", "r582", "r583", "r584" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r635" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r632" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r630" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "itci_ClinicalTrialAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "ClinicalTrialAdvances", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial advances", "label": "Clinical Trial Advances", "documentation": "Clinical Trial Advances" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r636" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r636" ] }, "itci_CollaborativeAgreementUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CollaborativeAgreementUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Company made an upfront payment", "label": "Collaborative Agreement Upfront Payments", "documentation": "Collaborative Agreement Upfront Payments" } } }, "auth_ref": [] }, "itci_CollaborativeArrangementAmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CollaborativeArrangementAmountPayable", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Obliged to make milestone payments", "label": "Collaborative Arrangement Amount Payable", "documentation": "Collaborative arrangement amount payable." } } }, "auth_ref": [] }, "itci_CollaborativeArrangementLicenseExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CollaborativeArrangementLicenseExpirationTerm", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License expiration period", "label": "Collaborative Arrangement License Expiration Term", "documentation": "Collaborative arrangement license expiration description." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper, at carrying value", "label": "Commercial Paper, at Carrying Value", "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r72", "r223", "r581", "r582", "r583", "r584" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r71", "r216", "r217", "r520", "r718", "r720" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r577", "r578", "r579", "r581", "r582", "r583", "r584", "r699", "r700", "r702", "r734", "r787", "r788" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r47" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r47", "r460" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r47" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r47", "r460", "r479", "r788", "r789" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.0001 par value: 175,000,000 shares authorized at September\u00a030, 2024 and December\u00a031, 2023, respectively; 105,998,786 and 96,379,811 shares issued and outstanding at September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r47", "r404", "r567" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r641" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r640" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r642" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r639" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r110", "r112", "r117", "r397", "r414", "r415" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r23", "r24", "r34", "r35", "r164", "r519" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r23", "r24", "r34", "r35", "r164", "r436", "r519" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r23", "r24", "r34", "r35", "r164", "r519", "r675" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r36", "r93" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r23", "r24", "r34", "r35", "r164" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r23", "r24", "r34", "r35", "r164", "r519" ] }, "itci_CorporateBondsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CorporateBondsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds ,at carrying value", "label": "Corporate Bonds, at Carrying Value", "documentation": "Corporate Bonds, at Carrying Value" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Notes/Bonds", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r548", "r550", "r556", "r568", "r575", "r784" ] }, "itci_CostOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CostOfProductSales", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales", "label": "Cost Of Product Sales", "documentation": "Cost of product sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r124", "r125", "r233", "r236", "r359", "r376", "r401", "r532", "r534" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r67", "r164" ] }, "itci_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CustomerOneMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer one." } } }, "auth_ref": [] }, "itci_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CustomerThreeMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three", "label": "Customer Three [Member]", "documentation": "Customer three." } } }, "auth_ref": [] }, "itci_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "CustomerTwoMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer two." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r712" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r208", "r542" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Continuous unrealized losses, value remaining", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r88", "r208", "r542" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate related fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r87", "r207", "r542" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r28", "r579", "r791" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositAssets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Production campaign deposits", "label": "Deposit Assets", "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }, "auth_ref": [ "r687" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r689" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r687" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r29" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r249", "r253", "r280", "r281", "r282", "r552" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r591" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r623" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r634" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r118", "r131", "r132", "r133", "r134", "r135", "r136", "r141", "r143", "r145", "r146", "r147", "r151", "r293", "r296", "r312", "r313", "r398", "r416", "r536" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r118", "r131", "r132", "r133", "r134", "r135", "r136", "r143", "r145", "r146", "r147", "r151", "r293", "r296", "r312", "r313", "r398", "r416", "r536" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r140", "r148", "r149", "r150" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs related to unvested RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r731" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Share-Based Payment Arrangement, Option [Member]", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r589" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r589" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r589" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r673" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r589" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r589" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r589" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r589" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r628" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r669" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r669" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r669" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r97", "r113", "r114", "r115", "r126", "r127", "r128", "r130", "r135", "r137", "r139", "r153", "r198", "r199", "r212", "r238", "r287", "r288", "r290", "r291", "r292", "r294", "r295", "r296", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r358", "r412", "r429", "r430", "r431", "r443", "r499" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r638" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r596", "r606", "r616", "r648" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r593", "r603", "r613", "r645" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r644" ] }, "itci_FDICCertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "FDICCertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "FDIC Certificates of Deposit", "label": "FDIC Certificates Of Deposit [Member]", "documentation": "FDIC certificates of deposit." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r315", "r316", "r329", "r556" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r315", "r316", "r329", "r556" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r315", "r316" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r330", "r557" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r330", "r557" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r234", "r242", "r243", "r244", "r245", "r246", "r247", "r314", "r316", "r317", "r318", "r319", "r328", "r329", "r331", "r363", "r364", "r365", "r543", "r544", "r548", "r549", "r550", "r556", "r559" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r315", "r316", "r317", "r319", "r556", "r739", "r742" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r324", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r394", "r556", "r560" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r234", "r242", "r247", "r316", "r329", "r363", "r548", "r549", "r550", "r556" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r234", "r242", "r247", "r316", "r317", "r329", "r364", "r543", "r544", "r548", "r549", "r550", "r556" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r234", "r242", "r243", "r244", "r245", "r246", "r247", "r316", "r317", "r318", "r319", "r329", "r365", "r543", "r544", "r548", "r549", "r550", "r556", "r559" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r315", "r316", "r317", "r319", "r556", "r739", "r742" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r234", "r242", "r243", "r244", "r245", "r246", "r247", "r314", "r316", "r317", "r318", "r319", "r328", "r329", "r331", "r363", "r364", "r365", "r543", "r544", "r548", "r549", "r550", "r556", "r559" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r556", "r736", "r737", "r738", "r739", "r740", "r742" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r200", "r201", "r202", "r203", "r204", "r206", "r209", "r210", "r235", "r237", "r310", "r336", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r413", "r542", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r713", "r714", "r715", "r716", "r735", "r738", "r739", "r740", "r741", "r742" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r633" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r59", "r483" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r727" ] }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GuaranteeObligationsCurrentCarryingValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor obligations, value", "label": "Guarantor Obligations, Current Carrying Value", "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r222" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r57", "r81", "r85", "r399", "r409", "r538", "r539", "r703", "r705", "r706", "r707", "r708" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r213", "r214", "r215", "r321", "r325", "r330", "r426", "r428", "r484", "r525", "r558", "r757" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r214", "r215", "r321", "r325", "r330", "r426", "r428", "r484", "r525", "r558", "r757" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r89", "r96", "r138", "r139", "r152", "r158", "r161", "r285", "r286", "r289", "r417", "r553" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r21", "r64", "r696", "r732", "r733" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "itci_IncreaseDecreaseInAccruedCustomerPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "IncreaseDecreaseInAccruedCustomerPrograms", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued customer programs", "label": "Increase Decrease In Accrued Customer Programs", "documentation": "Increase decrease in accrued customer programs." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r695" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r676", "r695" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r600", "r610", "r620", "r644", "r652", "r656", "r664" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r662" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r592", "r668" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r592", "r668" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r592", "r668" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r688", "r790" ] }, "itci_InventoriableCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "InventoriableCostsMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventoriable costs", "label": "Inventoriable Costs [Member]", "documentation": "InventoriableCostsMember." } } }, "auth_ref": [] }, "itci_InventoryCurrentAndNoncurrentNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "InventoryCurrentAndNoncurrentNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Current And Noncurrent, Net Of Reserves", "documentation": "Inventory, Current And Noncurrent, Net Of Reserves" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r211" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r69", "r529" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "negatedLabel": "Less: Current portion", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r106", "r528", "r567" ] }, "itci_InventoryNetSubjectToSupplementalRegulatoryProcedures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "InventoryNetSubjectToSupplementalRegulatoryProcedures", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory subject to supplemental regulatory procedures", "label": "Inventory, Net, Subject To Supplemental Regulatory Procedures", "documentation": "Inventory, Net, Subject To Supplemental Regulatory Procedures" } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail_1": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, non-current", "verboseLabel": "Total inventory, non-current", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r687" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r69", "r531" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "itci_InventoryCurrentAndNoncurrentNetOfReserves", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r69", "r530" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r152", "r157", "r161", "r539", "r694" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r677", "r678", "r710" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r446", "r447", "r448", "r449", "r450", "r502", "r504", "r506", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r579" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r446", "r447", "r448", "r449", "r450", "r502", "r504", "r506", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r579" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r349", "r566" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r745" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r356" ] }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "documentation": "Lessee operating lease liability payments due after Year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Three months ending December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r745" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r356" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of long term lease", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r744" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r39", "r40", "r41", "r42", "r43", "r44", "r45", "r123", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r299", "r302", "r303", "r337", "r459", "r537", "r587", "r723", "r746", "r747" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r52", "r80", "r407", "r567", "r698", "r717", "r743" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r41", "r100", "r123", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r299", "r302", "r303", "r337", "r567", "r723", "r746", "r747" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities measured using quoted prices", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r316", "r736" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r164", "r547", "r570", "r573", "r726", "r756", "r758", "r759", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r248", "r283", "r319", "r392", "r425", "r427", "r435", "r451", "r452", "r503", "r505", "r507", "r508", "r512", "r523", "r524", "r541", "r545", "r551", "r559", "r560", "r564", "r565", "r571", "r725", "r748", "r749", "r750", "r751", "r752", "r753" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r636" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r636" ] }, "itci_MichaelI.HalsteadTradingArrangementAug13PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "MichaelI.HalsteadTradingArrangementAug13PlanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael I. Halstead Trading Arrangement, Aug 13 Plan [Member]", "documentation": "Michael I. Halstead Trading Arrangement, Aug 13 Plan" } } }, "auth_ref": [] }, "itci_MichaelI.HalsteadTradingArrangementJan2PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "MichaelI.HalsteadTradingArrangementJan2PlanMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael I. Halstead Trading Arrangement, Jan 2 Plan [Member]", "documentation": "Michael I. Halstead Trading Arrangement, Jan 2 Plan" } } }, "auth_ref": [] }, "itci_MichaelIHalsteadMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "MichaelIHalsteadMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael I. Halstead [Member]", "documentation": "Michael I. Halstead" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r248", "r283", "r319", "r392", "r425", "r427", "r435", "r451", "r452", "r503", "r505", "r507", "r508", "r512", "r523", "r524", "r541", "r545", "r551", "r559", "r560", "r564", "r571", "r725", "r748", "r749", "r750", "r751", "r752", "r753" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r728" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r663" ] }, "stpr_NJ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "NJ", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NEW JERSEY", "label": "NEW JERSEY" } } }, "auth_ref": [] }, "stpr_NY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "NY", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK", "label": "NEW YORK" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r164", "r547", "r570", "r573", "r726", "r756", "r758", "r759", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r637" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r120" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r120" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r62", "r63", "r65" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r58", "r65", "r82", "r98", "r108", "r111", "r115", "r123", "r129", "r131", "r132", "r133", "r134", "r135", "r138", "r139", "r144", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r293", "r296", "r313", "r337", "r411", "r481", "r497", "r498", "r585", "r723" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r636" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r600", "r610", "r620", "r644", "r652" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r627" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r626" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r644" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r663" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r540", "r704" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r85", "r538", "r703", "r705", "r706", "r707", "r708" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r350", "r566" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r348" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "negatedTerseLabel": "Less: Current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r348" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r348" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r347" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r355", "r566" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r354", "r566" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r37", "r76", "r437", "r438" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid and Other Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "verboseLabel": "Total other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r103" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on investment securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r3", "r8", "r77" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r9", "r13", "r109", "r112", "r116", "r135", "r338", "r339", "r344", "r396", "r412", "r691", "r692" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive gain:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "itci_OtherInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "OtherInformationAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Other information", "label": "Other Information [Abstract]", "documentation": "Other information." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r636" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r598", "r608", "r618", "r650" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r625" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r60" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r61" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r635" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r635" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r627" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r644" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r637" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r626" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r628" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r672" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r627" ] }, "itci_PossibleMilestonePaymentsRemaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "PossibleMilestonePaymentsRemaining", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of milestone amount", "label": "Possible Milestone Payments Remaining", "documentation": "Payment of milestone amount." } } }, "auth_ref": [] }, "itci_PrefundedCustomerProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "PrefundedCustomerProgram", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prefunded customer programs", "label": "Prefunded Customer Program", "documentation": "Prefunded Customer Program" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "negatedTerseLabel": "Less: Current portion", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r690" ] }, "itci_PrepaidOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "PrepaidOperatingExpenses", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails_1": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/PrepaidandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid operating expenses", "label": "Prepaid Operating Expenses", "documentation": "Prepaid Operating Expenses" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock, net", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r12" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Product sales, net", "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r546" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r162", "r393", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r526", "r546", "r569", "r571", "r572", "r574", "r576", "r721", "r722", "r726", "r756", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r162", "r393", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r526", "r546", "r569", "r571", "r572", "r574", "r576", "r721", "r722", "r726", "r756", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r98", "r108", "r111", "r119", "r123", "r129", "r135", "r138", "r139", "r197", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r293", "r296", "r297", "r300", "r301", "r313", "r337", "r399", "r410", "r442", "r481", "r497", "r498", "r554", "r555", "r586", "r693", "r723" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r357" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r357", "r400", "r408", "r567" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r70", "r357" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r44", "r79" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r44", "r79" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]", "label": "Purchase Commitment, Excluding Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes long-term purchase arrangement and unconditional purchase obligation." } } }, "auth_ref": [ "r44", "r79" ] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment", "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": [ "r44", "r79" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r625" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r625" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r241", "r248", "r276", "r277", "r278", "r283", "r319", "r366", "r375", "r392", "r425", "r427", "r435", "r451", "r452", "r503", "r505", "r507", "r508", "r512", "r523", "r524", "r541", "r545", "r551", "r559", "r560", "r564", "r565", "r571", "r579", "r719", "r725", "r739", "r749", "r750", "r751", "r752", "r753" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r218", "r219", "r220", "r221", "r241", "r248", "r276", "r277", "r278", "r283", "r319", "r366", "r375", "r392", "r425", "r427", "r435", "r451", "r452", "r503", "r505", "r507", "r508", "r512", "r523", "r524", "r541", "r545", "r551", "r559", "r560", "r564", "r565", "r571", "r579", "r719", "r725", "r739", "r749", "r750", "r751", "r752", "r753" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r521", "r522", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r521", "r522", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r593", "r603", "r613", "r645" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r124", "r125", "r233", "r236", "r359", "r376", "r401", "r533", "r534" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r284", "r525", "r539", "r754" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r594", "r604", "r614", "r646" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r595", "r605", "r615", "r647" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r602", "r612", "r622", "r654" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r686", "r697" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r49", "r73", "r406", "r432", "r434", "r441", "r461", "r567" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r97", "r126", "r127", "r128", "r130", "r135", "r137", "r139", "r198", "r199", "r212", "r287", "r288", "r290", "r291", "r292", "r294", "r295", "r296", "r304", "r306", "r307", "r309", "r311", "r345", "r346", "r429", "r431", "r443", "r788" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r83", "r84", "r152", "r155", "r156", "r159", "r161", "r162", "r163", "r164", "r239", "r240", "r393" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets under operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r353", "r566" ] }, "itci_RightOfUseAssetsAndLeaseLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Right of Use Assets and Lease Liabilities", "label": "Right Of Use Assets And Lease Liabilities [Text Block]", "documentation": "Right of use assets and lease liabilities." } } }, "auth_ref": [] }, "itci_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty payment, percentage (as a percent)", "label": "Royalty Payment Percentage", "documentation": "Royalty Payment Percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r663" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Offering price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r164", "r674" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r15", "r53", "r54", "r55" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information About Operating Leases", "label": "Schedule of Quantitative Information About Operating Leases [Table Text Block]", "documentation": "Schedule of Quantitative Information About Operating Leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r250", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r74" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Information Regarding RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r588" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r590" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's cancelled, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r270" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r268" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of year, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r265", "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r265", "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock outstanding, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's vested, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r250", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options canceled or expired, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r729" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r730" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r257", "r258" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share)", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r257", "r258" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r273" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r273" ] }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r30" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "itci_SharonMatesPh.DMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "SharonMatesPh.DMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Sharon Mates, Ph.D [Member]", "documentation": "Sharon Mates, Ph.D" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r351", "r566" ] }, "itci_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r66", "r122" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r47", "r50", "r51", "r97", "r113", "r114", "r115", "r126", "r127", "r128", "r130", "r135", "r137", "r139", "r153", "r198", "r199", "r212", "r238", "r287", "r288", "r290", "r291", "r292", "r294", "r295", "r296", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r358", "r412", "r429", "r430", "r431", "r443", "r499" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r126", "r127", "r128", "r153", "r346", "r393", "r439", "r445", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r480", "r482", "r483", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r580" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r126", "r127", "r128", "r153", "r165", "r346", "r393", "r439", "r445", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r480", "r482", "r483", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r580" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r597", "r607", "r617", "r649" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services (in shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r46", "r47", "r73", "r440", "r499", "r518" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r9", "r46", "r47", "r73" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r46", "r47", "r73", "r262" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r46", "r47", "r73", "r443", "r499", "r518", "r586" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r9", "r73" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r47", "r50", "r51", "r68", "r462", "r479", "r500", "r501", "r567", "r587", "r698", "r717", "r743", "r788" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r643" ] }, "itci_ThreeMajorWholesalersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "ThreeMajorWholesalersMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Three Major Wholesalers", "label": "Three Major Wholesalers [Member]", "documentation": "Three Major Wholesalers" } } }, "auth_ref": [] }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20240930", "localname": "TimeBasedRestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Time Based Restricted Stock Units", "label": "Time Based Restricted Stock Units R S U [Member]", "documentation": "Time based restricted stock units." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r635" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r642" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r662" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r664" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r235", "r237", "r310", "r336", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r413", "r556", "r557", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r713", "r714", "r715", "r716", "r735", "r738", "r739", "r740", "r741", "r742" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r665" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r666" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r666" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r664" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r664" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r667" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r665" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Agency Securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r535", "r548", "r755" ] }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in commercial paper, government securities", "label": "US Government Agencies Securities, at Carrying Value", "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r661" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r91", "r92", "r94", "r95" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r352", "r566" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicle Lease", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r631" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in share)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r142", "r147" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r141", "r147" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r629" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 66 0001628280-24-044196-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-044196-xbrl.zip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itci-20240930_htm.xml IDEA: XBRL DOCUMENT 0001567514 2024-01-01 2024-09-30 0001567514 2024-10-28 0001567514 2024-09-30 0001567514 2023-12-31 0001567514 us-gaap:ProductMember 2024-07-01 2024-09-30 0001567514 us-gaap:ProductMember 2023-07-01 2023-09-30 0001567514 us-gaap:ProductMember 2024-01-01 2024-09-30 0001567514 us-gaap:ProductMember 2023-01-01 2023-09-30 0001567514 us-gaap:GrantMember 2024-07-01 2024-09-30 0001567514 us-gaap:GrantMember 2023-07-01 2023-09-30 0001567514 us-gaap:GrantMember 2024-01-01 2024-09-30 0001567514 us-gaap:GrantMember 2023-01-01 2023-09-30 0001567514 2024-07-01 2024-09-30 0001567514 2023-07-01 2023-09-30 0001567514 2023-01-01 2023-09-30 0001567514 us-gaap:CommonStockMember 2022-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001567514 us-gaap:RetainedEarningsMember 2022-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001567514 2022-12-31 0001567514 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001567514 2023-01-01 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001567514 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001567514 2023-04-01 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001567514 us-gaap:CommonStockMember 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001567514 2023-06-30 0001567514 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001567514 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001567514 us-gaap:CommonStockMember 2023-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001567514 us-gaap:RetainedEarningsMember 2023-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001567514 2023-09-30 0001567514 us-gaap:CommonStockMember 2023-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001567514 us-gaap:RetainedEarningsMember 2023-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001567514 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001567514 2024-01-01 2024-03-31 0001567514 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001567514 us-gaap:CommonStockMember 2024-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001567514 us-gaap:RetainedEarningsMember 2024-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001567514 2024-03-31 0001567514 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001567514 2024-04-01 2024-06-30 0001567514 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001567514 us-gaap:CommonStockMember 2024-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001567514 us-gaap:RetainedEarningsMember 2024-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001567514 2024-06-30 0001567514 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001567514 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001567514 us-gaap:CommonStockMember 2024-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001567514 us-gaap:RetainedEarningsMember 2024-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001567514 2024-04-01 2024-04-30 0001567514 2024-04-30 0001567514 itci:ThreeMajorWholesalersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001567514 itci:FDICCertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:CertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:CommercialPaperMember 2024-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:DebtSecuritiesMember 2024-09-30 0001567514 us-gaap:DebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001567514 stpr:NY 2018-09-30 0001567514 stpr:NJ 2024-05-31 0001567514 us-gaap:VehiclesMember 2024-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2024-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2024-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2024-01-01 2024-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2024-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2023-12-31 0001567514 itci:InventoriableCostsMember 2024-07-01 2024-09-30 0001567514 itci:InventoriableCostsMember 2023-07-01 2023-09-30 0001567514 itci:InventoriableCostsMember 2024-01-01 2024-09-30 0001567514 itci:InventoriableCostsMember 2023-01-01 2023-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001567514 2023-01-01 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2024-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001567514 itci:MichaelIHalsteadMember itci:MichaelI.HalsteadTradingArrangementAug13PlanMember 2024-07-01 2024-09-30 0001567514 itci:MichaelIHalsteadMember itci:MichaelI.HalsteadTradingArrangementAug13PlanMember 2024-09-30 0001567514 itci:MichaelIHalsteadMember itci:MichaelI.HalsteadTradingArrangementJan2PlanMember 2024-07-01 2024-09-30 0001567514 itci:MichaelIHalsteadMember itci:MichaelI.HalsteadTradingArrangementJan2PlanMember 2024-09-30 0001567514 itci:SharonMatesPh.DMember 2024-07-01 2024-09-30 0001567514 itci:SharonMatesPh.DMember 2024-09-30 shares iso4217:USD iso4217:USD shares itci:segment pure 0001567514 --12-31 2024 Q3 false P140D P98D P104D 10-Q true 2024-09-30 false 001-36274 INTRA-CELLULAR THERAPIES, INC. DE 36-4742850 135 Route 202/206, Suite 6 Bedminster NJ 07921 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 106017103 464312000 147767000 542250000 350174000 1750000 1750000 145608000 114018000 23539000 11647000 94272000 42443000 1271731000 667799000 2005000 1654000 14011000 12928000 30479000 38621000 6219000 7293000 1324445000 728295000 10338000 11452000 51540000 27944000 70536000 53173000 29496000 27364000 4203000 3612000 166113000 123545000 13506000 13326000 179619000 136871000 0.0001 0.0001 175000000 175000000 105998786 105998786 96379811 96379811 11000 10000 2818137000 2208470000 -1674951000 -1617160000 1629000 104000 1144826000 591424000 1324445000 728295000 175159000 125810000 481278000 330669000 216000 363000 351000 1602000 175375000 126173000 481629000 332271000 15304000 9129000 36558000 23043000 132101000 105207000 366760000 305144000 66819000 41550000 165835000 129368000 214224000 155886000 569153000 457555000 -38849000 -29713000 -87524000 -125284000 12899000 5498000 30523000 14377000 -25950000 -24215000 -57001000 -110907000 374000 43000 790000 188000 -26324000 -24258000 -57791000 -111095000 -0.25 -0.25 -0.25 -0.25 -0.57 -0.57 -1.16 -1.16 105768386 105768386 96143083 96143083 102135530 102135530 95745641 95745641 -26324000 -24258000 -57791000 -111095000 2297000 933000 1525000 2855000 -24027000 -23325000 -56266000 -108240000 94829794 9000 2137737000 -1477486000 -4190000 656070000 849827 1000 3639000 3640000 408 22000 22000 10439000 10439000 -44053000 -44053000 1492000 1492000 95680029 10000 2151837000 -1521539000 -2698000 627610000 402994 8585000 8585000 364 23000 23000 13226000 13226000 -42784000 -42784000 430000 430000 96083387 10000 2173671000 -1564323000 -2268000 607090000 141780 2581000 2581000 450 24000 24000 14311000 14311000 -24258000 -24258000 933000 933000 96225617 10000 2190587000 -1588581000 -1335000 600681000 96379811 10000 2208470000 -1617160000 104000 591424000 1097668 9989000 9989000 339 23000 23000 13843000 13843000 -15247000 -15247000 -534000 -534000 97477818 10000 2232325000 -1632407000 -430000 599498000 7876713 1000 543085000 543086000 270026 2093000 2093000 345 23000 23000 16370000 16370000 -16220000 -16220000 -238000 -238000 105624902 11000 2793896000 -1648627000 -668000 1144612000 373638 6734000 6734000 246 18000 18000 17489000 17489000 -26324000 -26324000 2297000 2297000 105998786 11000 2818137000 -1674951000 1629000 1144826000 -57791000 -111095000 399000 392000 47702000 37976000 64000 69000 6043000 5861000 31590000 27481000 3750000 19066000 50755000 16805000 -1114000 218000 23596000 8172000 -17363000 -9997000 2132000 2452000 -312000 -1106000 -60099000 -122138000 482077000 310805000 297568000 369192000 749000 268000 -185258000 58119000 18816000 14806000 543086000 0 561902000 14806000 316545000 -49213000 149517000 150365000 466062000 101152000 2548000 0 1364000 0 464312000 99402000 1750000 1750000 466062000 101152000 Organization <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.</span></div>In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.1 million. 7876713 73.00 575000000 543100000 Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality. </span></div>Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div>The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders. 1 1 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span>, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div>The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. </span></div>Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality. 0.98 0.37 0.33 0.28 0.36 0.32 0.29 Investment Securities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">315,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">563,917</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">565,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,570 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(386)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2024 and December 31, 2023, the Company held $164.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. Accrued interest receivable from investment securities as of September 30, 2024 and December 31, 2023 was $3.7 million and $2.3 million, respectively, and are included within prepaid expenses and other current assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate related fair value of investments with unrealized losses as of September 30, 2024 was $66.2 million, which consisted of $30.5 million of U.S. government agency securities, $6.0 million of commercial paper, and $29.7 million of corporate notes/bonds. $1.0 million of the aggregate fair value of investments with unrealized losses as of September 30, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $65.2 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for more than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months. </span></div>The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,637</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">315,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">563,917</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">565,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,570 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(386)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 135801000 158000 13000 135946000 980000 0 0 980000 60000000 0 0 60000000 51637000 63000 1000 51699000 315499000 1453000 31000 316921000 563917000 1674000 45000 565546000 150651000 148000 204000 150595000 4410000 2000 12000 4400000 60000000 0 0 60000000 78610000 59000 27000 78642000 118899000 281000 143000 119037000 412570000 490000 386000 412674000 164000000.0 77800000 3700000 2300000 66200000 30500000 6000000.0 29700000 1000000.0 65200000 165200000 70100000 95100000 Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value method under ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $225.1 million as of September 30, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $6.4 million, corporate bonds of $4.8 million, and U.S. government agency securities of $12.1 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September 30, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">790,645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">565,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">423,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 225100000 10700000 6400000 4800000 12100000 2500000 60000000.0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">980</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">316,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">790,645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">225,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">565,546</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">423,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">412,674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 225099000 225099000 0 0 135946000 0 135946000 0 980000 0 980000 0 60000000 0 60000000 0 51699000 0 51699000 0 316921000 0 316921000 0 790645000 225099000 565546000 0 10698000 10698000 0 0 150595000 0 150595000 0 4400000 0 4400000 0 60000000 0 60000000 0 78642000 0 78642000 0 119037000 0 119037000 0 423372000 10698000 412674000 0 Inventory <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">54,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(23,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, the Company has recorded $8.0 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but the Company believes it is probable that such inventory has future economic benefit.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,048</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">54,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(23,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory, non-current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30479000 38621000 13048000 4277000 10491000 7370000 54018000 50268000 23539000 11647000 30479000 38621000 8000000.0 7700000 Prepaid and Other Assets<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production campaign deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prefunded customer programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(94,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production campaign deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial advances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,389</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prefunded customer programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,736 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(94,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,293 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 31400000 19465000 30139000 15127000 33389000 11630000 5563000 3514000 100491000 49736000 94272000 42443000 6219000 7293000 Right of Use Assets and Lease Liabilities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In May 2024, the Company entered into a long-term lease of office space in Bedminster, New Jersey. The lease has a term of 5.7 years ending in February 2030.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into agreements (the “Vehicle Leases”) with providers (the “Lessors”) to acquire motor vehicles for certain employees. The Vehicle Leases provide for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the related Lessor may draw upon in the event the Company defaults on the related Vehicle Leases, which has been recorded as restricted cash on the condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,921</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,254</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,130</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,808</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ending December 31, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,798 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,506 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P14Y3M18D P5Y8M12D P12M P12M 1750000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,921</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,254</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,130</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,135</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,808</span></td></tr></table></div> P4Y8M12D P5Y3M18D 0.0882 0.0907 3027000 2921000 1254000 1130000 1854000 1757000 6135000 5808000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ending December 31, 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,798 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,709 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,506 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1112000 4436000 4513000 4573000 4707000 2457000 21798000 4089000 17709000 4203000 13506000 Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Commitments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments </span></div>The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The manufacturing service agreements commit the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (“API”) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan set forth in their respective agreements. The Company has paid deposits of $30.1 million and $15.1 million as of September 30, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $30.1 million balance as of September 30, 2024, $24.0 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $6.1 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after September 30, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet. 10800000 5000000.0 14750000 0.05 0.09 P10Y 30100000 15100000 30100000 24000000.0 6100000 15100000 7900000 7200000 Share-Based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,094</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14,374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,311 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239,982</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(933,601)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,460)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.74 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,968,706</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.00 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 years</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,645,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,100,255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(732,992)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,611)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,950,782</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.35 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 years</span></td></tr></table></div>As of September 30, 2024, there were $95.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,094</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14,374</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,311 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">47,702</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 497000 424000 1405000 1186000 11898000 9564000 31923000 25269000 5094000 4323000 14374000 11521000 17489000 14311000 47702000 37976000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239,982</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(933,601)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,460)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.74 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,968,706</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.00 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 years</span></td></tr></table></div> 4239982 28.22 P5Y2M12D 34539 933601 11460 3329460 30.74 P5Y2M12D 3329460 30.74 2968706 28.00 P4Y9M18D Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows: <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,645,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,100,255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(732,992)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,611)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,950,782</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.35 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 years</span></td></tr></table></div> 1645130 48.92 P1Y 1100255 732992 61611 1950782 60.35 P1Y2M12D 95500000 Loss Per Share <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,175,284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,755,460</span></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,329,460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,175,284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,755,460</span></td></tr></table></div> 3329460 3329460 4385555 4385555 2175284 2175284 1755460 1755460 <div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On August 13, 2024, Michael I. Halstead, President, adopted a Rule 10b5-1 Sales Plan having an end date of December 31, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 41,583 shares of our common stock upon the exercise of stock options. On August 13, 2024, Mr. Halstead adopted a subsequently commencing Rule 10b5-1 Sales Plan with a start date of January 2, 2025 and an end date of April 10, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 32,717 shares of our common stock upon the vesting of restricted stock units and (ii) an indeterminate number of shares of our common stock sufficient to cover Mr. Halstead’s tax liability upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On September 3, 2024, Sharon Mates, Ph.D., Chairman and Chief Executive Officer, adopted a Rule 10b5-1 Sales Plan having an end date of December 16, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 102,697 shares of our common stock upon the exercise of stock options.</span></div> August 13, 2024, Michael I. Halstead President true December 31, 2024 41583 August 13, 2024 Mr. Halstead true April 10, 2025 32717 September 3, 2024 Sharon Mates, Ph.D. Chairman and Chief Executive Officer, true December 16, 2024 102697 false false false